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Mitochondria supply the majority of cellular ATP and have additional important 
roles in calcium signalling, apoptosis and lipid metabolism. Mutations in or loss of 
mitochondrial DNA (mtDNA) can cause neurodegeneration and has been linked to 
Parkinson‟s disease. However, the pathological consequences of mtDNA loss in 
neurons are very poorly understood.  
We have used the fruitfly, Drosophila melanogaster, to study how loss of mtDNA 
affects neuronal function. We find that both ubiquitous RNAi and overexpression of 
the mtDNA binding protein TFAM causes reduced mtDNA content and lethality. 
TFAM RNAi or overexpression specifically in motor neurons causes locomotion 
defects during development and age-related behavioural defects in adult flies. This 
demonstrates that maintenance of mtDNA is required for normal motor neuron 
function. 
In further behavioural assays we show reductions in evoked jump response, 
demonstrating that mtDNA loss inhibits motor neuron activity. Also, using confocal 
imaging we find that mtDNA loss does not cause neuronal loss or changes in 
synaptic bouton number during development. However, we observe a significant 
decrease in the number of mitochondria and the number of pre-synaptic active zones 
(the sites of neurotransmitter release) in motor neurons with reduced mtDNA 
content. Taken together these data show that neuronal mtDNA loss results in defects 
in synaptic development and reduced motor neuron function. We further show that 
these phenotypes can also result from other methods of mtDNA depletion, such as 
mitochondrial specific expression of the restriction enzyme XhoI. Furthermore, 
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possible roles of TOR pathway and autophagy on motoneuron synapses were 
investigated. The phenotypes observed may represent the initial pathological 




Table of Contents 
Declaration ............................................................................................................................................ 2 
Acknowledgement ................................................................................................................................ 3 
Abstract ................................................................................................................................................. 4 
Table of Contents ................................................................................................................................. 6 
List of Figures ..................................................................................................................................... 11 
List of Tables ...................................................................................................................................... 13 
List of abbreviations .......................................................................................................................... 14 
CHAPTER 1. GENERAL INTRODUCTION ............................................................ 17 
1.1 Mitochondrial basics ................................................................................................................ 17 
1.1.1 The discovery of mitochondria ......................................................................................... 17 
1.1.2 The structure and function of mitochondria ..................................................................... 19 
1.2 The Mitochondrial Genome ..................................................................................................... 24 
1.2.1 General Properties of mtDNA ........................................................................................... 24 
1.2.2 Mitochondrial transcription and translation ..................................................................... 26 
1.2.3 MtDNA replication ............................................................................................................ 28 
1.2.4 The mtDNA nucleoid ......................................................................................................... 32 
1.3 Mitochondrial dynamics and mitochondrial diseases ............................................................ 37 
1.3.1 Mitochondrial diseases ..................................................................................................... 37 
1.3.2 Mitochondrial transport .................................................................................................... 39 
1.3.3 Mitochondrial fusion and fission ....................................................................................... 41 
1.3.4 Mitochondrial turnover ..................................................................................................... 42 
1.3.5 Mitochondrial dysfunction in neurodegenerative diseases .............................................. 44 
1.4 mtDNA and disease .................................................................................................................. 48 
1.4.1 Mitochondrial diseases caused by mutations in the mitochondrial genome. .................. 48 
1.4.2 Mitochondrial diseases caused by mutations in nuclear genes ........................................ 51 
7 
 
1.4.3 mtDNA depletion syndrome ............................................................................................. 53 
1.4.4 mtDNA in neurodegenerative diseases and ageing .......................................................... 56 
1.5 Animal models mtDNA of diseases .......................................................................................... 60 
1.5.1 The importance of modelling mtDNA diseases ................................................................. 60 
1.5.2 Modelling mtDNA mutations ............................................................................................ 61 
1.5.3 Modelling nuclear DNA mutations in mtDNA replication genes ....................................... 63 
AIMS OF PROJECT ......................................................................................................................... 75 
CHAPTER 2. MATERIALS AND METHODS ......................................................... 76 
2.1 Materials .................................................................................................................................... 76 
2.2 Methods ..................................................................................................................................... 77 
2.2.1 Fly breeding ....................................................................................................................... 77 
2.2.2 Fly stocks ........................................................................................................................... 79 
2.2.3 Lifespan Assays.................................................................................................................. 81 
2.2.4 Measuring mtDNA Levels .................................................................................................. 82 
2.2.5 Measuring TFAM transcript level ...................................................................................... 83 
2.2.6 Measuring ATP Levels ....................................................................................................... 85 
2.2.7 Generation of transgenic flies ........................................................................................... 86 
2.2.8 Immunohistochemistry ..................................................................................................... 87 
2.2.9 Axonal mitochondrial membrane potential analysis ........................................................ 89 
2.2.10 Microscopy and image Processing ............................................................................... 90 
2.2.11 NMJ analysis ................................................................................................................. 90 
2.2.12 Behavioural assays ....................................................................................................... 91 
2.2.13 Statistical tests and graphs ........................................................................................... 93 
CHAPTER 3. DEVELOPMENT OF A NEURONAL MODEL FOR MTDNA LOSS 
IN DROSOPHILA ............................................................................................................... 94 
8 
 
3.1 Introduction .............................................................................................................................. 94 
3.2 The effect of ethidium bromide treatment on Drosophila development and longevity ....... 95 
3.3 Knockdown of mtDNA replication genes to deplete mtDNA in Drosophila ...................... 100 
3.4 Knockdown of mtDNA replication genes using a pan-neuronal driver ............................. 105 
3.5 Neuroblast-specific knockdown of Polγ, Twinkle and TFAM reduces mtDNA copy number 
and affects behaviour. ...................................................................................................................... 108 
3.6 Knockdown of Polγ, Twinkle and TFAM in mushroom body neurons............................... 116 
3.7 Motoneuron specific knockdown of Polγ, Twinkle and TFAM affects larval and adult 
behaviour .......................................................................................................................................... 119 
3.8 Summary ................................................................................................................................. 125 
CHAPTER 4. MANIPULATION OF TFAM LEVELS TO INDUCE MTDNA LOSS 
IN MOTONEURONS ....................................................................................................... 127 
4.1 Introduction ............................................................................................................................ 127 
4.2 Ubiquitous knockdown and overexpression of TFAM causes different levels of mtDNA 
depletion ............................................................................................................................................ 128 
4.3 TFAM RNAi and overexpression disrupts wing development ............................................ 131 
4.4 Effect of TFAM RNAi and overexpression on TFAM protein in motoneuron cell bodies 136 
4.5 TFAM RNAi and overexpression in motoneurons causes behavioural defects ................. 139 
4.6 TFAM overexpression disrupts synapse development ......................................................... 145 
4.7 TFAM RNAi and overexpression causes depletion of synaptic mitochondria ................... 155 
4.8 Effects of TFAM RNAi and overexpression on motoneuron cell body and axonal 
mitochondria ..................................................................................................................................... 160 
4.9 Summary ................................................................................................................................. 164 
CHAPTER 5. USE OF A MITOCHONDRIALLY TARGETED RESTRICTION 
ENZYME TO INDUCE MTDNA LOSS IN MOTONEURONS ................................... 166 
9 
 
5.1 Introduction ............................................................................................................................ 166 
5.2 Expression of a mitochondrially-targeted restriction enzyme affects mtDNA nucleoid 
morphology ....................................................................................................................................... 167 
5.3 Motoneuron specific expression of mitoXhoI results in synaptic defects ........................... 173 
5.4 Motoneuron specific mitoXhoI expression depletes synaptic mitochondria ...................... 176 
5.5 Motoneuron specific mitoXhoI expression affects axonal and cell body mitochondria .... 179 
5.6 Summary ................................................................................................................................. 184 
CHAPTER 6. INVESTIGATING THE AFFECTS OF MANIPULATION OF THE 
TOR PATHWAY ON MOTONEURON DEVELOPMENT AND SYNAPTIC 
MITOCHONDRIA............................................................................................................ 185 
6.1 Introduction ............................................................................................................................ 185 
6.2 Effects of motoneuron specific TOR pathway manipulation on behaviour....................... 188 
6.3 Motoneuron specific manipulation of the TOR pathway affects synapse development ... 190 
6.4 Motoneuron specific manipulation of the TOR pathway alters synaptic mitochondrial 
localization ........................................................................................................................................ 193 
6.5 Directly increasing autophagy depletes synaptic mitochondria ......................................... 197 
6.6 Summary ................................................................................................................................. 203 
CHAPTER 7. DISCUSSION, CONCLUSION AND FUTURE DIRECTIONS ..... 204 
7.1 Characterization of a Drosophila model of neuronal mtDNA loss ..................................... 204 
7.2 Manipulation of TFAM expression to deplete mtDNA in motoneurons ............................ 211 
7.3 mitoXhoI as a tool to induce mtDNA loss in motoneurons ................................................. 223 
7.4 Potential mechanisms contributing to the defects in motoneuron development caused by 
mtDNA loss ....................................................................................................................................... 226 
7.4.1 Motoneuron specific TOR inhibition or Atg1 overexpression phenocopy TFAM 
overexpression .............................................................................................................................. 226 
10 
 
7.4.2 Potential mechanisms responsible for bouton size and active zone number reduction in 
motoneurons with depleted mtDNA ............................................................................................. 230 
7.4.3 Potential mechanisms that contribute to the mitochondrial phenotypes caused by 
motoneuron mtDNA loss ............................................................................................................... 233 
7.5 Conclusion and Future Directions ......................................................................................... 236 





List of Figures 
Figure 1.1 Structure of mitochondria. ........................................................................ 20 
Figure 1.2 Schematic representation of mitochondrial ETC complexes.................... 24 
Figure 1.3 Map of human mtDNA. ............................................................................ 26 
Figure 1.4 mtDNA transcription and translation........................................................ 28 
Figure 1.5 The mtDNA replication fork. ................................................................... 30 
Figure 1.6 Two models of mtDNA replication. ......................................................... 32 
Figure 1.7 The structure and localization of TFAM. ................................................. 37 
Figure 1.8 Roles of mitochondrial dynamics. ............................................................ 39 
Figure 1.9 Mitochondrial turnover. ............................................................................ 44 
Figure 1.10 Neurodegenerative diseases caused by dysfunctional mitochondrial 
dynamics. ................................................................................................................... 47 
Figure 1.11 Clonal expansion of mutated mtDNA molecules. .................................. 51 
Figure 1.12 Mutations in Polγ and diseases caused by these mutations. ................... 53 
Figure 1.13 Genes causing mtDNA depletion syndrome (MDS). ............................. 54 
Figure 1.14 Proteins implicated in mtDNA depletion syndrome (MDS). ................. 55 
Figure 3.1 Effect of EtBr on Drosophila development and ageing ........................... 99 
Figure 3.2 Schematic representation of RNAi lines used to knockdown mtDNA 
replication genes ubiquitously ................................................................................. 104 
Figure 3.3 Pan-neuronal RNAi of Polγ, Twinkle and TFAM does not cause mtDNA 
depletion. .................................................................................................................. 106 
Figure 3.4 Pan-neuronal RNAi of Polγ, Twinkle and TFAM shows a reduction in 
ATP level in male flies. ............................................................................................ 107 
Figure 3.5 RNAi of mtDNA replication genes using MZ1407-Gal4 causes mtDNA 
loss. .......................................................................................................................... 111 
Figure 3.6 The MZ1407-Gal4 driver has a broad expression in the CNS. .............. 112 
Figure 3.7 TFAM knockdown using MZ1407-Gal4 driver causes reduced viability 
and reduced larval locomotion. ................................................................................ 113 
Figure 3.8 TFAM RNAi expressed using MZ1407-Gal4 causes developmental and 
behavioural defects in adults. ................................................................................... 114 
Figure 3.9 Effect of TFAM RNAi on neuroblasts .................................................... 115 
Figure 3.10 Mushroom body specific RNAi of Polγ and TFAM results in thinner 
axons. ....................................................................................................................... 118 
Figure 3.11 Motoneuron specific RNAi of Twinkle and TFAM causes larval 
locomotion defects. .................................................................................................. 122 
Figure 3.12 Motoneuron specific RNAi of Polγ, Twinkle and TFAM causes reduction 
in climbing ability. ................................................................................................... 123 
Figure 3.13 Motoneuron specific knockdown of TFAM causes age dependent defects 
in the climbing performance of female flies. ........................................................... 124 
Figure 4.1 Ubiquitous TFAM knockdown and overexpression causes variable levels 
of mtDNA depletion. ................................................................................................ 130 
Figure 4.2 TFAM staining in the larval wing disc. .................................................. 134 
Figure 4.3 RNAi or overexpression of TFAM disrupts wing development. ............ 135 
Figure 4.4 Manipulating TFAM levels in motoneuron cell bodies. ......................... 138 
Figure 4.5 Motoneuron specific TFAM knockdown or overexpression causes 
behavioural defects at larval stage. .......................................................................... 142 
Figure 4.6 Manipulating TFAM levels results in behavioural defects in adult flies. 144 
Figure 4.7 TFAM RNAi or overexpression does not affect the number of 
motoneurons in the VNC. ........................................................................................ 149 
12 
 
Figure 4.8 OK371-Gal4 drives strongly in type Ib, but weakly in type Is motoneurons.
 .................................................................................................................................. 150 
Figure 4.9 Motoneuron specific TFAM over expression results in smaller boutons 
and fewer active zones at NMJ 4. ............................................................................ 152 
Figure 4.10 Overexpression of TFAM results in similar synaptic phenotypes to 
overexpression of TFAMGFP in motoneurons ........................................................ 154 
Figure 4.11 TFAM overexpression results in boutons that lack mitochondria. ....... 159 
Figure 4.12 TFAM overexpression disrupts the mitochondrial network in motoneuron 
cell bodies................................................................................................................. 162 
Figure 4.13 TFAM knockdown and overexpression results in a decrease in axonal 
mitochondria. ........................................................................................................... 163 
Figure 5.1 Introduction to restriction enzyme mediated mtDNA loss in flies. ........ 169 
Figure 5.2 Motoneuron specific expression of UASp-mitoXhoI disrupts nucleoid 
structure. ................................................................................................................... 172 
Figure 5.3 Motoneuron specific expression of mitoXhoI results in smaller boutons 
and fewer active zones. ............................................................................................ 175 
Figure 5.4 Motoneuron specific expression of mitoXhoI depletes synaptic 
mitochondria. ........................................................................................................... 178 
Figure 5.5  Axonal mitochondrial distribution is affected upon mitoXhoI expression.
 .................................................................................................................................. 182 
Figure 5.6 Expression of mitoXhoI in motoneurons reduces the membrane potential 
of axonal mitochondria. ........................................................................................... 183 
Figure 6.1 Schematic representation of TOR signalling pathway and its possible 
interaction with mitochondrial homeostasis............................................................. 187 
Figure 6.2 Manipulation of the TOR pathway causes climbing defects. ................. 189 
Figure 6.3 The effect of TOR activity on motoneuron synapse development. ........ 192 




  affects synaptic mitochondria in 
motoneurons. ............................................................................................................ 196 
Figure 6.5 Activation of autophagy affects synaptic development. ......................... 200 





List of Tables 
Table 2.1 List of Gal4 driver lines used in this study. ............................................... 80 
Table 2.2 Primer sequences for measuring mtDNA level by qPCR. ......................... 83 
Table 2.3 Primer sequences used to measure TFAM transcript level by qPCR. ........ 85 
Table 2.4 Primer sequences used for cloning TFAM and TFAMGFP. ...................... 87 
Table 3.1 List of RNAi lines used to cross to the Actin-Gal4 driver ....................... 102 
Table 4.1 Summary of the developmental phenotypes observed at NMJ 4 upon 
TFAM knockdown and overexpression .................................................................... 165 
Table 4.2 Summary of the mitochondrial localization phenotypes observed in the 
motoneurons upon TFAM knockdown and overexpression. .................................... 165 
Table 5.1 Motoneuron specific expression of mitoXhoI results in developmental 




List of abbreviations 
 
5‟ dRP:  5‟-deoxyribose phosphate 
AD:   Alzhmeimer‟s disease 
ALS:   amyotropic lateral scelerosis 
APP:   amyloid precurson protein 
Aβ:   β-amyloid 
CMT:   Charcot-Marie-Tooth disease 
CMT2A:  Charcot-Marie-Tooth type 2A 
cPEO:   chronic progressive external opthalmoplegia 
dGK:   deoxyguanosine kinase 
DNK:  deoxyribonucleoside kinase 
DOA:   dominant optic atrophy 
Drp1:   dynamin-related protein 1 
DSB:   double-strand break 
EtBr:  ethidium bromide 
ETC:  electron transport chain 
HD:   Huntington‟s disease 
HIG1:   hypoxia inducible group 1 
HMG:   high mobility group 
HSP:   hereditary spastic paraplegia 
HTT:   Huntingtin 
15 
 
IMM:   inner mitochondrial membrane 
IMS:   intermembrane space 
KIFs:   kinesin superfamily proteins 
KSS:   Kearns-Sayre syndrome 
LHON:  Leber‟s hereditary neuropathy 
lopo:   low power 
MB:   Mushroom Body 
MDS:   mtDNA depletion syndrome 
Mfn:   mitofusin 
MIRO:  mitochondrial rho 
MNGIE:  mitochondrial neurogastrointestinal encephalomyopathy 
MnSOD:  manganese superoxide dismutase 
MtDNA:  mitochondrial DNA 
mTERF:  mitochondrial transcription termination factor 
mtTFB1:  mitochondrial transcription factor B1 
mtTFB2:  mitochondrial transcription factor B2 
NMJ:   neuromuscular junction 
OA:   optic atrophy 
OH:  origin of replication for the heavy strand 
OL:  origin of replication for the light strand 
OMM:  outer mitochondrial membrane 
Opa1:   optic atrophy 1 
OXPHOS:  oxidative phosphorylation 
16 
 
PD:  Parkinson‟s disease 
PGC1-α: peroxisome proliferator-activated receptor-γ-coactivator 1-α 
PI3K:   phosphatidylinositol 3-kinase  
POLRMT:  mitochondrial RNA polymerase 
RE:   restriction enzyme 
RIs:  replication intermediates 
ROS:   reactive oxygen species 
SCA:   spinocerebellar ataxia 
SDH:   succinate dehydrogenase 
SIM:   structured illumination microscopy 
SSBP:   single strand binding protein 
STED:  stimulated emission depletion 
T7 gp4:  T7 gene 4 protein 
TBP:   TATA-box binding protein 
TCA:   tricarboxylic acid  
TFAM:  mitochondrial transcription factor A 
TFB2M:  mitochondrial transcription factor B2 
TK2:   thymidine kinase 
TOPO:  topoisomerase 
TOR:   target of rapamycin 




Chapter 1. General introduction 
1.1 Mitochondrial basics 
1.1.1 The discovery of mitochondria  
 
In 1897 Carl Benda first used the term “mitochondria” to describe granules, rods or 
filaments found in the cytoplasm of nearly all cells. These tiny structures were 
previously refered to as chondriosomes, chromidia, microsomes. The word 
mitochondria derives from the Greek words “mitos” meaning thread and “chondrin” 
meaning small grain. Mitochondria are organelles found in eukaryotic cells that are 
believed to be the result of a symbiotic event where an aerobic bacterium colonized a 
primordial eukaryotic cell that lacked the ability to use oxygen metabolically. This 
symbiotic relationship became permanent and these bacteria evolved into 
mitochondria, which allowed the cells to perform aerobic respiration to produce 
energy, together with anaerobic glycolysis (DIMAURO and SCHON 2003). The widely 
accepted hypothesis (although it has been questioned by some researchers) for the 
origin of mitochondria is endosymbiosis (MARGULIS 1970). It has been suggested 
that mitochondria evolved from eubacteria like precursors via endosymbiosis (LANG 
et al. 1997). More specifically members of the rickettsial subdivision of α-
proteobacteria, a group of obligate intracellular parasites such as Rickettsia, 
Anaplasma and Ehrlichia, are considered to be the closest relatives of mitochondria 
(GRAY et al. 1999). The mechanism of this symbiotic event is not known, but could 
be linked to the increase in atmospheric oxygen (LANE 2005). One strong selective 
pressure for the evolution of mitochondria may have been the increase in oxygen in 
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the atmosphere and the oceans, which selected for new biochemical pathways needed 
to survive in the oxygen-rich environment. The advantage of having mitochondria 
lay in the fact that cells were able to use the newly available atmospheric oxygen to 
generate energy. In the original endosymbiotic hypothesis it was proposed that an 
early eukaryotic cell engulfed an aerobic eubacterium. There are several classes of 
single celled eukaryotes (all classified under the group archezoa, including 
V.necatrix, Nosema, Entamoeba histolytica, Giardia lamblia) that lack mitochondria, 
that would seem to support this hypothesis. However, studies over the last 15 years 
have shown that all extant eukaryotes that lack mitochondria that have been analysed 
did at one time contain mitochondria, which have subsequently been lost (discussed 
in (LANE 2005)). Therefore the evolution of mitochondria may have occurred 
simultaneously with the occurrence of eukaryotic cells and so may have been the 
defining event that allowed eukaryotic cells to proliferate and populate the planet (as 
proposed by Nick Lane, (LANE 2005)). Also there is now evidence the symbiotic 
event may have occurred between a methanogen (a bacteria that uses sulphur as a 
carbon source) and a eubacterium, which existed in an oxygen deficient environment. 
Whatever the origin of mitochondria there is a strong argument to suggest that they 
have been a major driving force in the shaping the evolution of multi-cellular life.  
So why is this small organelle crucial for eukaryotic cells? The primary answer is 
summarized by one word: energy. It was first hypothesized in 1912 by B.F. 
Kingsbury that mitochondria were the respiratory centres of the cells (ERNSTER and 
SCHATZ 1981). This was proved to be the case in 1949 by Eugene Kennedy and 
Albert Lehninger, when they showed that respiratory enzymes are located in 
mitochondria (KENNEDY and LEHNINGER 1949). The primary function of 
mitochondria is to supply energy for the cell in the form of ATP and so they are often 
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referred to as the „power house‟ of the cell. Most processes in cells depend in some 
way on the energy supplied by mitochondria. Mitochondria also have roles in 
biochemical pathways such as the citric acid cycle, β-oxidation of fatty acids, 
biosynthesis of haem and they are also key organelles regulating calcium signalling 
and apoptosis. 
 
1.1.2  The structure and function of mitochondria 
 
The double membrane structure of mitochondria reflects their function in ATP 
production and their architecture was revealed nearly half a century ago by electron 
microscopy (PALADE 1953). Mitochondria are formed of four compartments, the 
outer mitochondrial membrane (OMM), the inner mitochondrial membrane (IMM), 
the intermembrane space (IMS) and the matrix. The IMM is folded inside the matrix 
forming structures known as cristae (Figure 1.1). Electron microscopic images taken 
from cross sections of cells revealed the kidney-shaped or bean-shaped structure of 
mitochondria. However advances in confocal microscopy have shown that 
mitochondria are found in dynamic and interconnected networks (Figure 1.1) 





Figure 1.1 Structure of mitochondria. 
Kidney shaped cartoon illustration shows the double membrane morphology and 
electron microscopy shows similar structures (on left). Immunofluorescence reveals 
the tubular and interconnected network (green). Adapted from Westermann 2010 
(WESTERMANN 2010). 
 
Oxidative phosphorylation (OXPHOS), is the process responsible for synthesizing 
ATP by the passage of electrons through the electron transport chain (ETC) (Figure 
1.2). The ETC consists of five multiprotein complexes (complex I to complex V) and 
two electron carriers (coenzyme Q and cytochrome c) (Figure 1.2) (HATEFI 1985; 
SARASTE 1999). These complexes are located in the IMM and so the efficiency of the 
ETC is increased by the folded structure of the cristae, which increases the surface 
area of the IMM (PERIER and VILA 2012). The passage of electrons (derived from the 
oxidation of NADH and FADH2 in intermediary metabolism) through the first four 
ETC complexes results in a proton gradient across mitochondrial membrane. More 
specifically, pumping of H
+
 across the IMM by complex I (NADH hydrogenase), 
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complex III (cytochrome c reductase) and complex IV (cytochrome c oxidase) 
generates the proton gradient which allows complex V (ATP synthase) to use this 
proton gradient to convert ADP to ATP. ATP is transported to the cytosol by 
adenosine nucleotide translocators in the IMM and OMM (PERIER and VILA 2012). 
ATP synthesis via OXPHOS from the primary energy source glucose is 
advantageous for the cell compared to glycolysis. Glycolysis occurs in the cytosol 
and converts glucose to pyruvate resulting in production of 2 ATP molecules. 
However, once pyruvate is transported into mitochondria, it is converted into 8 
NADH, 2 FADH2 and 2 ATP molecules by the TCA (tricarboxylic acid) cycle. 
Energy stored in 8 NADH and 2 FADH2 are converted into 32 ATP molecules by 
OXPHOS under optimal conditions (LIEMBURG-APERS et al. 2011). This shows that 
ATP production via OXPHOS is highly advantageous to eukaryotic cells compared 
to glycolysis. It is interesting to note that prokaryotes use the cellular membrane to 
generate a proton gradient that drives an ATP synthase and so this represents a 
universal mechanism for energy generation (Figure 1.2).  
The action of the ETC also generates reactive oxygen species (ROS) via complex I 
and complex III. Under normal conditions antioxidant mechanisms such as the ROS-
scavenging enzyme SOD2 (superoxide dismutase) functions to reduce ROS levels 
(ANDREYEV et al. 2005). ROS can damage various macromolecules including lipids, 
proteins and nucleic acids (MURPHY 2009). Complex I and complex III both have 
nuclear and mitochondrial encoded subunits and therefore mutations in both 
genomes can increase ROS production (FUKUI and MORAES 2009). Increased ROS 
production has also been linked to neurodegenerative diseases (see below). 
The ETC complexes are multimeric complexes each formed of different number of 
subunits. Complex I is formed of 46 subunits, complex II (succinate dehydrogenase-
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ubiquinone oxireductase) is much smaller and formed of 4 subunits, whereas 
complex III, IV and V are formed of 11, 14 and 16 subunits respectively. Most of the 
components of the OXPHOS system are encoded by the nuclear genome. However 
13 of these components (in complex I, III, IV and V, but none of complex II) are 
encoded by the mitochondrial genome (Figure 1.2). Mitochondria are the only 
organelle in most animal cells to have their own genome, known as mitochondrial 
DNA (mtDNA). Correct assembly of the OXPHOS complexes is crucial for the 
function of the ETC and mutations in either of the nuclear or mitochondrial genome 
can result in mitochondrial respiratory chain diseases (reviewed in (DIMAURO and 
SCHON 2003; FERNANDEZ-VIZARRA et al. 2009)). OXPHOS deficiency can result in 
a wide range of phenotypes. Cells that cannot produce ATP using the OXPHOS 
system shunt pyruvate to lactate to produce ATP instead and this results in lactic 
acidosis (BREUER et al. 2012). Therefore aerobic respiration using the OXPHOS 
system is highly advantageous both for maintaining healthy cells and supplying 
enough energy. 
The OXPHOS system, shown in figure 1.2, is formed of five separate complexes, 
however recent studies have demonstrated the existence of higher-order structures, so 
called “supercomplexes” (SHOUBRIDGE 2012). These respiratory supercomplexes are 
made up of two or more individual respratory chain complexes and can help to 
increase the efficiency of electron transport, control ROS levels, or increase 
individual complex stability (BOEKEMA and BRAUN 2007). Three independent 
studies characterized the Rcf1 protein as a supercomplex assembly factor (using 
baker‟s yeast) (CHEN et al. 2012; STROGOLOVA et al. 2012; VUKOTIC et al. 2012). 
This protein is a member of the hypoxia inducible group 1 (HIG1) family and has 
two human homologs, HIGD1A and HIGD2A. Rcf1 has roles in the assembly of the 
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complex III/complex IV supercomplex by incorporating peripheral complex IV 
subunits (cox13, the human coxVIa homologue) (CHEN et al. 2012; STROGOLOVA et 
al. 2012; VUKOTIC et al. 2012).  
There are approximately 1500 proteins in the mitochondrial proteome (CALVO and 
MOOTHA 2010). The vast majority of these proteins are encoded by the nuclear 
genome and transported to mitochondria. However, 13 of these proteins are encoded 
by mtDNA. All of these 13 polypeptides encoded by mtDNA have roles in the 
OXPHOS system. The remaining OXPHOS proteins, which number around 100, are 
encoded by the nuclear genome. The remaining >1000 proteins in mitochondria are 
also encoded by the nuclear genome and function in processes such as maintenance 
and expression of mtDNA, mitochondrial protein synthesis, mitochondrial 
proteolysis, mitochondrial protein import, mitochondrial morphology, iron-sulfur 
cluster synthesis, citric acid cycle metabolism and fatty acid oxidation (LARSSON 
2010). Therefore, the interplay between the nuclear and mitochondrial genome is 







Figure 1.2 Schematic representation of mitochondrial ETC complexes.  
The respiratory chain is localized in the inner mitochondrial membrane (IMM). The 
OXPHOS system is formed of approximately 100 proteins and 13 of them are 
encoded by mtDNA (shown in yellow). H
+
 ions are pumped through the IMM and 
electrons are transported through the ETC complexes resulting in ATP synthesis. 
Adapted from Perier 2012(PERIER and VILA 2012). 
 
1.2 The Mitochondrial Genome  
 
1.2.1  General Properties of mtDNA 
 
It is nearly 50 years since the discovery of mtDNA in chicken tissue sections by 
electron microscopy, where it was described as „intramitochondrial fibrous material 
with DNA characteristics‟ (NASS and NASS 1963a; NASS and NASS 1963b). After the 
discovery of the mitochondrial genome, further studies showed the existence of DNA 
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in mitochondria in various different cell types and organisms. mtDNA has 
fundamentally the same evolutionarily conserved role in all eukaryotes, to encode a 
limited number of RNAs and proteins to maintain mitochondrial function 
(TZAGOLOFF and MYERS 1986).  
Many of the nuclear encoded mtDNA related proteins are evolutionarily conserved. 
For example, sequence alignment of the mtDNA polymerase (Polγ) from multiple 
organisms (S. cerevisiae, S. Pombe, P. pastoris, D. melonagaster, X. laevis and M. 
musculus) showed that they exhibit sequence similarity and belong to the same 
family of polymerases (LECRENIER et al. 1997). 
The size and structure of mtDNA was first reported over 40 years ago using mtDNA 
from human leukaemic leucocytes (CLAYTON and VINOGRAD 1967). Another 
keystone in mitochondrial research was the sequencing of the mtDNA, which was 
considered as the initiation of the Human Genome Project (ANDERSON et al. 1981; 
ANDREWS et al. 1999). Although the function of mtDNA is conserved, it has 
variations in conformation, size, as well as gene content and expression between 
species (CUMMINGS 1992). For example, genome size varies between <6kb in the 
human malaria parasite to >200 kb in land plants, due mostly to variation in the size 
of the noncoding D-loop region (GRAY et al. 1999). The human mitochondrial 
genome is a circular, double-stranded 16,569bp molecule (Figure 1.3) (ANDERSON et 
al. 1981). Human mtDNA is compact and very gene-dense containing 37 genes of 
which 13 encode components of the OXPHOS system, 22 are tRNAs and 2 are 
rRNAs required for translation of the 13 polypeptides (FALKENBERG et al. 2007). 
There are no introns in mtDNA genes and non-coding bases between genes are very 
few. The only non-coding region is the D-loop, which contains control elements for 
mtDNA replication and transcription and is 1.1kb in human mtDNA (SHADEL and 
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CLAYTON 1997). The two strands of the mtDNA are known as the heavy (H) and the 
light (L) strand and each has a different pyrimidine versus purine content (ANDREWS 
et al. 1999). 
 
Figure 1.3 Map of human mtDNA. 
The D-Loop is the non-coding region (shown in blue). The genes encoded by 
mtDNA are shown in different colours depending on whether they are encoded on 
the heavy strand or the light strand Adapted from Falkenberg 2007(FALKENBERG et 
al. 2007). 
 
1.2.2  Mitochondrial transcription and translation 
 
Mitochondrial transcription and translation (Figure 1.4) are dependent on the nuclear 
genome since the proteins needed for these processes are encoded by nuclear DNA 
and imported into mitochondria (FALKENBERG et al. 2007). Mitochondria have their 
own ribosomes, which are structurally similar to bacterial ribosomes (RORBACH et al. 
2007). Transcription of mtDNA is also important for mtDNA replication as it 
produces RNA primers required for the initiation of mtDNA replication at the OH  
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replication origin (FALKENBERG et al. 2007). The core proteins required for 
mitochondrial transcription are mitochondrial RNA polymerase (POLRMT), 
mitochondrial transcription factor B2 (TFB2M) and mitochondrial transcription 
factor A (TFAM) (FALKENBERG et al. 2002). These three proteins are necessary for 
transcription of mtDNA encoded genes, while other factors modulate the activity of 
this process, such as mitochondrial transcription termination factors (MTERF1-4) 
(LINDER et al. 2005). TFAM is of particular importance as POLRMT and TFB2M 
will not even initiate transcription in the absence of TFAM (GASPARI et al. 2004). 
Moreover, recombinant TFAM together with partially purified POLRMT is 
sufficient for transcription activation in vitro (DAIRAGHI et al. 1995; FALKENBERG et 








Figure 1.4 mtDNA transcription and translation 
Nuclear encoded factors are needed for mtDNA replication and transcription. There 
are 13 mRNAs, 22tRNAs and 2 rRNAs (12S and 16S rRNA) transcribed from 
mtDNA. 2 rRNAs and other nuclear encoded ribosomal proteins make 
mitoribosomes. Various other nuclear encoded factors are transported into 
mitochondria to synthesize the 13 polypeptides. This process is composed of three 
steps: posttranscriptional modification (1), polyadenylation (2) and tRNA processing 
(3). Adapted from Smeitink 2001(SMEITINK et al. 2001).  
 
1.2.3  MtDNA replication 
 
MtDNA is maternally inherited and the copy number in each cell varies between 
tissues depending on the energy demand (TAYLOR and TURNBULL 2005). In order to 
have an adequate mtDNA copy number it has to be replicated at a rate required to 
meet the energetic needs of the cell. The mitochondrial DNA polymerase, Polγ, is the 
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sole DNA polymerase in mitochondria and is found in a heterotrimeric form, 
consisting of the catalytic subunit Polγ-α and the dimeric accessory subunit Polγ-β 
(KAGUNI 2004). The catalytic subunit is 140 kDa in size and has 3‟-5‟ exonuclease 
and 5‟ dRP (5‟-deoxyribose phosphate) lyase activity. Together with this activity, 
Polγ catalyzes the release of the 5‟ terminal sugar from apurinic/apyrimidinic sites 
and fills the single nucleotide gap by generating a substrate for DNA ligase 
(LONGLEY et al. 1998). The accessory subunit is 55 kDa in size and is needed for 
tight DNA binding and processive DNA synthesis (GRAZIEWICZ et al. 2006; LIM et 
al. 1999). A DNA helicase, Twinkle, that unwinds mtDNA in the 5‟ to 3‟ direction is 
also required for mtDNA replication (KORHONEN et al. 2003). The mtDNA single 
stranded binding protein (SSBP) stabilizes the single strand once it is unwound by 
Twinkle (VAN TUYLE and PAVCO 1985). The core factors needed for the mtDNA 
replication are Polγ-α, Polγ-β, Twinkle and SSBP (Figure 1.5). The mtDNA 
replisome consists of these proteins and has been shown to be sufficient to synthesize 






Figure 1.5 The mtDNA replication fork. 
Diagram shows the factors needed for replication and maintenance of mtDNA, which 
all are encoded by the nuclear genome and are transcriptionally regulated by NRF1. 
The replication fork consists of mtDNA (in blue) and factors that have a direct role in 
mtDNA replication: Polγ (α and β subunits), Twinkle (helicase), SSBP (single strand 
binding protein), TOPO (topoisomerase) and TFAM (mitochondrial transcription 
factor A). The mitochondrial dNTP pool is supplied by TP (thymidine 
phosphorylase), TK2 (thymidine kinase 2), DGUOK (deoxyguanosine kinase) and 
p53R2 (ribonucleotide reductase subunit). There are other factors such as MPV17 (a 
mitochondrial membrane protein) and HSP40 (a mitochondrial chaperone) which 
when inactivated can inhibit mtDNA replication. Adapted from Tynissima 2009 
(TYYNISMAA and SUOMALAINEN 2009). 
 
The mechanism of mammalian mtDNA replication is under debate. There are two 
possible models, the strand-displacement model and the strand coupled model 
(Figure 1.6) (BOGENHAGEN and CLAYTON 2003b).  The strand-displacement model, 
based on data from electron microscopy and end-mapping of mtDNA (CLAYTON 
1982), states that replication begins with the leading-strand (known as the heavy 
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strand because it is guanine rich) synthesis from OH (origin of replication for the 
heavy strand) proceeding for a significant distance before the initiation of lagging 
strand synthesis. Lagging strand (also known as the light strand) synthesis starts from 
OL (origin of replication for the light strand), which is exposed when two thirds of 
the genome has been replicated by leading strand synthesis. This mode of replication 
does not result in Okazaki fragments and is therefore classified as unidirectional, 
continuous and asymmetric (BOGENHAGEN and CLAYTON 2003a; BOGENHAGEN and 
CLAYTON 2003b; LARSSON 2010). The bidirectional model was developed through 
studies using 2DAGE (2D-gel electrophoresis) (HOLT et al. 2000; REYES et al. 2005; 
YANG et al. 2002). This technique is based on application of restriction-enzyme 
digested DNA to a native gel, firstly in the absence of ethidium bromide (EtBr; the 
first dimension) and then in the presence of EtBr (the second dimension) (BREWER 
and FANGMAN 1987). Three types of patterns were observed when 2DAGE was used 
to analyse mtDNA replication: (i) spots, which represent fragments that are not 
involved in replication, (ii) Y-arcs, which represents fragments involved in 
replication and do not contain an origin and (iii) bubble-arcs, which represent 
fragments containing replication origins (OH and OL). This showed that one class of 
replication intermediates (RIs) was resistant to single strand nuclease digestion and 
mobility of these RIs represents coupled leading and lagging strand synthesis (HOLT 
et al. 2000). Both the models have both supporting and contradictory data and more 
work needs to be done in order to understand if the differences observed are real or 
experimental artefacts (STUMPF and COPELAND 2011). It is possible that both modes 





Figure 1.6 Two models of mtDNA replication. 
 (a) mtDNA replication starts unidirectionally from OH and as the leading strand 
(red) reaches the OL, lagging strand synthesis starts. (b) Lagging strand synthesis can 
be initiated at multiple sites and can result in discontinuous synthesis of Okazaki 
fragments. Adapted from Bogenhagen 2003 (BOGENHAGEN and CLAYTON 2003b). 
 
1.2.4 The mtDNA nucleoid 
 
Understanding the morphological features of mtDNA was one of the milestones in 
mtDNA research. mtDNA is not naked but is found in nucleoprotein complexes 
called nucleoids (GARRIDO et al. 2003).  The precise number of proteins interacting 
with and maintaining mtDNA is not known, but may be around 30 (CHEN and 
BUTOW 2005). Cross-linking studies have been used to identify nucleoid proteins in 
yeast, xenopus and HeLa cells (BOGENHAGEN et al. 2003; KAUFMAN et al. 2000; 
WANG and BOGENHAGEN 2006). These studies identified known DNA binding 
proteins and replication factors, but also several metabolic proteins not previously 
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thought to interact with mtDNA. However, several of these „bifunctional proteins‟ 
have been shown to be required for mtDNA maintenance and to directly bind 
mtDNA (BATEMAN et al. 2002a; BATEMAN et al. 2002b; CHEN and BUTOW 2005). 
These studies identified and classified nucleoid proteins based on their co-
purification with mtDNA after formaldehyde cross-linking. In contrast, Larsson 
suggested much stricter criteria for the characteristics of nucleoid proteins : (i) the 
protein should interact with mtDNA (by copurification or cross-linking); (ii) the 
protein should have intrinsic biophysical properties consistent with packaging DNA; 
(iii) the protein should be sufficiently abundant to coat mtDNA; (iv) the protein 
should colocalize with mtDNA by high-resolution microscopy; (v) the protein should 
be essential for maintenance of mtDNA in vivo (PARK and LARSSON 2011). To date 
TFAM is the only protein that fulfils all of these criteria (ALAM et al. 2003; PARK 
and LARSSON 2011). Apart from its roles in mitochondrial transcription TFAM 
packages mtDNA (ALAM et al. 2003). Human TFAM is a 25.6kDa high mobility 
group (HMG) protein, since it has two HMG boxes (Figure 1.7A) (KANKI et al. 
2004; PARISI and CLAYTON 1991; RUBIO-COSIALS et al. 2011). The yeast homologue 
of TFAM, ABF2, can bend, unwind and package DNA (FISHER et al. 1992; 
KAUFMAN et al. 2007). Studies in mice have shown that there is one TFAM molecule 
per 10-20 bp of mammalian mtDNA (EKSTRAND et al. 2004; PELLEGRINI et al. 
2009). More precise visualization and calculations showed that there is one TFAM 
molecule per 16.6 bp of mtDNA (KUKAT et al. 2011). The mechanism of packaging 
of mtDNA by TFAM has been investigated using X ray crystallography. These 
studies showed that TFAM shapes mtDNA, forcing a U-turn in the DNA by 
reversing the direction of DNA helix (NGO et al. 2011; RUBIO-COSIALS et al. 2011). 
To achieve this, the two HMG boxes in TFAM bend DNA 90
0 
each and the linker 
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region interacts with the bent DNA resulting a reversal in direction. It is also 
believed that this bending of mtDNA by TFAM can result in organizing the 
transcription initiation complex, similar to the role of the TATA-box binding protein 
(TBP) in nuclear transcription. More specifically, this results in placing the C-
terminus of TFAM (which is important for transcription activation) close to the 
transcription start site, which is occupied by the POLRMT-TFB2M complex 
(DAIRAGHI et al. 1995; HALLBERG and LARSSON 2011; SOLOGUB et al. 2009). Future 
studies will further elucidate the dual-role of TFAM in mtDNA nucleoid structure 
and mtDNA transcription, but the current model is shown in figure 1.7B.  
In order to understand mtDNA organization and dynamics various tools have been 
used to visualize mtDNA nucleoids. A  GFP tagged form of the Twinkle helicase 
was found to colocalise with mitotracker, which is a mitochondrial specific dye 
(SPELBRINK et al. 2001). TFAM and mtSSB have also been shown in imaging studies 
to colocalise with nucleoids (GARRIDO et al. 2003). Other studies reported that 
mtDNA nucleoids are punctate structures which are enriched in TFAM, as shown in 
figure 1.7C (LEGROS et al. 2004). Antibody staining against DNA showed an 
overlapping staining pattern with TFAM puncta (LEGROS et al. 2004). These studies 
all used confocal microscopy to visualise nucleoids and nucleoid proteins. Confocal 
microscopy is limited by the diffraction limit of light and so cannot accurately 
resolve structures below approximately 0.5 µm, which is the upper range of the size 
of mtDNA nucleoids. Super-resolution microscopy has therefore been used to more 
accurately determine the characteristics of nucleoids. Two studies have used this 
approach, one using stimulated emission depletion (STED) microscopy (KUKAT et 
al. 2011) and another using structure illumination microscopy (SIM) (KOPEK et al. 
2012). In the study carried out by Kukat and co-workers, it was shown that nucleoids 
35 
 
have a uniform size of around 100 nm, in cultured mammalian cells, compared with 
300 nm measured by confocal microscopy and that there is usually one copy of 
mtDNA (average 1.4 molecules) per nucleoid (KUKAT et al. 2011).  This was 
surprising as it had been reported previously that each nucleoid contains multiple 
copies of the mitochondrial genome, such as 6 to 10 copies (IBORRA et al. 2004), 2 to 
8 copies (LEGROS et al. 2004) or 5 copies (GILKERSON et al. 2008). The finding of a 
single copy per nucleoid is consistent with the so-called “faithful” model of mtDNA 
inheritance, which posits that nucleoids do not exchange DNA with each other 
(GILKERSON et al. 2008; KUKAT et al. 2011). Furthermore, studies performed by 
Kopek and Brown have shown that nucleoids can vary in size resulting from 
differences in sample preparation and labelling techniques (e.g. antibody labelling 
versus protein fusions) (BROWN et al. 2011; KOPEK et al. 2012). Future studies will 
be required to directly compare results obtained using different super-resolution 
techniques, and importantly, to study the properties of nucleoids in vivo, rather than 






















Figure 1.7 The structure and localization of TFAM. 
 (A) The structure of TFAM protein (adapted from Rubio-Cosials 2011). (B) TFAM 
packages mtDNA by introducing U-turns (adapted from Hallberg 2011). (C) TFAM 
is associated with nucleoids. Green is TFAM staining, red is TOM20 staining 
showing the mitochondrial network and blue is nuclear staining using DAPI. 
Differences in the resolution using confocal and STED microscopy are compared. 
Adapted from Kukat 2011(KUKAT et al. 2011). 
 
1.3  Mitochondrial dynamics and mitochondrial diseases  
 
1.3.1  Mitochondrial diseases 
 
Mitochondrial dysfunction can lead to human disease and mitochondrial disorders 
are one of the most common inherited disorders of metabolism (SCHAEFER et al. 
2008). Recent studies have described the prevalence of mitochondrial disease to be 
around at least 1 in 5,000 (YLIKALLIO and SUOMALAINEN 2011). The first disease 
described as a mitochondrial disorder was a case of hypermetabolism with defects in 
the maintenance of mitochondrial respiratory control (LUFT et al. 1962). The 
symptoms of mitochondrial diseases are very diverse, reflecting the broad function of 
mitochondria in different tissues. Transmission of mitochondrial diseases can be 
maternal, autosomal or X-linked due to the dual control of the organelle by nuclear 
and mitochondrial genomes. Since most of the mitochondrial proteins are encoded by 
the nuclear genome, most of the mitochondrial diseases are caused by defects in 
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nuclear encoded proteins. I will firstly summarize the mechanisms causing 
mitochondrial diseases and then focus specifically on mtDNA related disorders. 
In addition to its roles in the biosynthesis of amino acids and steroids, oxidation of 
fatty acids and apoptosis, the main function of the mitochondrion is to produce ATP 
through the combined efforts of the TCA and OXPHOS systems. Most of the 
syndromes characterized as mitochondrial diseases result from OXPHOS defects and 
clinical symptoms include neuronal seizures, myoclonus ataxia, progressive muscle 
weakness, stroke-like episodes and cognitive impairment (DIMAURO and SCHON 
2003). Mitochondrial dysfunction has been implicated in various neurodegenerative 
diseases including Alzheimer‟s disease (AD), amyotrophic lateral sclerosis (ALS), 
Charcot-Marie-Tooth disease (CMT), Huntington‟s disease (HD), hereditary spastic 
paraplegia (HSP), optic atrophy (OA), Parkinson‟s disease (PD) and spinocerebellar 
ataxia (SCA) (SCHON and PRZEDBORSKI 2011). 
The dynamic nature of mitochondria is very important for the regulation of cellular 
redox status, mtDNA integrity, organellar function and cell death (LIESA et al. 2009). 
Defects in the proteins involved in mitochondrial dynamics can result in 
developmental abnormalities, neuromuscular degeneration and metabolic disorders 
(CHEN and CHAN 2009). Mitochondrial transport, fusion and fission of mitochondria 
and mitochondrial turnover are the main processes important for the dynamic nature 





Figure 1.8 Roles of mitochondrial dynamics.  
The processes that regulate the dynamic nature of mitochondria are fusion, fission 
(division), transport and mitophagy. Mitochondria with high membrane potential are 
shown in red and the ones with low membrane potential are in blue. Factors/proteins 
having roles in these processes are shown in blue circles. Adapted from Nunnari 
2012(NUNNARI and SUOMALAINEN 2012). 
 
1.3.2  Mitochondrial transport 
 
One of the key advances in the understanding of mitochondrial dynamics was the 
investigation of mitochondria using live imaging microscopy. These studies showed 
that mitochondria are motile organelles which move along the cytoskeleton 
(HOLLENBECK and SAXTON 2005). Mitochondrial dynamics in neurons is of 
particular importance since neurons have a highly polarised morphology and each 
compartment has different energy requirements. The main compartments of the 
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neuron are the cell body (soma), the axon, the dendrites and the synapse. The areas 
with particularly high energy demands are the presynaptic and postsynaptic 
terminals, active growth cones or axonal branches and the nodes of Ranvier, which 
contain more mitochondria than other parts of the cell (SHENG and CAI 2012). 
Axonal anterograde and retrograde transport of mitochondria occur along 
microtubules using multiple kinesin family members and cytoplasmic dynein 
molecules. Apart from this bidirectional movement, mitochondria frequently change 
direction, pause or switch to persistent docking (SHENG and CAI 2012). This allows 
the cell to transport healthy mitochondria generated in the soma to the parts of the 
neuron with high energy demands and metabolic requirements. Mitochondrial 
transport is an essential process for neuronal development and defects can contribute 
to neurodegenerative diseases such as AD (RUTHEL and HOLLENBECK 2003; STOKIN 
and GOLDSTEIN 2006). Two classes of proteins with important roles in mitochondrial 
transport are the kinesin superfamily proteins (KIFs) and the cytoplasmic dyneins. 
KIF5 (also known as kinesin1) has roles in anterograde transport (CAI et al. 2005). In 
Drosophila Milton is a well characterized motor adaptor protein that interacts with 
KIF5 and mitochondrial rho (MIRO) (a RHO family GTPase on the mitochondrial 
outer membrane) and takes part in anterograde mitochondrial transport. Mutations in 
MIRO cause depletion of mitochondria in distal synaptic terminals (GORSKA-





1.3.3 Mitochondrial fusion and fission 
 
The main processes regulating mitochondrial shape and size are fission and fusion. 
Continuous cycles of fission and fusion are controlled by conserved fission and 
fusion promoting factors. The fusion promoting factors in humans are the mitofusins 
(Mfn1 and Mfn2) and optic atrophy1 (Opa1), whereas fission is mainly regulated by 
dynamin-related protein 1 (Drp1). Drp1 is a cytosolic protein, while Opa1 and Mfn 
localise to the inner and outer mitochondrial membrane respectively (DETMER and 
CHAN 2007). The balance between these proteins determines the morphology of 
mitochondria throughout the cell. Mutations in fusion-related proteins have been 
linked with several diseases, such as mutations in Mfn2, which result in Charcot-
Marie-Tooth type 2A (CMT2A) that affects sensory and motor neurons (ZUCHNER et 
al. 2004). Additionally, autosomal dominant optic atrophy (DOA), which results in 
degeneration of retinal ganglia cells, can be caused by mutations in OPA1 
(ALEXANDER et al. 2000; DELETTRE et al. 2000). Mutations in the Mfns and Opa1 in 
mice cause embryonic lethality and mitochondrial dysfunction (ALAVI et al. 2007; 
CHEN et al. 2003; DAVIES et al. 2007). In yeast decreased fission result in 
longitudinal and interconnected tubular mitochondria, whereas decreased fusion 
results in fragmented mitochondria (SESAKI and JENSEN 1999). 
The correct functioning of mitochondrial dynamics is crucial for the segregation and 
transmission of mtDNA. Early studies carried out in yeast showed that mutations in 
Fzo1p and Mgm1p (Mfns and Opa1 orthologs) caused loss of mtDNA (HERMANN et 
al. 1998; RAPAPORT et al. 1998). Studies in mammals showed similar results in that 
the fusion proteins Mfns and Opa1 are required for mtDNA maintenance (CHEN et 
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al. 2007). It has also been reported that depletion of Drp1 results in mitochondrial 
dysfunction through mtDNA loss (PARONE et al. 2008). One explanation for the loss 
of mtDNA in these mutants is that mitochondrial fusion increases the tolerance of  
cells to mutant mtDNA and protects the integrity of mtDNA through intermolecular 
exchange (SEO et al. 2010). Fission and fusion may also have general protective 
effects on the mitochondrial network by buffering of the matrix contents (including 
mtDNA) (CHEN et al. 2007; CHEN et al. 2010).  
 
1.3.4  Mitochondrial turnover 
 
Mitochondrial turnover is controlled by two processes: mitochondrial biogenesis and 
mitochondrial specific autophagy (mitophagy). It is generally believed that 
mitochondrial biogenesis is inefficient in aged individuals (FANNIN et al. 1999; 
SUGIYAMA et al. 1993). Mitochondrial biogenesis can be adjusted by physiological 
stimuli such as exercise and calorie restriction. The major regulatory pathway for 
mitochondrial biogenesis is through the peroxisome proliferator-activated receptor-γ- 
coactivator 1α (PGC1-α) (SCARPULLA 2008; WU et al. 1999), and downstream of this 
includes the estrogen-related receptor-α (ERR-α), NRF-1, NRF-2 and Mfn2 
(CARTONI et al. 2005; SORIANO et al. 2006). Figure 1.9 shows the relationship 
between fusion/fission, mitochondrial biogenesis and mitophagy and highlights the 
interplay between these events (SEO et al. 2010). 
Degradation of dysfunctional mitochondria is a key process in maintaining a robust 
mitochondrial network. Cells eliminate dysfunctional and damaged mitochondria 
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through the autophagic process, which involves lysosomal degradation of cellular 
components by hydrolytic enzymes (HE and KLIONSKY 2009). One of the main 
functions of autophagy is to supply recycled molecules to the cell under nutrient 
deprivation. Autophagy also functions as a quality control mechanism by degrading 
dysfunctional organelles and protein aggregates. In mitophagy, defective 
mitochondria are labelled by other proteins that are recognised by the autophagy 
machinery. It has been shown in yeast that this process is independently regulated 
from bulk autophagy (KANKI and KLIONSKY 2008). Dysfunctional mitochondria 
have low membrane potential and presumably high ROS levels due to a 
dysfunctional OXPHOS system, which results in their elimination by the autophagic 
machinery (TWIG and SHIRIHAI 2011). The mitochondrial fusion/fission machinery is 
closely linked to mitophagy, such that loss of fusion or increased fission correlates 
with increased mitophagy; overexpression of Drp1 results in mitophagy under pro-
apoptotic stimuli (ARNOULT et al. 2005). Although fission is an important process for 
the clearance of mitochondria, it is hypothesized that it is permissive for mitophagy 
rather than directly activating it, since only a small percentage of fragmented 
mitochondria are cleared by mitophagy (TWIG et al. 2008b). Several studies have 
shown that increased fission, via Opa1 knockdown, can result in reduced 
mitochondrial size and increased autophagy (CHEN and CHAN 2005; CIPOLAT et al. 
2004). Mitochondrial fusion is also implicated in quality control as it can blunt or 
eliminate the deleterious effects of misfolded proteins or mutant mtDNA by mixing 
rare dysfunctional mitochondria with a functional network (GILKERSON et al. 2008; 
TWIG and SHIRIHAI 2011).  Defects in proteins responsible for mitochondrial quality 





Figure 1.9 Mitochondrial turnover. 
The relationship between the continuous fission/fusion cycle with biogenesis and 
degradation of mitochondria are represented by arrows. Adapted from Seo 2010 (SEO 
et al. 2010). 
 
1.3.5  Mitochondrial dysfunction in neurodegenerative diseases 
 
The brain is particularly dependent on mitochondrial generated energy since it 
represents 2% of body weight but consumes 20% of the available oxygen (COSKUN 
et al. 2012). Mitochondrial morphology and localisation in neurons is highly 
regulated and reflects the energetic requirements of specific compartments. As in 
other cell types, fusion/fission, transport and mitophagy regulate mitochondrial 
morphology and localisation in neurons (Figure 1.9). Mitochondrial defects in 




Mitochondrial dysfunction and abnormalities in the dynamics of mitochondria have 
been reported in neurodegenerative diseases such as AD, HD, ALS and PD 
(reviewed in (SHENG and CAI 2012)). Figure 1.10 is a schematic representation 
showing neurodegenerative diseases caused by defects in mitochondrial dynamics. 
One of the hallmarks of AD is the accumulation of β-amyloid (Aβ) containing 
plaques derived from APP (amyloid precursor protein). It has been reported that 
overexpression of APP in neurons results in mitochondrial fragmentation as a result 
of alterations in fusion/fission proteins (WANG et al. 2008). Furthermore, defects in 
mitochondrial axonal transport have been implicated in AD (STOKIN and GOLDSTEIN 
2006; WANG et al. 2009). HD is caused by mutations in the Huntingtin gene (HTT) 
and results in impaired energy metabolism, abnormal Ca
2+
 signalling and changes in 
mitochondrial membrane potential and mitochondrial structure (SEO et al. 2010). It 
was also reported that mutations in HTT can affect fusion/fission by altering Drp1 
localization (BOSSY-WETZEL et al. 2008). The HTT protein has been proposed to act 
as a molecular switch for organellar transport in neurons as a positive regulator of 
vesicular transport. Anteriograde transport is promoted when HTT is phosphorylated 
by Akt at serine 421 causing recruitment of kinesin-1, whereas un-phosphorylated 
HTT results in promotion of retrograde transport (COLIN et al. 2008). In support of 
this, mutations in HTT result in impaired axonal transport of mitochondria in neurons 
(CHANG et al. 2006; ORR et al. 2008; SONG et al. 2011; TRUSHINA et al. 2004).   
Another widely studied neurodegenerative disease is PD, which in the inherited form 
can be caused by defects in Parkin (PARK) and PINK1 (DODSON and GUO 2007). 
PD is the second most common neurodegenerative disease and is characterized by 
degeneration of dopaminergic neurons in the substantia nigra (EXNER et al. 2007). 
The PINK1 gene encodes a mitochondrially targeted Ser/Thr kinase and parkin 
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encodes an E3 ubiquitin-protein ligase. Some fraction of PINK1 protein is localized 
to mitochondria, while Parkin is mainly cytoplasmic (WHITWORTH and PALLANCK 
2009; ZHOU et al. 2008). More specifically, mutations in Park2 (which encodes 
Parkin) can cause the most common form of autosomal recessive juvenile 
parkinsonism (KITADA et al. 1998). In a Drosophila model of PD, parkin mutants 
were shown to cause dopaminergic cell loss (WHITWORTH et al. 2005). Furthermore, 
knockout of pink and parkin in Drosophila cause muscle degeneration and enlarged 
mitochondria (CLARK et al. 2006; GREENE et al. 2003) by promoting mitochondrial 
fission (DENG et al. 2008; POOLE et al. 2008). PINK1 knockdown in mouse 
dopaminergic neurons also results in swollen mitochondria (WOOD-KACZMAR et al. 
2008). However, in human PD patient PINK1 mutant fibroblasts fragmented 
mitochondria were reported, suggesting increased fission. Furthermore the same 
study showed that reduction of PINK1 in HeLa cells affected mitochondrial 
morphology and membrane potential and that this could be rescued by expression of 
parkin (EXNER et al. 2007). PINK1 and Parkin are also involved in mitochondrial 
quality control mechanisms (DAGDA and CHU 2009; NARENDRA et al. 2008; POGSON 
et al. 2011; WHITWORTH and PALLANCK 2009). It has been shown that Parkin can be 
selectively recruited to damaged mitochondria with decreased membrane potential 
and this leads to mitophagy (NARENDRA et al. 2008). This suggests that mutations in 
Parkin in PD patients may cause dysregulation of mitochondrial quality control. 
Furthermore PINK1 forms a complex with MIRO-Milton, which in turn can affect 
transport of mitochondria (WEIHOFEN et al. 2009). MIRO, which is a component of 
motor/adaptor complex on the mitochondrial surface can be phosphorylated by 
PINK1, which subsequently activates proteasomal degradation of MIRO in a Parkin-
dependent manner. Removal of MIRO also prevents mitochondrial movement and 
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results in quarantine of mitochondria prior to their clearance (KANE and YOULE 
2011; WANG et al. 2011). This shows the importance of PINK1 to label damaged 
mitochondria and prevent more global damage to other parts of the cell by blocking 
their transport. However, mitochondrial abnormalities in a mouse TFAM knockout 
were not dependent on Parkin activity; this will be discussed further in section 1.5.3. 
Therefore the importance of PINK1/Parkin still needs to be confirmed in other 
disease models. 
 
Figure 1.10 Neurodegenerative diseases caused by dysfunctional mitochondrial 
dynamics. 







1.4  mtDNA and disease 
 
1.4.1  Mitochondrial diseases caused by mutations in the mitochondrial 
genome. 
 
In order to study mtDNA diseases a multidisciplinary approach is essential linking 
clinical, histochemical and biochemical data obtained from relevant tissues 
(GREAVES et al. 2012; MCFARLAND et al. 2010). All mtDNA disorders result in 
defects in oxidative phosphorylation, regardless of the mutation (BETTS et al. 2004). 
COX (cytochrome c oxidase) deficiency is the most common and penetrant 
phenotype and was first reported in chronic progressive external ophthalmoplegia 
(cPEO) patients (JOHNSON et al. 1983).  COX/SDH (succinate dehydrogenase) 
immunohistochemical staining is commonly used to classify normal and deficient 
neurons in mitochondrial diseases  
Diseases caused by mutations in mtDNA were first reported in the late 1980‟s (HOLT 
et al. 1988; WALLACE et al. 1988). One of the mutations characterized was in an 
American Leber‟s hereditary neuropathy (LHON) pedigree, which is an ocular 
disease characterized by rapid onset blindness, caused by a mutation in mtDNA 
nt11778, encoding subunit 4 of the NADH dehydrogenase (complex I) (WALLACE et 
al. 1988). After the characterization of the first patients with mtDNA disorders, many 
other studies followed confirming the link between mtDNA mutations and disease 
(reviewed in (GREAVES et al. 2012; TAYLOR and TURNBULL 2005)). 
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The tissues affected in mtDNA disorders are highly variable. However tissues with a 
high metabolic demand such as the cerebellum, the extra-ocular muscles, heart, liver, 
smooth muscle of the colon, kidney and skeletal muscles are commonly affected. 
The true impact of mtDNA disease is hard to determine because of the tissue 
heterogeneity, the occurrence of multiple mutations and complex diagnostic criteria. 
In a study carried out in the north east of England it was reported that 9.2 in 100,000 
adults have mtDNA disease, while 16.5 in 100,000 children and young adults were at 
the risk of developing mtDNA disease (SCHAEFER et al. 2008). This makes mtDNA 
disorders one of the most common neuromuscular disorders. 
Mutant forms of mtDNA are usually found in a heteroplasmic state, i.e. the 
coexistence wild-type and mutant mtDNA in the same cell (LARSSON and CLAYTON 
1995). The proportion of mutant mtDNA versus wild-type is a critical factor in 
determining the severity of the disease. In mammalian cells there can be 1000-10000 
copies of mtDNA per cell. This ensures that mutations in a single copy do not affect 
overall mitochondrial function (TRIFUNOVIC and LARSSON 2008). However, clonal 
expansion of mtDNA copies can still result in mitochondrial dysfunction. 
Furthermore, stochastic inheritance of mtDNA molecules during cell division can 
result in daughter cells with high amounts of mutant mtDNA. It is widely believed 
that there is a “critical threshold” of mutant mtDNA copies above which disease 
symptoms will manifest.  This threshold ranges from 90% mutant mtDNA copies for 
some tRNA mutations to 60% for mtDNA deletions (LARSSON and CLAYTON 1995; 
WALLACE and FAN 2009) (Figure 1.11). MtDNA nucleoid segregation during cell 
division is poorly understood, but could be critical in regulating heteroplasmy and 
thus the severity of mtDNA diseases. 
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Primary mtDNA disorders (disorders caused by mutations in the mitochondrial 
genome) are mostly caused by single large-scale deletions and there are more than 
120 different characterized deletions published in mitochondrial databases 
(www.mitomap.org, MITOMAP, 2009). These deletions mostly occur at tandem 
repeat sequences and are formed by aberrant repair of damaged mtDNA in somatic 
tissues and are sporadic and not transmitted to offspring (CHINNERY et al. 2004; 
KRISHNAN et al. 2008; SCHON et al. 1989). The most common diseases observed 
caused by mtDNA deletions are Pearson‟s syndrome, Kearns-Sayre syndrome (KSS) 
and cPEO, which usually result from a single large scale deletion affecting more than 
one gene (MORAES et al. 1989; ROTIG et al. 1990; ZEVIANI et al. 1988). Point 
mutations in protein encoding and mitochondrial rRNA and tRNA genes also cause 
primary mtDNA disorders. Mutations in rRNA and tRNA genes cause defects in 
overall mitochondrial protein synthesis, while mutations in protein encoding genes 
result in abnormalities in individual respiratory chain complexes (MARIOTTI et al. 
1994). One of the most common mitochondrial disorders caused by point mutations 
is LHON, which is caused by three mutations (3460 G>A, 11778G>A and 
14484T>C) affecting ND1, ND4 and ND6 respectively (HOWELL et al. 1991; JOHNS 
et al. 1992; WALLACE et al. 1988). Another common mtDNA disease is Leigh 
syndrome, which results from a mutation (8993T>C) in the ATP6 gene (SHOFFNER et 
al. 1992).  MELAS (mitochondrial encephalomyopathy with lactic acidosis and 
stroke-like episodes) is another common disease resulting from individual mutations 
in TRNL1 (3243A>G and 3271T>C), and ND1 and ND5 genes (GOTO et al. 1990; 




Figure 1.11 Clonal expansion of mutated mtDNA molecules. 
MtDNA mutations occur frequently and low levels of mutated mtDNA do not result 
in dysfunction. mtDNA is replicated independent from the cell cycle and postmitotic 
cells can have mtDNA replication. Mitotic segregation of mtDNA can result in cells 
with high amounts of mutated mtDNA. Adapted from Larsson 2010 (LARSSON 
2010). 
 
1.4.2  Mitochondrial diseases caused by mutations in nuclear genes  
 
There are two genetic mechanisms that can result in defects in mitochondrial 
function. The first is from maternally inherited mutations in the mtDNA. The second 
is via mutations in nuclear encoded mitochondrial genes. Proteins encoded by the 
nuclear genome that function in mtDNA replication have been frequently found to 
cause mtDNA-related disorders. mtDNA related nuclear genes that cause disease fall 
into two categories: those that directly affect the mtDNA replication fork (such as the 
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mtDNA polymerase Polγ and the helicase Twinkle) and genes that affect the supply 
of nucleotides for mtDNA replication (such as the mitochondrial thymidine kinase 
TK2, the deoxguanosine kinase dGK and the adenine nucleotide transporter ANT1)  
(COPELAND 2008).  
Polγ is one of the most widely studied nuclear genes implicated in mtDNA-related 
disorders. In vitro studies have shown that Polγ has an error rate of 1 in 50,000 bp 
(LONGLEY et al. 2001). More than 150 mutations in Polγ have been identified in 
patients with mitochondrial diseases (Human DNA Polymerase Gamma Mutation 
Database (http://tools.niehs.nih.gov/polg/). These mutations can be found in all 
domains of Polγ and cause PEO, Alpers syndrome (NAVIAUX and NGUYEN 2004), 
Ataxia-neuropathy (VAN GOETHEM et al. 2004) and male infertility (ROVIO et al. 
2001) (Figure 1.12). mtDNA mutations have been identified in the affected tissues in 
all of these syndromes (STUMPF and COPELAND 2011). Most of the mutations in Polγ 
(reported as shown in Figure 1.12) are recessive and commonly found in 
combination with other mutations in Polγ or other mtDNA replication related genes 
such as Twinkle and ANT1 (KUJOTH et al. 2007). It has also been reported that 




Figure 1.12 Mutations in Polγ and diseases caused by these mutations. 
The box below shows groups of diseases in different colours, such as PEO causing 
mutations which are in red (Human DNA Polymerase Gamma Mutation Database 
(http://tools.niehs.nih.gov/polg/)). 
 
1.4.3  mtDNA depletion syndrome 
 
MDS (mtDNA depletion syndrome) is a group of diseases characterized by a 
reduction in mtDNA copy number and is caused by defects in nuclear encoded 
genes. MDS was first characterized as an autosomal recessive disorder (MORAES et 
al. 1991). This disease is widely reported in childhood respiratory deficiency 
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conditions (SARZI et al. 2007). One of the distinct properties of MDS is that it mainly 
affects the liver, skeletal muscles, kidney and brain, however other tissues can also 
exhibit symptoms (Figure 1.13) (SUOMALAINEN and ISOHANNI 2010). 
 
Figure 1.13 Genes causing mtDNA depletion syndrome (MDS). 
Tissues affected by MDS and the genes in which mutations have been identified are 
shown in boxes.  Adapted from Suomalainen 2010 (SUOMALAINEN and ISOHANNI 
2010). 
 
Mitochondrial dNTPs are supplied either through active transport of cytosolic dNTPs 
or through a salvage pathway that requires TK2 (Figure 1.14).  Mutations in TK2 
have been reported as the most common cause of MDS (SAADA et al. 2001). 
Deoxyguanosine kinase (dGK) is an essential kinase for the purine nucleoside 
salvage pathway and mutations in dGK cause MDS (FREISINGER et al. 2006; 
MANDEL et al. 2001). Ribonucleotide reductase is another important enzyme for 
supplying the dNTP pool and defects in this gene have also been reported to cause 
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MDS (BORNSTEIN et al. 2008; BOURDON et al. 2007; KOLLBERG et al. 2009). 
Another widely studied enzyme in dNTP pool regulation is thymidine phosphorylase 
(TP). Mutations in TP have been found in most common forms of mitochondrial 
neurogastrointestinal encephalomyopathy (MNGIE) (NISHINO et al. 1999; NISHINO 
et al. 2001). 
 
Figure 1.14 Proteins implicated in mtDNA depletion syndrome (MDS). 
Mitochondrial dNTP metabolism and proteins that have been found to be mutated in 
MDS are shown in yellow. Adapted from Suomalainen 2010 (SUOMALAINEN and 
ISOHANNI 2010). 
 
Mutations in nuclear genes encoding components of the mtDNA replication 
apparatus can, in addition to mtDNA mutations, cause mtDNA depletion and thus 
MDS. MtDNA depletion caused by mutations in Polγ can cause early childhood 
diseases such as Alpers syndrome (NAVIAUX et al. 1999). Defects in Polγ account for 
25% of the mitochondriopathies in Britain and Italy (CHINNERY and ZEVIANI 2008). 
mtDNA depletion has also been detected in PEO and mitochondrial myopathy 
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resulting from mutations in Twinkle (SPELBRINK et al. 2001), where mtDNA 
depletion was found in the brain and liver but not in skeletal muscles (HAKONEN et 
al. 2007; NIKALI et al. 2005; SARZI et al. 2007). 
Additional mechanisms that can cause mtDNA depletion are defects in metabolic 
enzymes, such as the alpha and beta subunit of succinyl-CoA ligase (ELPELEG et al. 
2005) (OSTERGAARD et al. 2007). Recently a protein of unknown function, MPV17, 
was linked with MDS (SPINAZZOLA et al. 2006). Although its function is not clear, 
MPV17 is known to be an integral mitochondrial inner membrane protein. 
Functional studies on its yeast homologue showed that it has roles in regulating the 
flux of TCA cycle intermediates into the cytoplasm, maintenance of cristae structure 
and nucleoid structure (DALLABONA et al. 2010). 
 
1.4.4  mtDNA in neurodegenerative diseases and ageing  
 
Neuronal dysfunction is a common symptom of mitochondrial disease (MCFARLAND 
et al. 2010). Complex I deficiency has been widely observed in primary mtDNA 
disorders resulting in neurodegeneration. Pathological features in the CNS are 
usually progressive and clinical features include optic atrophy, seizures, dementia, 
ataxia, extrapyrimidal features, stroke like episodes and progressive weakness 
(BETTS et al. 2004). Widely studied neurological disorders caused by mtDNA 
abnormalities include MELAS, MERRF, multiple mtDNA deletions causing PEO, 
ataxia and neuropathy and Leigh‟s Syndrome (BETTS et al. 2004). Neuropathological 
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features include nonspecific histological lesions, neuronal loss, necrosis, gliosis, 
demyelination and spongiform degeneration (TANJI and BONILLA 2001). 
As mentioned before mitochondrial dysfunction via, for example, defects in 
mitochondrial dynamics, has been linked to neurodegenerative diseases such as AD, 
PD and ALS. Although in the majority of cases these diseases are sporadic and 
caused by a combination of genetic and environmental factors, mutations in either 
nuclear encoded mitochondrial genes or mtDNA encoded genes may be a 
contributory factor.  Accordingly, for example complex I deficiency has been 
implicated in Parkinson‟s disease (SCHAPIRA et al. 1990; SCHAPIRA et al. 1989). 
Furthermore mtDNA deletions accumulate in the substantia nigra of aged 
individuals, but are more frequent in patients with PD (BENDER et al. 2006; 
KRAYTSBERG et al. 2006). AD has also been linked to mtDNA abnormalities and 
respiratory chain dysfunction (CAMPBELL et al. 2012b; COTTRELL et al. 2001a; 
COTTRELL et al. 2001b; KRISHNAN et al. 2012; ONYANGO et al. 2006). 
Mitochondrial dysfunction in neurodegenerative and age-related diseases has been 
widely studied. In 1972, Harman hypothesized that ROS leak from the mitochondrial 
ETC causes damage to macromolecules and also to mtDNA. mtDNA mutations then 
lead to further respiratory dysfunction and this vicious cycle contributes to ageing 
(HARMAN 1972). This hypothesis has become known as the “mitochondrial theory of 
ageing” (MIQUEL et al. 1980). Although this theory has not been proven, studies 
have linked mitochondrial dysfunction with ageing. The rate of OXPHOS deficiency 
has been shown to correlate with age in skeletal muscles (TROUNCE et al. 1989) and 
the rate of COX-deficiency has been correlated with age in cardiomyocytes 
(MULLER-HOCKER 1989). Moreover, aged human muscle biopsies have an 
association between COX-deficiency and clonally expanded mtDNA mutations 
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(FAYET et al. 2002). A number of studies have also demonstrated a link between 
COX-deficiency and ageing in other tissues (reviewed in (GREAVES et al. 2012)).  
Mutations in mtDNA have also been identified in ageing pathologies. Early studies 
linked mtDNA damage with ageing in rats: increased levels of mtDNA deletions 
were observed in aged animals (PIKO et al. 1988). Increased levels of mtDNA 
deletions have also been found in aged human brains (CORRAL-DEBRINSKI et al. 
1992a; CORRAL-DEBRINSKI et al. 1992b). An increased accumulation of mtDNA 
mutations in aged tissues can potentially lead to an increase in ROS levels (LINNANE 
et al. 1989). Furthermore, enhancing the antioxidant defence mechanism, therefore 
decreasing the net ROS production, can increase lifespan. For example, 
overexpressing manganese superoxide dismutase (MnSOD) and methionine 
sulphoxide reductase can extend lifespan in short-lived strains of Drosophila (RUAN 
et al. 2002; SUN et al. 2002). Overexpressing mitochondrially-targeted catalase can 
increase lifespan in already long-lived mouse strains (SCHRINER et al. 2005). 
MtDNA dysfunction has been linked with ROS accumulation (KUJOTH et al. 2005). 
However, contradictory results were also reported where mtDNA mutations were not 
accompanied by ROS-induced damage in a mouse model expressing an error-prone 
version of the catalytic subunit of Polγ (TRIFUNOVIC et al. 2005). These mice had 
normal levels of ROS production and no increased sensitivity to oxidative stress-
induced cell death. The results of this study were therefore contradictory to the 
mitochondrial theory of ageing. More studies should be carried out to better 
understand the effect of ROS in ageing.  
Since the proportion of mutant mtDNA in tissues is usually low, recent studies have 
focused on single-cell analysis of mtDNA mutations. Using this method, respiratory 
chain deficiency was observed in a subset of cardiomyocytes associated with cellular 
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ageing (MULLER-HOCKER 1989). Neurons in the substantia nigra are particularly 
affected in PD and COX deficiency was observed in these neurons under normal 
ageing conditions (ITOH et al. 1996). Micro-dissection of COX deficient neurons also 
showed increased levels of mtDNA deletions in aged individuals and higher levels in 
PD patients than aged controls (BENDER et al. 2006; KRAYTSBERG et al. 2006). 
The generation of „cybrid‟ cell lines is a widely used technique to study mtDNA 
abnormalities in AD and PD. The cybrid technique was developed during the 1970s 
in order to investigate the functional consequences of mutant mtDNA species and 
was subsequently used to study human neurodegenerative diseases (BUNN et al. 
1974). Cybrid cells are generated by fusing nucleated, mtDNA depleted cells with 
cytoplasts, which are enucleated mtDNA containing cells, to generate cybrid cells 
containing the donor (cytoplast) mtDNA. Many studies have used platelets (which 
lack nuclei, but contain mitochondria and mtDNA) from AD patients to generate 
cybrid cell lines that contain AD patient mtDNA. These AD patient cybrid cell lines 
have been consistently shown to have reduced membrane potential, reduced 
OXPHOS activity, increased free radical production and oxidative stress markers, 
altered calcium homeostasis and activated stress signalling and apoptosis pathways  
(SWERDLOW 2007; SWERDLOW et al. 1997). These studies have demonstrated that 
AD patient mitochondria, or mtDNA, are dysfunctional and has in part led to the 
“mitochondrial cascade hypothesis” of sporadic AD (SWERDLOW and KHAN 2004). 
This hypothesis proposes that both nuclear and mtDNA encoded genes determine a 
person‟s basal ETC efficiency and ROS production. Mitochondrial function declines 
with age until a critical threshold is reached that is determined by the starting 
mitochondrial population and the rate of mitochondrial decline. Dysfunctional 
mitochondria ultimately initiate AD histopathology via increases in Aβ production, 
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tau phosphorylation, synaptic loss, cell cycle re-entry and neurodegeneration 
(SWERDLOW et al. 2010).  
Cybrid studies have also been used to model means of preventing mtDNA loss. 
Human NT2 teratocarcinoma cells carrying the mtDNA mutation 3243A>G (which 
causes MELAS) result in mtDNA loss (TURNER et al. 2005), but this mtDNA loss 
phenotype can be rescued by overexpression of TIM17A, a conserved mitochondrial 
IMM translocase (IACOVINO et al. 2009). The mechanism of how TIM17A prevents 
mtDNA loss is not known, however this was the first study to identify a gene that can 
restore mtDNA levels in human cells.  
 
1.5  Animal models mtDNA of diseases 
 
1.5.1 The importance of modelling mtDNA diseases 
 
There are a number of important questions about the biology of mitochondrial 
diseases that can be addressed using animal models. Firstly, although mtDNA 
diseases all cause OXPHOS defects and insufficient ATP synthesis, the phenotypes 
are hugely variable and cannot be explained by energy deficits alone, so why are 
mtDNA diseases are phenotypically variable? Secondly, mutant mtDNA is found in 
a heteroplasmic state and the relationship between heteroplasmy and disease 
outcome is poorly understood. Thirdly, the mechanisms of controlling mtDNA 
segregation are not known. Fourthly, what are the physiological consequences of 
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mtDNA disorders? Finally, how does the mtDNA nucleoid regulate mtDNA 
replication, gene expression and segregation? (TYYNISMAA and SUOMALAINEN 
2010). The organisation of the mtDNA genome varies between animal species, but 
the proteins needed for mtDNA transactions are conserved (BOORE 1999). Therefore, 
animal modelling of mtDNA diseases through genetic manipulation of conserved 
proteins can provide novel insight into these diseases.  
 
1.5.2 Modelling mtDNA mutations 
 
The so called „Mito-mouse‟ was generated by isolating mtDNA containing natural 
deletions from aged mice in synaptosome preparations and fusing these with a cell 
line lacking mtDNA. Cybrid lines were screened for mtDNA deletions and one such 
line (containing a 4696bp deletion of 6 tRNA genes and 7 ETC genes) was 
enucleated, fused to donor embryos by electrofusion and implanted into 
pseudopregnant female mice. The offspring were then screened for heteroplasmic 
animals containing mutant and wild-type mtDNA and used for breeding to obtain 
germline transmission (INOUE et al. 2000).These mice had heteroplasmic single 
mtDNA deletions in high amounts, which resulted in respiratory chain deficiency in 
tissues such as heart, skeletal muscles and kidneys. The Mito-mice developed 
abnormalities characteristic of mitochondrial diseases such as anaemia, myopathy, 
cardiomyopathy, deafness, renal failure and shortened lifespan (INOUE et al. 2000; 
NAKADA et al. 2004). The inheritance of the mutant mtDNA was a key advantage for 
this model for studying the mitochondrial disease pathogenesis. Furthermore the 
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symptoms observed overlap with early-onset Pearson syndrome, which is caused by 
a single heteroplasmic mtDNA deletion (TYYNISMAA and SUOMALAINEN 2009).  
Another direct method of manipulation of mtDNA was developed using transgenic 
mice expressing mitochondrial-targeted bacterial endonucleases. The aim of this 
model was to study the effects of double-stand breaks (DSB) in mtDNA. Large 
deletions in mtDNA can occur via defects in mtDNA replication, or by a DSB 
followed by aberrant DNA repair (KRISHNAN et al. 2008). MtDNA DSBs have been 
modelled in Drosophila Schneider cells via bleomycin treatment. DNA Repair 
mechanisms were shown to repair deleted parts in a time course manner, 
demonstrating the importance of DSBs and the DNA repair system in maintenance of 
mtDNA (MOREL et al. 2008). Moraes and co-workers expressed a mitochondrially-
targetted version of the PstI endonuclease in skeletal muscles and this induced DSB 
breaks. Mitochondrial myopathy was seen in these mice and mtDNA isolated from 
skeletal muscle contained 7kb deletions and mtDNA depletion also occurred 
(SRIVASTAVA and MORAES 2001; SRIVASTAVA and MORAES 2005). Mitochondrially-
targetted PstI was also expressed in neurons (in subset of CNS neurons in a 
doxycycline-regulated manner) and age related neurological phenotypes were 
observed in these mice (FUKUI and MORAES 2009). One of the advantages of this 
model is the ability to control the mito-PstI expression spatially and temporally, since 
constitutive expression can result in severe mtDNA depletion and loss of cell. 
Furthermore, this model is potentially useful to understand the mechanisms behind 
the clonal expansion of mutant mtDNA, which can either result from random genetic 




Similar studies have been carried out in flies by expressing a mitochondrially-
targetted form of XhoI (mitoXhoI), which is a single cutter of Drosophila mtDNA at 
position 2369 in the mtCoI gene. Ubiquitous expression of mitoXhoI resulted in 
embryonic lethality, with a few escapers reaching the third instar larval stage, and 
eye specific expression severely affected eye development (XU et al. 2008).The main 
focus of this study was to generate suppressor lines where the DSB had been 
incorrectly repaired to introduce a point mutation. They expressed the RE in the 
germ line and most of the flies were sterile, but there were rare escapers. These rare 
escaper flies had a mtDNA point mutation in the XhoI site in the mtCoI gene and had 
mitochondrial phenotypes and defects such as growth retardation, neurodegeneration, 
muscular atrophy and reduced lifespan. The authors suggested the same technique 
could be used in mice to generate heritable point mutations in specific mtDNA 
genes. This method has the advantage that many different restriction enzymes singly 
cut mtDNA and so could potentially be used to isolate point mutants in a number of 
different mtDNA genes.  
 
1.5.3 Modelling nuclear DNA mutations in mtDNA replication genes 
 
Engineering mutations in nuclear genes that regulate mtDNA is another method to 
model mtDNA diseases. As previously mentioned, mutations in Polγ are one of the 
major causes of mitochondrial diseases, since 2% of the population carries 
pathogenic variants (HAKONEN et al. 2005; HUDSON and CHINNERY 2006). Polγ 
deficient models have been extensively studied in mice. Polγ knockout mouse are 
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embryonic lethal with no COX activity and loss of mtDNA (HANCE et al. 2005). 
This study showed that heterozygous Polγ mice develop into adulthood with no 
apparent phenotype and no effect on mtDNA level, although Polγ transcript level is 
halved. This suggests that a 50% reduction in Polγ expression is not limiting for 
mtDNA replication. The Polγ mouse model POLG Y955C was developed to 
specifically target to cardiac tissue (LEWIS et al. 2007). These mice express a version 
of Polγ with a mutation at position 955 (Y955C), which is the most common disease 
causing mutation in Polγ and is accociated with PEO and Parkinsonism (LUOMA et 
al. 2004). The tyrosine 955 in Polγ maintains the high fidelity of DNA synthesis by 
interacting with incoming dNTPs in the active site within the polymerase domain 
(PONAMAREV et al. 2002). Mutation of this residue results in stalling of mtDNA 
synthesis due to minimal catalytic activity and severely reduced processivity. POLG 
Y955C mice had a shorter median lifespan and cardiac tissues showed mtDNA 
depletion, oxidative stress and dysmorphic mitochondria (LEWIS et al. 2007). 
Although this model provided important information about Polγ dysfunction, 
transgenic overexpression may not be as informative as loss-of-function and gene 
replacement models (STUMPF and COPELAND 2011). 
Mouse models have been created that increase the rate of mtDNA mutations by 
substituting the catalytic aspartates for alanines (at position 181 in exon 1 
proofreading domain) in the exonuclease domain of Polγ, which results in 
proofreading deficiency. Expression of this mutant Polγ in cardiac tissues resulted in 
an over 23-fold increase in mtDNA point mutations, large mtDNA deletions and 
increased in pro-apoptotic gene expression, but had no effect on respiratory function 
or oxidative stress (MOTT et al. 2004; MOTT et al. 2001; ZHANG et al. 2000). In 
addition to the observation of increased apoptosis in cardiac tissue, targeting the 
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proofreading mutant Polγ to pancreatic islet cells also resulted in increased apoptosis 
(BENSCH et al. 2009; MOTT et al. 2001). Although the mechanism linking mtDNA 
mutations to apoptosis is not clear, it has been suggested that signalling from the 
mitochondria to the nucleus could result in failure of the anti-apoptotic response or 
enhanced expression of pro-apoptotic and stress response genes (MOTT et al. 2001; 
SOMEYA et al. 2008). Furthermore, release of cytochrome c from mitochondria may 
directly enhance apoptosis as a result of mtDNA mutation (DUBEC et al. 2008). 
An important mouse model in this field is known as the „mutator mouse‟. These mice 
contain a knocked-in version of Polγ containing a mutation in the second 
exonuclease domain (D257A) (this mutation is at a different position to the previous 
model and is in exon 2) in the catalytic subunit that decreases the proofreading 
activity of the enzyme, but has no effect on the DNA polymerase activity (KUJOTH et 
al. 2005; TRIFUNOVIC et al. 2004). Mutation frequency was significantly increased in 
heart, liver and duodenum, but only a slight increase was observed in sperm (KUJOTH 
et al. 2005). These mice showed premature-ageing like phenotypes such as weight 
loss, reduced subcutaneous fat content, hair loss, osteoporosis and reduced fertility. 
Histological analysis showed abnormalities in tissues such as spleen, liver, heart and 
testis.  Similar to the cardiac-specific expression model, there was no effect on 
oxidative stress or ROS production. Furthermore, there was no defect in cell 
proliferation, but mutator mice showed early onset activation of a caspase-3 
mediated apoptotic pathway (KUJOTH et al. 2005). This model was initially seen as 
particularly valuable since it linked mtDNA mutations with ageing pathologies.  
This mutator mouse model has been controversial as it was originally claimed it 
showed that mtDNA mutations cause ageing. However, subsequent studies showed 
that the mtDNA mutations in these mice occurred throughout development, which is 
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different to what happens in ageing, when mtDNA mutations occur later in life. The 
mutator mouse was further investigated for its relationship with ageing by using 
more sensitive assays. Although mutator mice have an 11-fold increase in mtDNA 
point mutations with age, they can sustain a 500-fold mtDNA mutation burden 
compared to control mice, which suggests that mtDNA mutations do not limit the 
lifespan of wild-type mice (VERMULST et al. 2007). Similar Polγ mutations to those 
in the mutator mice, causing a high rate of mtDNA mutations, have not been 
identified in humans, further questioning the direct relevance of this model. 
Manipulation of Polγ levels has also been analysed in tissue culture cells. 
Knockdown of Polγ-β in human 143B osteosarcoma cells resulted in mtDNA 
depletion and an increased number of nucleoids. Conversely overexpression of Polγ-
β in HEK and U2OS cells resulted in fewer but larger nucleoids, without affecting 
mtDNA copy number. These data suggest that Polγ can affect mtDNA nucleoid 
structure, but the affects may depend on cell type (DI RE et al. 2009).  
Drosophila has been used as a model to study mtDNA related diseases, with 
particular emphasis on Polγ. Flies with mutations in the catalytic subunit of Polγ 
(tamas; identified from an EMS screen) were pupal-lethal and showed defects in the 
larval response to light (IYENGAR et al. 1999). Flies with a null mutation in the 
accessory subunit of Polγ (Polγ-β) showed loss of mtDNA, disruption of 
mitochondrial morphology, impairment in cell proliferation in larval CNS and 
lethality at the pupal stage (IYENGAR et al. 2002). Mutations in Polγ-β cause PEO 
and this was the first Polγ-β animal model (COPELAND 2008; VAN GOETHEM et al. 
2001). tamas and Polγ- β mutations also caused mtDNA depletion, an increase in 
mitochondrial density in proximal nerves and an increase in bidirectional 
mitochondria flux. Velocity of anteriograde mitochondrial transport was also slightly 
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reduced, but retrograde transport velocity was not changed (BAQRI et al. 2009). 
These mitochondrial transport phenotypes could result from a compensatory 
mechanism where neurons attempt to supply the nerve terminals with mitochondria 
produced in the cell body. However, increased transport of dysfunctional 
mitochondria may have deleterious effects.  
In a more recent study, tamas expression was silenced by RNAi in Drosophila in 
order to model neurodegeneration. Ubiquitous knockdown of tamas resulted in 
lowered respiratory chain activity and developmental lethality. tamas RNAi in 
dopaminergic neurons caused cell loss, but had no effect in cholinergic neurons. The 
lethality caused by ubiqitous knockdown of tamas was partially rescued by 
overexpression of components of the mitochondrial quality control system, parkin 
and Drp1, but was fully rescued (as was the dopaminergic neuron cell loss) by 
overexpression of the alternative oxidase AOX, which bypasses complex III/IV 
deficiency (HUMPHREY et al. 2012). This study provided further evidence of the 
sensitivity of dopaminergic neurons to mitochondrial dysfunction. 
Another Drosophila study used overexpression of tamas either ubiquitously, or 
specifically in the nervous system. Constitutive overexpression of tamas caused 
pupal lethality and mtDNA loss. It was proposed that this was due to replication 
stalling either via reduced catalytic activity, or interaction of excess Polγ-α with 
other components of the replication apparatus (LEFAI et al. 2000). Flies 
overexpressing tamas specifically in the nervous system only had a mild reduction in 
adult eclosion, but adult fly lifespan was decreased more than 50%. Furthermore, 
OXPHOS activity was significantly reduced in these flies and they had reduced 
resistance to the ROS-generating agent paraquat.  Both mtDNA replication rate and 
mtDNA copy number were reduced in these flies (in the whole organism) and there 
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was increased cell death in larval CNS (MARTINEZ-AZORIN et al. 2008).  It is 
possible that increasing the amount of Polγ might result in un-favourable interactions 
with other components of the mtDNA replication apparatus, such as mtSSB and 
Twinkle, which results in dysfunction or inhibition in mtDNA replication. The 
phenotypes observed are analogous to MDS diseases and correlate with the reduction 
in mtDNA level. 
Mutations in the Twinkle helicase have been reported in dominant adult onset PEO 
and this has been modelled in mice that express murine Twinkle with mutations 
homologous to those found in the patients. Twinkle
dup
 mice expressed a version of 
Twinkle containing a duplication of amino acids 353-365, the same as found in 
patients with PEO (TYYNISMAA et al. 2005).  These „deletor mice‟ had respiratory 
chain deficiency in skeletal muscles and some neuronal populations, with 
accumulation of multiple mtDNA deletions in muscle and brain tissues (TYYNISMAA 
et al. 2005). Analysis of mtDNA levels showed that mtDNA copy number was 
reduced 40% in the brain, but was not changed in the heart and muscles.  Detailed 
investigation of replication intermediates (RIs) suggested replication stalling in the 
heart, muscle, kidney and brain, but not in the liver. The differences observed may be 
due to tissue specific differences in Twinkle expression (GOFFART et al. 2009). 
Mitochondrial myopathy was first observed in Twinkle
dup 
mice around 12 months 
and was progressive, mimicking the relative age of onset in human PEO patients. In 
human patients the amount of mtDNA deletions can be between 40-60% of total 
mtDNA, however the percentage was very low in young deletor mice and increased 
with age (SUOMALAINEN et al. 1992; ZEVIANI et al. 1989). The dynamics of mtDNA 
depletion with age are hard to compare between the mouse model and human disease 
since human mtDNA deletions have only been detected from 20 years of age. 
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Although Polγ and Twinkle act together in mtDNA replication, the main difference 
between “mutator mice” and “deletor mice” is the fact that mutator mice show 
premature aging phenotypes and deletor mice do not. This suggests that dysfunction 
of Twinkle may not be sufficient to cause extensive mtDNA mutagenesis, or 
alternatively dysfunction in Polγ could result in premature ageing via other 
mechanisms. Overexpression of wild-type Twinkle resulted in increased mtDNA 
copy number but did not cause any pathological phenotypes (TYYNISMAA et al. 
2004). 
Kaguni and co-workers modelled PEO in Drosophila tissue culture cells by 
expressing mutated versions of Drosophila Twinkle (CG5924). Two forms of 
CG5924 with mutations at positions analogous to lysine
318
 (Drosophila, K388A) and 
aspartate
424
 (Drosophila, D483A) in the active site of human Twinkle, which are 
essential for helicase activity but not for hexamer formation, were expressed in 
Drosophila Schneider cells. This resulted in cell death in 4-6 weeks and caused 
severe reduction in mtDNA copy number (4-20% of the control cells), demonstrating 
that this system could be used for assaying CG5924 function. Overexpression of 
CG5924 variants with mutations in the linker and helicase domains, homologous to 
those affected in PEO patients, in Drosophila cells resulted in a 7-11 fold reduction 
in mtDNA copy number (MATSUSHIMA and KAGUNI 2007). The N-terminal domain 
of the Drosophila mtDNA helicase was also studied by the same group since 
mutations in this region are also linked to PEO. The mtDNA helicase shows 
sequence similarity to the bacteriophage primase-helicase T7 gene 4 protein (T7 
gp4). The T7 gp4 N-terminal region contains the primase domain, but the function of 
the N-terminal domain in the mtDNA helicase has not been described in detail. 
Drosophila Schneider cells expressing versions of CG5924 with mutations in the N-
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terminal region, analogous to those found in PEO patients, had reduced mtDNA copy 
number. However, the mutated residues are not thought to be important for primase 
activity, suggesting that the N-terminal region plays a role in the helicase function of 
the enzyme in flies (MATSUSHIMA and KAGUNI 2009).  
The C-terminal domain of Twinkle was also studied using deletions and alanine 
substitution mutations which revealed that K574, R576, Y577, F588 and Y595 are 
the important residues for mtDNA maintenance, since mutation of these residues 
resulted in reduced mtDNA copy number and cell death. Furthermore, the C-
terminus is important for nucleotide hydrolysis, since amino acid substitution 
mutants in this region cause defects in this process (MATSUSHIMA et al. 2008). These 
studies have provided important insight into the structure and function of Twinkle 
and its role in mtDNA maintenance. 
Another protein that is essential for mtDNA replication is the mtSSB (mitochondrial 
single stranded binding protein). It is one of the three components of the minimal 
mtDNA replisome, together with Polγ and Twinkle and can stimulate the unwinding 
activity of the Twinkle helicase (KORHONEN et al. 2003; KORHONEN et al. 2004). 
The Drosophila homologue of mtSSB is lopo (low power) and mutations in lopo 
result in lethality at the third instar larval stage. lopo mutant larvae have reduced cell 
proliferation in CNS, loss of mtDNA and reduced respiratory capacity (MAIER et al. 
2001). These findings are supported by knockdown experiments in Drosophila 
Schneider cells, which results in mtDNA depletion and proliferation defects. These 
phenotypes in Schneider cells were rescued by overexpression of wild-type mtSSB, 
but not with overexpression of double mutants in ssDNA-binding and Polγ 
stimulating domains (FARR et al. 2004). Although there are no reports linking 
mutations in mtSSB to MDS in humans, these studies showed the importance of lopo 
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in mtDNA maintenance and survival. Overexpression of wild-type mtSSB could 
potentially be used as a therapeutic strategy to rescue mtDNA loss. 
The mtDNA transcription machinery consists of an RNA polymerase, TFAM, 
transcription factors B1 and B2 (mtTFB1 and mtTFB2) and termination factors 
(mTERFs). TFAM is the best studied component and has a dual role in transcription 
and maintenance of mtDNA (FISHER et al. 1989; KANKI et al. 2004; KAUFMAN et al. 
2007). TFAM knockout models have been generated as a way to deplete mtDNA and 
model MDS.  Homozygous TFAM-/- mice are embryonic lethal with severely 
reduced TFAM protein levels and loss of mtDNA copy number (LARSSON et al. 
1998). These mice had reduced COX expression and abnormalities in mitochondrial 
structure. Heterozygous TFAM+/- mice were viable, but had a 50% reduction in 
TFAM expression levels, which resulted in a 34% reduction in mtDNA level and a 
22% reduction in mitochondrial transcript level (LARSSON et al. 1998). Human 
TFAM expression did not rescue the lethality observed in TFAM homozygous 
knockout mice, owing to the fact that expression of hTFAM did not alter 
mitochondrial transcript level, respiratory chain function and mitochondrial mass, 
although it did increase mtDNA copy number (EKSTRAND et al. 2004). These 
experiments suggested that differences between human and mouse TFAM in the C-
terminal region, which is required for transcriptional activity (DAIRAGHI et al. 1995), 
prevented expression of hTFAM from rescuing the mouse TFAM mutant.  
The importance of TFAM in maintaining mtDNA copy number has also been 
demonstrated in Drosophila Kc167 cells. RNAi of TFAM in these cells resulted in a 
40% reduction in mtDNA copy number. Surprisingly, this did not result in any 
change in membrane potential, cell proliferation, or in mitochondrial mRNA 
transcript levels (GOTO et al. 2001). Although not much is known about the role of 
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TFAM in transcription of mtDNA in insects, these data suggested that TFAM is 
dispensable for transcription of mitochondrial mRNAs in Kc167 cells. Studies in 
HeLa cells showed that of TFAM knockdown resulted in mtDNA depletion and 
caused defects in mtDNA nucleoid segregation (KASASHIMA et al. 2011). These cell 
culture studies confirm the role of TFAM in maintaining mtDNA levels and nucleoid 
organisation. 
Tissue specific manipulation of TFAM levels in mouse models has been very 
informative. Mice with heart and muscle-specific inactivation of TFAM are viable, 
but they die at around postnatal day 20. MtDNA depletion was observed both in 
heart and skeletal muscles together with a reduction in respiratory complexes I and 
IV levels, but not in complex II levels and increased apoptosis in cardiomyocytes 
(WANG et al. 1999).  Homozygous TFAM knockout mice also show massive 
apoptosis at E (embryonic day) 9.5 (WANG et al. 2001).  
Skeletal muscle-specific inactivation of TFAM was studied as a model for human 
mitochondrial myopathy. Inactivation of TFAM in skeletal muscles of mice resulted 
in progressive myopathy characterized by enlarged mitochondria and abnormal 
cristae (WREDENBERG et al. 2002). Loss of TFAM resulted in reduced mtDNA and 
mitochondrial transcript levels, dysfunction of the respiratory chain and reduced ATP 
production. Immunohistochemistry, electron microscopy and analysis of citrate 
synthase activity showed increased mitochondrial mass, which was suggested as a 
way to compensate for the respiratory chain deficiency and insufficient ATP 
production (WREDENBERG et al. 2002). TFAM was also knocked out specifically in 
pancreatic β-cells and resulted in a reduction in COX activity, with no effect on SDH 
activity and dysmorphic enlarged mitochondria. These mice subsequently developed 
diabetes (SILVA et al. 2000). 
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Neuronal specific manipulation of TFAM is a useful model to understand the 
importance of mtDNA in neurons and the role of mtDNA loss in neurodegenerative 
diseases. PD and also normal ageing results in a decline in respiratory chain function 
and accumulation of mtDNA mutations (KRISHNAN et al. 2007; LARSSON 2010). PD 
patients have respiratory chain deficient dopaminergic neurons and an increased rate 
of mtDNA deletions in these neurons (BENDER et al. 2006; BENDER et al. 2008).  PD 
has been modelled in mice by inactivation of TFAM in dopaminergic (DA)-neurons 
(EKSTRAND et al. 2007). These „MitoPark mice‟ start to show decreased 
mitochondrial COI expression from 6 weeks of age in the substantia nigra and 
ventral tengmental area and by 14 weeks of age have behavioural symptoms, starting 
with decreased locomotion and reduced exploratory behaviour and progressively 
affecting tremor, twitching and limb rigidity. These phenotypes were associated with 
progressive loss of DA neurons and nerve terminals. L-DOPA treatment was found 
to improve the motor function in these mice. Intraneuronal inclusions (Lewy bodies) 
were observed from 6 weeks of age and these structures were associated with 
mitochondrial membrane structures, suggesting a possible role for mitochondrial 
dysfunction in the development of inclusions (EKSTRAND et al. 2007). MitoPark 
mice also have altered synaptic ion channel properties and impaired DA release, 
which may explain the locomotor phenotypes (GOOD et al. 2011). Mitochondrial 
morphology was studied in MitoPark mice and mitochondrial fragmentation and 
enlarged mitochondrial aggregates were observed in DA neurons. Moreover, distal 
pools of mitochondria were reduced in number but had normal mitochondrial 
morphology. The mechanism suggested to cause depletion of mitochondria in axon 
terminals was impaired retrograde axonal transport of mitochondria (STERKY et al. 
2011). These phenotypes suggest that defects in mitochondrial quality control 
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mechanisms may be responsible for DA neuron degeneration in this mouse model. 
The ubiquitin ligase Parkin is an important factor in mitochondrial quality control. 
However, there was no evidence of Parkin recruitment to defective mitochondria and 
knockout of Parkin did not modify the mitochondrial phenotypes observed (STERKY 
et al. 2011). Mitopark mice have been a useful model demonstrating the 
requirements for TFAM in DA neuron function and the importance of mitochondrial 
function in these neurons. However, recent data showing Parkin-independent 




AIMS OF PROJECT 
 
In order to understand how mtDNA contributes to neurodegenerative diseases, I 
aimed to understand the consequences of mtDNA loss in neurons. The aims of the 
project were: 
-To model mtDNA depletion in neurons in Drosophila melanogaster. 
-To investigate the consequences of mtDNA loss in motoneurons. 





Chapter 2.  MATERIALS AND METHODS 
 
2.1  Materials 
 
Kits:  
Wizard Genomic DNA Purification Kit (Promega) 
LightCycler FastStart DNA Master
PLUS
 SYBER Green I (Roche)  
First strand cDNA synthesis kit (Fermentas) 
ATP Bioluminescence Assay Kit HSII (Roche)  
Bradford protein assay (Bio-Rad) 
Antibodies and dyes: 
Miranda (mouse, 1 in 10, Dr. Richard Tuxworth) 
Wingless (mouse, 1 in 200, DSHB) 
Elav (mouse, 1 in 100, DSHB) 
TFAM (rabbit, 1 in 1000, Abcam) 
HRP-Cy3 (goat, 1 in 500, Dr. Richard Tuxworth) 
Nc82/bruchpilot (mouse, 1 in 30, DSHB) 
DAPI (already added in Vectashield mounting media, Vector Laboratories) 
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Secondary antibodies (1 in 500 dilution): Alexa Flour 488, Alexa Flour 594, Alexa 
Flour 633 (Invitrogen) 
Rhodamine1,2,3 (13 μm, Sigma-Aldrich) 
 
2.2   Methods 
 
2.2.1  Fly breeding 
 
All flies were maintained on cornmeal, glucose, yeast extract, agar media in 
temperature-controlled incubators at 25
0
C. Incubators had a 12 hour light/dark cycle 
and virgin flies used to set up crosses were collected in the morning and afternoon.  
Fly food used for crosses (R2 recipe): 
For 10L of dH2O: 
Agar---80g (Fisher) 
Ground yellow corn---200g 
Glucose---800g (Sigma) 




These ingredients were mixed and cooked in a Systec MediaPrep media 
preparator/steriliserand the rest (listed below) were mixed and put in after the 
temperature had cooled to below 60
0
C: 
methyl 4-hydroxybenzoate (Sigma)---22.5 g; 
propionic acid (Fisher Scientific) ---37.5 ml; 
ethanol ---200 ml. 
After 10 minutes or more of mixing, the media were dispensed into vials and bottles 
(Regina Industries Ltd.) as required. 
Fly food for lifespan experiment (German food recipe): 
For 1 L of dH2O: 
Agar---8g (Fisher) 
Brewer‟s Yeast---80g (MP Biomed Europe) 
Yeast extract---20g (Sigma) 








The ingredients were mixed and the microwaved until they reached boiling point and 
then boiled for several minutes, then allowed to cool to 60
0
C in a water bath. 6ml of 
propionic acid and 1g of methyl 4-hydroxybenzoate in 10ml of EtOH were then 
added. The solution was mixed well and 7ml poured into each vial and allowed to 
cool. 
 
2.2.2 Fly stocks 
 
In Drosophila, one of the widely used tools for targeted gene expression is the UAS-
Gal4 system. Using this method, the expression of a gene of interest can be directed 
to different tissues or cell types by using Gal4 driver lines (BRAND and PERRIMON 




Driver Tissue Expressed Source Stock Number 
Actin-Gal4 (II) Ubiquitous Bloomington 4414 
Actin-Gal4 (III) Ubiquitous Bloomington 3954 
MZ1407-Gal4 Neurons and 
Neuroblasts 
Sousa-Nunes et al. 
2009 
 
Elav-Gal4 Nervous system 
beginning 
embryonic stage 12 
Bloomington 458 




Table 2.1 List of Gal4 driver lines used in this study. 
Other stocks:  
Wild type/control flies: Oregon R (Bloomington, 5), w
1118
 (Bloomington, 6326), 
w
DAH
 (Linda Partridge‟s lab), PRSP2 (RFP expressing stock, Kaul and Bateman, 
2009) 
UAS stocks: 
UAS-TFAM (this study), UAS-TFAMGFP (this study), UAS-mitoXhoI (O‟Farell lab), 





 (Bloomington, 8294), UAS-Atg1 (Shen 2009), UAS-CD8GFP (Tear lab), 
UAS-Dcr2 (Bloomington, 24648). 




2.2.3 Lifespan Assays 
 
Ethidium bromide (EtBr) experiment: Isogenised w
1118
 flies were used to carry out 
the EtBr lifespan experiments. In order to synchronize the age of the flies and 
minimize environmental effects, grape-juice plate cages were set up. Adult flies were 
crossed in these cages and embryos collected twice per day. Approximately similar 
numbers of embryos (500) were developed in bottles containing German food, 
maintained at 25
0
C. Eclosed adult flies were grown in vials of control and EtBr 
containing food. Two different concentrations of EtBr (Fisher Scientific) were used: 
0.2mM and 2mM. 20 flies were placed in each tube and 100 flies were aged in five 
tubes per condition. Flies were flipped into new tubes every two days and the number 
of dead flies recorded. This was continued until all of the flies in their corresponding 
vials were dead. This experiment was repeated three times on different dates. 
Genetic manipulation: motoneuron driver (OK371-Gal4, UAS-Dcr2, UAS-CD8GFP) 
virgin flies and various (w, UAS-TFAMIR-3 and UAS-TFAMGFP) male flies were 
crossed in grape-juice plate cages. Approximately similar numbers of embryos (500) 
were developed in bottles containing German food, maintained at 25
0
C.  Eclosed 
flies were placed in five vials containing German food, with 20 flies in each vial. The 






2.2.4 Measuring mtDNA Levels 
 
EtBr treatment  
The effect of EtBr on mtDNA was investigated both at the larval and adult stage. 
Approximately 100 w
1118
 embryos were collected using grape juice plates and these 
were then placed on control and 1mM EtBr containing food. 5 third instar L3 larvae 
per sample were used to extract genomic DNA and three samples were prepared per 
condition. For adult flies, w
1118
 flies (collected on grape juice plates) were aged on 
0.2mM and 2mM containing food or normal food. 5 adult flies were used to extract 
genomic DNA from flies grown on normal food at day 2 and day 40 together, or 
from flies grown on 0.2mM and 2mM EtBr containing food at day 40.  A total of 
three samples were prepared per condition.  
 
DNA extraction and quantitative real time PCR 
Genomic DNA was purified either from larvae or adult flies, depending on the 
experiment. Samples were homogenized by using a glass 0.1ml mortar and pestle 
(Fisher Scientific) on ice. Genomic DNA isolation was carried out using the 
Wizard® Genomic DNA Purification Kit (Promega) according to the manufacturer‟s 
protocol. Real time qPCR, which uses fluorescent reporters to measure absolute or 
relative amounts of DNA, was performed by using a Corbett Rotor-Gene RG-3000 
machine, LightCycler® FastStart DNA Master
PLUS
 SYBR Green I (Roche) reaction 
mixture and gene specific primers. PCR reactions were carried out for 40 cycles: 
denaturation at 95
0
C for 10 s, annealing at 60
0
C for 15 s and extension at 72
0
C for 20 
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C) uniqueness of 
amplicons was analyzed. CT (threshold cycle) values for the mitochondrial gene 
cytochrome c oxidase subunit I (mt:CoI) and the nuclear gene glyceraldehyde 3-
phosphate dehydrogenase  (Gapdh1) were then used to calculate the CT between 
these two genes for each sample. This value was used as the relative mtDNA level. 
Standard curves for mt:CoI and Gapdh1, using a series of 8 (3-fold) dilutions of 
genomic DNA, were run in all experiments to determine the efficiency of the 
reaction and were only used when the efficiency was >95%.  Primer sequences for 
mtCoI and Gapdh1 are shown in Table 2.2. 
Gene Primers Sequence 
mtCoI Forward primer 5`-GAGCTGGAACAGGATGAACTG-3` 
 Reverse primer 5`-TTGAAGAAATCCCTGCTAAATGT-3` 
Gapdh1 Forward primer 5`-GACGAAATCAAGGCTAAGGTCG-3` 
 Reverse primer 5`-AATGGGTGTCGCTGAAGAAGTC-3` 
Table 2.2 Primer sequences for measuring mtDNA level by qPCR. 
 
2.2.5 Measuring TFAM transcript level 
 
20 third instar larvae were homogenized in TRIzol® reagent (Invitrogen) and stored 
at -80
0
C. The next day, the homogenate was incubated at room temperature for 5 
minutes and 0.2ml of chloroform/1ml of TRIzol was added. After centrifuging at 4
0
C 
at 12000g, the aqueous layer (containing the RNA) was transferred into a new tube 
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and RNA was precipitated by adding 0.5 ml of isopropanol and centrifugation at 4
0
C 
at 12000g. The precipitated RNA was washed with 75% EtOH and centrifuged at a 
lower speed (at 7,500g) for 5 minutes. After air drying the pellet, the RNA was re-
suspended in 30 μl of dH2O. 2μg of RNA was incubated with oligonucleotide 
hexamers (Fermentas) for 10 minutes at 65
0
C in order to prime cDNA synthesis. 
MuLV RT (reverse transcriptase), dNTPs, RNase inhibitor and reaction buffer (First 
strand cDNA synthesis kit, Fermentas) were added to the RNA-hexamer mix. This 
mixture was incubated at 25
0
C for 5 minutes and then 37
0
C for 1 hour.  The reaction 
was terminated by heating to 70
0




Quantitative PCR (qPCR), was carried out to measure TFAM transcript levels by 
using the same Real-Time PCR machine and enzyme mixture as used for the mtDNA 
levels measurement protocol. CT values for TFAM and the housekeeping gene RpL1 
were used to calculate the CT between these two genes for each sample and thus the 
relative level of TFAM transcript. Standard curves for TFAM and RpL1, using a 
series of 8 (3-fold) dilutions of cDNA, were run in all experiments to determine the 
efficiency of the reaction and were only used when the efficiency was >95%. Primers 







Gene Primers Sequence 
TFAM Forward Primer 5‟-GAGTCGCGCAAGGAGATG-3‟ 
 Reverse Primer 5‟-GGATCGATAAGATTTCCGTGAC-3‟ 
RpL1 Forward Primer 5‟-TCCACCTTGAAGAAGGGCTA-3‟ 
 Reverse Primer 5‟-TTGCGGATCTCCTCAGACTT-3‟ 
Table 2.3 Primer sequences used to measure TFAM transcript level by qPCR. 
 
2.2.6 Measuring ATP Levels 
 
The effect of neuronal knockdown of various genes on ATP levels was analysed by 
dissecting 20 adult brains. The ATP Bioluminescence Assay Kit HSII (Roche) was 
used to measure ATP levels. Brains were dissected in PBS and the cell lysis reagent 
(in the kit) was used to homogenise dissected brains in glass homogeniser (mortar 
and pestle). Samples were diluted in 1 in 10 using the dilution buffer supplied. ATP 




 moles. 50 μl 
of experimental samples and 8 serial dilution standard samples were used together 
with 50 μl of luciferase reagent. 96-well plates (Thermo Scientific, nunc) were used 
to measure the level of ATP by measuring the level of luminescence using a 
luminometer (9100-001, VERITAS
TM
 Microplate Luminometer, TURNER 
Biosytems, Currently Promega).  
Samples homogenized using the cell lysis reagent were used to measure the amount 
of total protein for normalization using a Bradford micro-assay (Bio-Rad) kit and a 
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MRX microplate reader (DYNEX Techynologies Inc., MAGELLAN 
BIOSCIENCES). A  BSA (bovine serum albumin) serial dilution standard was used 
in the range of 8-80μg/ml. This standard was then used to determine the amount of 
protein in each experimental sample. Then, the ATP level was divided by the total 
protein level in order to determine the normalised level of ATP in each sample. 
 
2.2.7 Generation of transgenic flies 
 
The UAS-TFAM construct was generated by PCR amplification of the full length 
TFAM coding sequence from the cDNA clone LD40493 (DGRC) using primers 
Tfam.EcoRI.Fw and Tfam.XbaI.Rv (Table 2.4) containing EcoRI and XbaI sites 
(restriction enzyme sites are underlined in Table 2.4). The PCR product was then 
cloned into EcoRI and XbaI sites in pUAST. 
The UAS-TFAMGFP construct was generated by PCR amplification of the full 
length TFAM coding sequence from the cDNA clone LD40493 (DGRC) using 
primers TFAM 5 and TFAM pENT R (Table 2.4). The PCR product was 
directionally cloned into the topoisomerase charged pENTR Gateway® system 
vector (Invitrogen). Gateway® recombination cloning was then used to clone the 
TFAM cDNA into the pTWG vector 
(http://www.ciwemb.edu/labs/murphy/Gateway%20vectors.html), which contains the 












 TFAM pENTR R 5‟TATATCTTTGGAGGCCAGCGTCT
TG-3‟ 
Table 2.4 Primer sequences used for cloning TFAM and TFAMGFP. 
Restriction enzyme cutting sites are underlined for EcoRI and XbaI. 
 
UAS-TFAM and UAS-TFAMGFP constructs were generated by Ilaria Nissoli and 





Larval and adult CNS, wing disc dissections 
For adult CNS dissection flies were anesthesized with CO2 prior to dissections. L3 
larvae or adult fly heads were dissected with fine forceps (Agar Scientific) in ice cold 
88 
 
phosphate buffered saline (PBS: sodium chloride 8.0 g/l, potassium chloride 0.2 g/l, 
di-sodium hydrogen phosphate 1.15 g/l, potassium dihydrogen phosphate 0.2 g/l, 
pH7.4, OXOID) under a dissection microscope. Dissected brains and imaginal discs 
were placed in a 1.5ml tube containing 4% formaldehyde (Thermo Scientific)/PBS 
on ice. Once all samples were dissected, the tube was moved to a platform rocker 
(Rotarod) for 30-45 minutes to fix the tissues. They were then washed three times in 
PBST (PBS, 0.1% triton X100) for 10 minutes each. Tissues were then blocked in 
10% normal goat serum (NGS, SIGMA-ALDRICH)/PBS for 20-30 minutes prior to 
primary antibody incubation. Blocked tissues were incubated with primary 
antibodies at relevant dilutions in 10% NGS/PBST at 4
0
C overnight. Tissues were 
then washed three times with PBST for 10 minutes at room temperature (RT) on 
platform rocker. Corresponding secondary antibodies were prepared at appropriate 
dilutions and tissues were incubated in this solution in dark (by wrapping tubes in 
aluminium foil) for 1.5 hrs in RT. Tissues were then washed 3 times with PBST for 
10 minutes each. Finally these samples were dissected (by removing unwanted 
tissue) on microscope slides. Vectashield mounting media with DAPI (Vector 
Laboratories) was added to the slides and cover slips were placed carefully on top. 
Slides were kept at 4
0
C in dark until imaging.  
 
Larval flat preps 
Late third instar larvae were placed on a dish containing ice cold PBS, to reduce the 
muscle contractions, for 2-3 minutes. Then the larvae were transferred to a Sylgard 
dish containing a drop of cold PBS. Dissections were carried out using fine forceps, 
micro-pins (Entomoravia) and iridectomy scissors (Fine Science Tools). Larvae were 
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pinned dorsal side up by placing pins between the mouth hooks and the spiracles. 
Then using iridectomy scissors, the body wall was cut from anterior to posterior and 
the intestines, fat bodies and the tracheal system were removed using forceps. Larvae 
were then pinned out flat using micro-pins. Flat preps were fixed with 4% 
formaldehyde/PBS for 30 minutes. Fixed larvae were then transferred to 1.5ml tubes 
and washed 3 times with PBST for 10 minutes each. Subsequent staining and washes 
were carried out as for CNS dissections. The neuromuscular junction synapse on 
muscle group 4 and proximal and distal compartments of motoneuron axons were 
imaged using a Zeiss LSM710 confocal microscope.  
 
2.2.9 Axonal mitochondrial membrane potential analysis 
 
Larval tissue was prepared according to a method described by Brink and colleagues 
in order to maintain the properties of live, intact larvae (Brink 2009). Firstly larvae 
were placed in cold Schneider‟s media (Invitrogen), which contains 12.33mM L-
glutamate and so inhibits spontaneous muscle contraction. Larvae were then 
transferred to a Sylgard dish containing 1ml of Schneider‟s media. The posterior 
segments were then dissected using iridectomy scissors and using a micro-pin, the 
mouth parts were pushed backwards through the body cavity to turn the larva inside 
out. Next, the fat body and intestines were removed and the Scheinder‟s media was 
replaced twice.Rhodamine-1,2,3 (Invitrogen) was the added in Schneider‟s media to 
a final concentration of 13 μM and the samples were incubated for 10 minutes. The 
dye was washed by replacing twice with fresh Scheinder‟s media. The larval 
90 
 
preparation was mounted on a double-bridged slide. This slide was prepared by 
glueing two square 18mm (#1.5) coverslips (VWR) onto a slide, leaving a 2mm gap. 
The larval preparation was then placed in this gap containing Schneider‟s media and 
a clean coverslip was placed on top. 
2.2.10 Microscopy and image Processing 
 
Images were obtained using a Zeiss LSM710 confocal microscope with ZEN 
software. The resolution of all of the images was 1024 X 1024 pixels, taken with 4 
times averaging. The magnification and numerical apertures of lenses used were: 10 
X, 0.30 ; 20x,0.50 and 40X, 1.30 oil. Images were processed using Adobe Photoshop 
7.0.1. 
2.2.11 NMJ analysis 
 
Bouton number, bouton diameter, active zone number and density were determined 
by visualising the images in the Volocity Software (v5.5, Perkin Elmer) program and 
manually counting, or using the distance measurement tool. Bouton volume, 
mitochondrial number and mitochondrial volume measurements were performed in 
Volocity using the Measurements tool. The intensity threshold levels were adjusted 




2.2.12 Behavioural assays 
 
Viability  
Virgin motoneuron driver flies were crossed to UAS lines in grape-juice plate cages.  
50 first instar larvae from these plates were placed in vials containing fly food. 
Larvae were incubated at 25
0
C and the number of eclosed adult flies counted. Six 
vials were tested for each genotype. For TFAM overexpression the number of pupae 
were also counted. 
 
Larval Locomotion 
15cm petri dishes (Thermo Scientific, nunc) containing 1.5% agarose (Eurogentec) 
in PBS was prepared by adding 0.9g of agarose in 60ml of PBS per plate. This 
mixture was heated in the microwave until it became clear. The agarose solution was 
poured into each plate and allowed to cool to room temperature. 
Solidified agar plates were transferred to the dark room for the test. Third instar 
larvae were picked up gently using a moist paintbrush, to avoid any injury to larva. 
Food residue was removed by transferring the larvae in a small volume of water. 
Larvae were accustomed and trained in a small petri dish containing agar prior to 
testing for 30 seconds. Larvae were then placed in the middle of a 15cm petri dish for 
2 minutes under safe light conditions. The trail larvae left on agar surface was traced 
using a marker pen on the dish surface. The petri dish was then scanned and the 
distance travelled measured using ImageJ 1.45b software (Wayne Rosband, NIH, 
USA, http://imagej.nih.gov/ij).    
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Adult climbing (Negative geotaxis assay) 
Climbing assays were carried out on 2 to 3 day old male flies unless otherwise 
mentioned. After the eclosion adult flies were anaesthetised using CO2 and 
approximately 20 male flies separated into a fresh vial. These flies were kept at 25
0
C 
for around 24 hours to minimise the effect of anaesthetic on climbing performance.  
To standardise the effects of circadium rhythm, flies were tested at 9 o‟clock in the 
morning. The tip of a 5ml Falcon pipette was cut off and using a mouth aspirator, a 
single fly was aspirated into the pipette. The pipette was then inverted and tapped 
against bench so that the fly fell to the bottom of the pipette. The fly instinctively 
climbs the wall of the pipette and the distance travelled by each fly was measured 
after 10 seconds of continuous climbing (runs in which flies paused during the climb 
were ignored). Each fly was tested 3 times and the average value for each fly was 
used to determine the average distance climbed for each genotype. 
 
Jumping ability 
These experiments were performed by Dr. Chris Eliott as previously described in 







2.2.13 Statistical tests and graphs 
 
Data analysis and statistical analysis of data were performed using GraphPad Prism 5 
(GraphPad Software Inc) using the Student‟s t-test. Significance was determined 
using p value and values of p≤0.05 were considered significant. P values >0.05 were 




Chapter 3. Development of a neuronal model for mtDNA loss in 
Drosophila 
 
3.1 Introduction  
 
The principal function of mitochondria is to generate energy for the cell. 
Mitochondria have their own genome, encoding 37 genes. The number of 
mitochondrial DNA (mtDNA) copies varies between different cells and tissues. 
Maintaining a healthy mtDNA copy number is crucial for mitochondria to perform 
their cellular function within a dynamic network. Furthermore, morphological 
changes in mitochondrial structure through fusion/fission events have also been 
shown to be important for mtDNA maintenance (CHEN et al. 2007).  
Given that mitochondria are highly abundant in muscle, owing to their high ATP 
requirement, mitochondrial dynamics are of utmost importance in muscle cells. 
Another group of cells in which mitochondrial activity is vital are nerve cells. 
Neurons have a high energy demand and control the function of other cells and 
tissues via signal transmission. This signal transmission occurs via neurotransmitter 
release at contact sites known as synapses. Synapses need an abundant supply of 
ATP for signal transmission, thus synaptic mitochondria are critical to synaptic 
function (LI et al. 2004; SCHUMAN and CHAN 2004). One subset of neurons which 
are particularly dependent on mitochondrial activity are motoneurons. Their synapses 
terminate at neuromuscular junctions to regulate muscle activity. It has been reported 
that unhealthy mitochondria at the synapses can lead to neuronal dysfunction (DU et 
95 
 
al. 2010). However, the actual mechanism linking mtDNA abnormalities and 
neuronal dysfunction is not well studied. In this chapter I have developed a model 
utilising the powerful genetic tools available in the fruit fly Drosophila melanogaster 
in an attempt to understand the relationship between mtDNA loss and neuronal 
dysfunction.  
 
3.2 The effect of ethidium bromide treatment on Drosophila 
development and longevity 
 
It has been previously reported that the DNA intercalating agent ethidium bromide 
(EtBr) can bind to mtDNA and inhibit in vivo transcription of mtDNA (FUKUHARA 
and KUJAWA 1970). This binding can have adverse effects on mtDNA homeostasis 
and was previously demonstrated to induce mutations in the mtDNA of yeast 
(SLONIMSKI et al. 1968). Furthermore, EtBr treatment of Drosophila KC167 cells 
resulted in changes in mtDNA content between 2-184%, while most of the cases 
(90%) showed some level of reduction in mtDNA level (MOREL et al. 1999). 
Therefore, EtBr could be a useful tool for investigating the phenotypic consequences 
of mtDNA loss in Drosophila. Given the affect of EtBr on mtDNA and that it has 
previously been reported that EtBr treatment results in developmental defects 
(FLEMING et al. 1981), I hypothesized that EtBr consumption may be an effective 
method to deplete mtDNA in flies. Firstly, the effect of EtBr on larval development 
was tested.  A reduced number of third instar larvae were observed with increasing 
concentrations of EtBr in the food (Figure 3.1A). The pupal stage and adult stages 
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were still reached by larvae that consumed up to 1mM of EtBr. However, higher 
concentrations of EtBr caused developmental arrest at the larval stage (Figure 3.1A). 
 To investigate whether this phenotype was related to mtDNA maintenance, mtDNA 
levels were analysed at the third instar larval stage. Larvae grown in food containing 
1mM EtBr had slightly reduced levels of mtDNA, compared to control larvae grown 
on non-EtBr containing media (Figure 3.1B), which was close to reaching 
significance (p=0.0578).  In order to investigate the effects of EtBr on adults, larvae 
were grown in normal (non EtBr containing) food and fully developed adult flies 
were then transferred to EtBr containing food. Therefore by introducing EtBr in the 
growth media after larval development, the effects of EtBr consumption on adult 
flies could be investigated independently of developmental abnormalities. The effect 
of EtBr on the lifespan of adult flies was investigated by ageing flies in 0.2mM EtBr 
or 2mM EtBr containing food and normal food. The maximum lifespan of both EtBr 
treated and untreated flies was the same, at around 50 days (Figure 3.1C). Median 
lifespan, which is the time when 50% of the population are alive, was also calculated 
and for all of the conditions this was around 34 days (Figure 3.1D). In conclusion, no 
lifespan effect was observed for either low or high concentrations of EtBr and 
median survival was the same for control flies and flies grown on 0.2mM and 2mM 
EtBr containing food (Figure 3.1C and 3.1D).  
MtDNA levels in aged flies was analysed, achieved by extraction of DNA and qPCR 
from two day old control flies, 40 day old control and 40 day old flies grown on 
0.2mM and 2mM EtBr containing food. It has been previously reported that age-
related decline of mtDNA occurs in skeletal muscle and liver of rats (Barazzoni 
2000). Similar results were also recently reported in fish (the shortlived fish 
Nothobranchius furzeri) (HARTMANN et al. 2011). In accordance with these studies 
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old flies (40 days) had a significantly lower level of mtDNA than young flies (2 days 
old). In addition, mtDNA levels were found to decrease as EtBr concentration 
increased.  A slight but not significant reduction in mtDNA levels was observed in 
flies grown on food containing 0.2mM EtBr and a significant reduction was observed 
in those grown on food containing 2mM EtBr, when compared to age-matched flies 
grown on normal food (Figure 3.1E). To summarise, EtBr treatment results in 
developmental defects at larval stage and causes a slight but not significant decrease 
in mtDNA level. Interestingly, although EtBr treatment does not affect lifespan, it 
does reduce the mtDNA copy number significantly in aged adults. Although EtBr 
treatment may be useful to induce mtDNA loss, it may also induce non-specific 
toxicity and may not affect all tissues equally. Therefore I investigated ways of 
















Figure 3.1 Effect of EtBr on Drosophila development and ageing 
(A) High concentrations of EtBr has detrimental effects on larval development. 100 
wild-type embryos grown on EtBr concentrations ranging between 0.01 to 10 mM. 
Larval development was severely affected with 5 and 10mM EtBr. (B) Feeding 
larvae with 1mM EtBr during development causes slight a reduction (not significant 
but the p value was 0.0578) in mtDNA level at third instar larval stage. qPCR was 
performed on DNA isolated from 5 larva per sample. (C) Both low and high doses of 
EtBr do not affect adult lifespan. 100 flies were aged on either control, 0.2mM or 
2mM EtBr containing food at 25
0
C. (D) Graph showing median lifespan of flies aged 
in control, 0.2mM and 2mM EtBr containing media. Lifespan repeated three times 
and average median lifespan plotted. (E) EtBr reduces mtDNA level in aged flies. 
Adult flies developed on control media aged for 40 days on either control, 0.2mM or 
2mM EtBr containing media. QPCR was performed on DNA isolated from five male 
flies. Aged control flies had significantly less mtDNA content compared to young 
flies. 0.2mM EtBr treatment reduced the mtDNA level slightly (p=0.1104), however 
2mM treatment resulted in a significant reduction (p=0.0183). Mean values +/- SEM 





3.3 Knockdown of mtDNA replication genes to deplete mtDNA in 
Drosophila  
 
The maintenance of mtDNA is vital for a healthy and a functional mitochondrial 
network, which is itself crucial in cell functioning and survival. In order to 
investigate mtDNA maintenance, we decided to take a genetic approach.  Proteins 
encoded by the nuclear genome have a major role in assembling the mtDNA 
replication machinery and stabilizing mtDNA and defects in these genes can result in 
mitochondrial disease (SUOMALAINEN and KAUKONEN 2001). We investigated the 
hypothesis that mtDNA associated proteins encoded by the nuclear genome are 
necessary for the viability of the organism. We used various RNAi lines from 
different sources (shown in the Table 3.1) to knockdown nuclear genes, which 
encode proteins that are known to be required for mtDNA replication. The candidate 
genes included tamas (the catalytic subunit of mtDNA polymerase), Polγ-35 (the 
accessory subunit of mtDNA polymerase), DNK (deoxyribonucleoside kinase), 
Twinkle (the mtDNA helicase) and TFAM (mitochondrial transcription factor A). All 
of these genes have been shown to take part in regulating mtDNA copy number and 
are required in mtDNA replication (reviewed in (MORAES 2001)). Using these RNAi 
lines, we knocked-down the genes ubiquitously by crossing to the Actin-Gal4 driver 
(Table 2.1) and adult viability was then analysed for each cross (Table 3.1). All of 
the tamas-RNAi lines were viable. However, three of the five different RNAi lines 
against Polγ35 were lethal. Two of these lines target the same part of the gene, 
however the region targeted by the remaining line only partially overlaps with the 
others (Figure 3.2).  One of the Twinkle-RNAi, all of the DNK-RNAi and TFAM-
RNAi lines were lethal when ubiquitously expressed (Table 3.1). Only two of the 
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TFAM-RNAi lines targeted the same region of the gene, however two partially 
overlap with this region and one targets a completely different part of the gene 
(Figure 3.2). These results proved the requirement of these genes for the viability of 
Drosophila and helped us to narrow down our list for future experiments. 
Ubiquitous knockdown of mtDNA related genes by Actin-Gal4 highlighted the 
importance of these genes for survival of the organism. DNK, which is not directly 
associated with the mtDNA replication fork but takes part in maintaining the dNTP 
pool, has been identified to be a multisubstrate enzyme (JOHANSSON et al. 1999). In 
humans, the three essential enzymes which maintain the mitochondrial dNTP pool 
are dGK (deoxyguanosine kinase), TK2 (thymidine kinase) and dNT2 (5(3)-
deoxyribonucleotidase) (MATHEWS and SONG 2007; SAADA-REISCH 2004). It has 
been shown that mutations in dGK and TK2 are linked to mtDNA depletion in 
humans (MANDEL et al. 2001; SAADA et al. 2001). In Drosophila, DNK 
(deoxyribonucleoside kinase) is a global deoxynucleoside kinase and has a broader 
substrate specificity with roles in overall dNTP metabolism in the cell and higher 
catalytic activity compared to multiple enzymes in mammals (MUNCH-PETERSEN et 
al. 1998a; MUNCH-PETERSEN et al. 1998b). As DNK has a more general role 
compared to the mammalian dNTP maintenance enzymes, I did not use RNAi 
against DNK for the further experiments.  
In conclusion, these experiments demonstrate that mtDNA replication genes are 
necessary for viability in Drosophila 
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Stock name Source (Stock No) Gene (CG No) Inserted Chromosome Actin-Gal4 Phenotype 
tamasIR-1 VDRC (3135) tamas (CG8987) 2 Viable 
tamasIR-2 VDRC (3133) tamas (CG8987) 2 Viable 
tamasIR-3 VDRC (106955) tamas (CG8987) 2 Viable 
PolG35IR-1 VDRC (30483) PolG35 (CG33650) 3 Lethal 
PolG35IR-2 VDRC (30484) PolG35 (CG33650) 3 Viable 
PolG35IR-3 VDRC (49769) PolG35 (CG33650) 3 Viable 
PolG35IR-4 NIGFLY (8969R-2) PolG35 (CG33650) 3 Lethal 
PolG35IR-5 NIGFLY (8969R-3) PolG35 (CG33650) 2 Lethal 
DNKIR-1 VDRC (39137) DNK (CG5452) 3 Lethal 
DNKIR-2 VDRC (103385) DNK (CG5452) 2 Lethal 
TwinkleIR-1 NIGFLY (5924R-3) Twinkle (CG5924) 3 Viable 
TwinkleIR-2 NIGFLY (5924R-1) Twinkle (CG5924) 2 Lethal 
TFAMIR-1  NIGFLY (4217R-2) TFAM (CG4217) 2 Lethal 
TFAMIR-2  VDRC (107191) TFAM (CG4217) 2 Lethal 
TFAMIR-3  NIGFLY (4217R-1) TFAM (CG4217) 3 Lethal 
TFAMIR-4  Bloomington (26744) TFAM (CG4217) 3 Lethal 
TFAMIR-5  VDRC (37819) TFAM (CG4217) 3 Lethal 
 
Table 3.1 List of RNAi lines used to cross to the Actin-Gal4 driver 
First column shows the nomenclature used in this study. Second column showing the stock centre and stock number. Final column shows the 










Figure 3.2 Schematic representation of RNAi lines used to knockdown mtDNA 
replication genes ubiquitously 
 (A) Two of the three tamas RNAi lines target the same region. (B) There are three 
different regions targeted by five PolG35 RNAi lines. (C) Two partially overlapping 
dnk RNAi lines. (D) Both of the Twinkle RNAi lines target the same region. (E) Only 




3.4 Knockdown of mtDNA replication genes using a pan-neuronal 
driver 
In order to study the requirements for the mtDNA replication genes Polγ, Twinkle 
and TFAM in neurons the pan-neuronal driver Elav-Gal4 was used. Polγ, Twinkle 
and TFAM RNAi lines crossed to Elav-Gal4 resulted in viable progeny. Adult CNS 
tissue was dissected from the male progeny to quantify the mtDNA levels by qPCR. 
DNA was isolated from 5 brains per genotype and 3 samples were tested by qPCR. 
Most of the lines tested showed a variable result and had no effect on mtDNA levels 
apart from two Polγ RNAi lines, which resulted in a variable but significant increase 
(Figure 3.3). 
The main function of mitochondria is to produce energy in the form of ATP by 
oxidative phosphorylation. In order to analyse the ATP levels in neurons the Elav-
Gal4 driver was used to knockdown Polγ, Twinkle and TFAM by RNAi in the 
nervous system and luciferase assays were carried out on pools of twenty adult CNS 
preparations. TFAM and Twinkle RNAi lines showed a reduction in ATP levels in 
female flies. In contrast, Polγ RNAi resulted in increased levels (Figure 3.4A). The 
same assay was also carried out on male flies, with a reduced level of ATP observed 
in all of the RNAi lines tested (Figure 3.4B). These results suggested that, although I 
did not detect a reduction in mtDNA levels in the adult brain, ATP levels were 










Figure 3.3 Pan-neuronal RNAi of Polγ, Twinkle and TFAM does not cause 
mtDNA depletion. 
Three different Polγ, one Twinkle and two different TFAM RNAi lines were crossed 
to Elav-Gal4 driver. All of the brain samples tested had approximately the same level 
of mtDNA compared to the control apart from two Polγ lines. Control samples were 
obtained from OreR flies crossed to the Elav-Gal4 driver. QPCR was performed on 
DNA isolated from 5 brains dissected from adult flies. Results represent relative 






Figure 3.4 Pan-neuronal RNAi of Polγ, Twinkle and TFAM shows a reduction in 
ATP level in male flies. 
Samples were prepared by dissecting 20 adult CNS from 2-3 day old flies. One 
sample was prepared for each genotype and normalised to total protein level by 
Bradford assay. Luciferase assays show a slight reduction in the level of ATP in CNS 
in males upon knockdown of Polγ, Twinkle and TFAM (B), however there was no 
effect in female flies apart from an increase in ATP levels upon Polγ knockdown (A). 





3.5 Neuroblast-specific knockdown of Polγ, Twinkle and TFAM reduces 
mtDNA copy number and affects behaviour. 
 
Mutants and RNAi of nuclear encoded factors required for mtDNA replication have 
been associated with mtDNA depletion in different model organisms (OLIVEIRA et 
al. 2010). As explained in detail in the introduction, Polγ-α and Polγ-β, Twinkle, 
TFAM, mtSSB and RNase H1 knockdown have been previously used to induce 
mtDNA loss in cell culture (Section 1.4.4). Since RNAi of several of these genes in 
neurons using Elav-Gal4 did not induce a detectable reduction in mtDNA levels the 
neuroblast driver MZ1407-Gal4 was used to express the RNAi lines previously 
described. MZ1407-Gal4 drives expression in neuroblasts (from embryonic stage 
10/11) and subsequently in most neurons of the CNS and all neurons in PNS (LUO et 
al. 1994). Using the MZ1407-Gal4 driver, dsRNAs against Polγ, Twinkle and TFAM 
were expressed in developing neuroblasts and subsequently in neurons in the CNS 
and in the PNS. These crosses gave viable progeny at 21
0
C, so allowing us to carry 
out experiments at the adult stage. MtDNA levels were measured by qPCR using 
DNA isolated from fly heads. All of the RNAi lines tested showed a trend of slight 
reduction in the mtDNA levels but none of them reached a significant level (Figure 
3.5).  The expression pattern of the MZ1407-Gal4 driver was checked by crossing the 
driver to UAS-nlsGFP and staining with an antibody against Miranda, used as a 
neuroblast marker. Confocal imaging showed broad GFP expression throughout the 
CNS in Miranda positive neuroblasts and in neurons in the optic lobes, central brain 
and thoracic ventral nerve cord (VNC) (Figure 3.6). These data confirmed the 




As RNAi of TFAM produced the strongest decrease in the mtDNA levels (Figure 
3.5) when driven by MZ1407-Gal4, we analysed this gene in detail by using 
independent TFAM RNAi lines (Figure 3.2). TFAMIR-2 was lethal when crossed to 
MZ1407-Gal4 at 25
0
C (Figure 3.7A). Therefore TFAMIR-3 and TFAMIR-2 were 
crossed to MZ1407-Gal4 and developed at 21
0
C. Both of the lines were viable, 
however TFAMIR-3 flies had reduced viability compared to controls (Figure 3.7B). 
Furthermore, larval locomotion assays were carried out at the larval stage and both of 
the lines had significant defects in larval movement (Figure 3.7C), with a significant 
reduction observed in the total distance travelled by larvae in two minutes compared 
to the control (Figure 3.7C). All viable TFAM RNAi lines crossed to MZ1407-Gal4 
showed a wing expansion phenotype at 25
0
C (Figure 3.8 A-E). Climbing assays on 
adult flies grown at 21
0
C were also carried out and a significant reduction was 
observed both in males and females, for both TFAMIR-2 and TFAMIR-3 (Figure 3.8F 
and 3.8G). 
In order to investigate the reasons underlying the behavioural phenotypes caused by 
MZ1407-Gal4 induced knockdown of TFAM, CNS tissue was dissected and analysed 
by confocal microscopy. I hypothesised that loss of TFAM may cause reduced 
neuroblast proliferation. Therefore, Miranda staining was used to quantify neuroblast 
number in the larval VNC. No difference was observed in the number of neuroblasts 
in the larval VNC in TFAM RNAi animals compared to controls (Figure 3.9A,B). 
This shows that RNAi of TFAM using MZ1407-Gal4 driver does not affect 
neuroblast number and so the locomotion phenotype, at least at the larval stage, is 
unlikely to be caused by loss of neuroblasts.  
In conclusion, expression of several different dsRNAs against TFAM using MZ1407-
Gal4 all resulted in slight but not significant decrease in mtDNA levels and result in 
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developmental and behavioural defects. Therefore, RNAi of mtDNA replication 
genes using MZ1407-Gal4 could be a useful system for investigating the 
consequences of mtDNA loss in neuroblasts and differentiated neurons throughout 








Figure 3.5 RNAi of mtDNA replication genes using MZ1407-Gal4 causes 
mtDNA loss. 
MtDNA content of DNA extracted from 5 fly heads was quantified using qPCR. A 
slight reduction was observed with all of the dsRNA lines expressed using MZ1407-
Gal4 at 21
0
C compared to control samples. Control samples were obtained using the 
driver line crossed to CyO balancer flies. Mean values +/- SEM plotted on graph.. P 
values were 0.0942 for PolGIR-1, 0.2153 for TwinkleIR-2, 0.0529 for TFAMIR-2 and 







Figure 3.6 The MZ1407-Gal4 driver has a broad expression in the CNS.   
Confocal microscopy carried out to visualize the expression pattern of the MZ1407-
Gal4 driver.  MZ1407-Gal4 driver line flies crossed to UAS-nlsGFP. The expression 
pattern of the MZ1407 driver (green) shows wider signal compared to the neuroblast 
specific antibody Miranda (red) in the larval CNS (A-B‟‟), and adult CNS (C-D‟‟). 





Figure 3.7 TFAM knockdown using MZ1407-Gal4 driver causes reduced 
viability and reduced larval locomotion. 
Fifty first instar larvae were transferred to vials containing normal food and 
developed until they reached the adult stage. The number of eclosed adults was then 
quantified. (A) TFAMIR-3 affects viability and TFAMIR-2 causes lethality when flies 
were developed at 25
0
C. (B) TFAMIR-3 has a negative effect on viability when 
developed at 21
0
C. (C) Larval movement was reduced both in TFAMIR-2 and 
TFAMIR-3 crosses at 21
0
C. Five larvae per genotype were tested on an agar surface 
under light controlled conditions. For all of the assays separate control flies were 
used for each TFAM RNAi line. RNAi lines were balanced over an RFP reporter 
prior crossing to the driver line. RFP expressing progeny were used as a control in 








Figure 3.8 TFAM RNAi expressed using MZ1407-Gal4 causes developmental 
and behavioural defects in adults. 
Four different RNAi lines were crossed to the MZ1407-Gal4 driver at 25
0
C. 
TFAMIR-2 was lethal, however the other lines developed to the adult stage. (A-E) 
All of the TFAM RNAi lines tested had defects in wing expansion. Two of the TFAM 
RNAi lines were also tested for climbing behaviour. Both TFAMIR-2 (F) and 
TFAMIR-3 (G) flies had climbing defects when developed at 21
0
C. For both of the 
assays separate control flies used for each TFAM RNAi line. RNAi lines were 
balanced over an RFP reporter prior crossing to the driver line. RFP expressing 
progeny were used as a control in subsequent experiments. Mean values +/- SEM 










Figure 3.9 Effect of TFAM RNAi on neuroblasts 
 (A) Representative figure illustrating neuroblasts using Miranda staining. 
Highlighted region shows the area quantified. (B) Knockdown of TFAM using 
MZ1407-Gal4 does not affect the number of neuroblasts in the VNC. Control flies 
were RFP expressing flies either on the second chromosome (Control-2) or third 





3.6 Knockdown of Polγ, Twinkle and TFAM in mushroom body neurons 
 
The Drosophila CNS consists of many of different neuronal types. During 
development, axons extending from neuronal cell bodies follow a stereotypical path 
in order to reach to their targets. Mushroom body (MB) neurons have a very distinct 
axonal morphology (Figure 3.10A, (CRITTENDEN et al. 1998)) and are involved in 
olfactory learning and memory (MCGUIRE et al. 2001; ROMAN and DAVIS 2001; 
WOLF et al. 1998). These neurons have been previously used in many studies to 
assess the functions of genes needed for neuronal development and survival. 
Furthermore, MB neurons are very convenient to model axonal degeneration.  
In order to investigate mtDNA loss in neurons at a cellular level, RNAi lines were 
crossed to the MB specific driver OK107-Gal4 (CONNOLLY et al. 1996). Polγ, 
Twinkle and TFAM RNAi lines were crossed to the OK107-Gal4,CD8-GFP driver 
and the progeny aged for 30 days. A MB specific driver expressing a CD8-GFP 
reporter was used to analyse the morphology of these neurons in detail. Aged fly 
CNS‟ were dissected and investigated using confocal microscopy. The α/α‟ lobe, 
which is oriented dorsally, and the medially orientated β lobe were the two regions 
analysed (Figure 3.10A). Slightly thinner neuronal branches were observed in the α‟ 
lobe of the Polγ and TFAM knockdown flies (Figure 3.10C,E). Polγ RNAi flies 
displayed a slight axonal overextension phenotype at the β lobe, however β lobe 
morphology was normal in the other lines tested (Figure 3.10). Although MB 
neurons can be useful to analyse axonal degeneration, it is very difficult to assess 
functional phenotypes with this group of neurons.  
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Therefore, knockdown of mtDNA replication genes produce distinct phenotypes in 
MB neurons. This system could potentially be used to investigate the consequences 
of mtDNA loss on axonal pathfinding and degeneration and any resultant learning 






Figure 3.10 Mushroom body specific RNAi of Polγ and TFAM results in thinner 
axons. 
(A) Representative cartoon of mushroom body lobes (Crittenden et al. 1998). α /α‟ 
lobes are dorsal (up) and β/β‟ lobes face medially. Polγ (C) and TFAM RNAi (E) in 
mushroom bodies caused thinner α‟ lobes in aged flies. (B) However, the other 
branches looked similar to the control (OreR crossed to the OK107-Gal4,UAS-
cd8GFP driver). Arrows indicate thinner branches. All of the genotypes were imaged 





3.7 Motoneuron specific knockdown of Polγ, Twinkle and TFAM affects 
larval and adult behaviour 
 
The Drosophila nervous system is a powerful model, with an extensive genetic 
toolbox available. Drosophila motoneurons have been used as a model by many 
laboratories and there are various drivers available that are specific to these neurons.  
Approximately 80 motoneurons per hemisegment are generated during 
embryogenesis from 30 neuroblasts (LANDGRAF and THOR 2006a; LANDGRAF and 
THOR 2006b). In order to fulfil their functions, motoneuron axons extend to their 
particular target muscles to form synapses. These neurons are needed for motor 
function as they control muscle activity through synapses at neuromuscular junctions 
(NMJs). The requirement of proteins involved in mtDNA replication machinery was 
investigated in this neuronal population using the OK371-Gal4 driver. OK371-Gal4 
is an enhancer trap element inserted upstream of the vesicular glutamate transporter 
(VGlut), which is expressed specifically in motoneurons and some neuronal clusters 
in the brain (MAHR and ABERLE 2006). OK371-Gal4 was used to knock-down Polγ, 
Twinkle and TFAM in motoneurons. Larval motility assays were carried out in (see 
Behavioural Assays section in Chapter 2) to assess the effect of motoneuron-specific 
knockdown of mtDNA related genes on locomotion. Polγ RNAi larvae displayed no 
reduction in larval movement, however both Twinkle and TFAM RNAi larvae 
showed a significant reduction (Figure 3.11A). TFAMIR-3 was further tested with 
two controls. OK371-Gal4 crossed to OreR flies were used as external controls, 
while larvae expressing RFP developed in the same tube as the TFAMIR-3 larvae, 
were used as internal controls. In order to generate the internal control, PRSP2 flies 
were crossed to TFAMIR-3 and the progeny of this cross (TFAMIR-3/PRSP) was 
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subsequently crossed to the OK371-Gal4 driver. PRSP2 is a construct generated 
using an enhancer element from the gene pointed to drive RFP expression in 
oenocytes and other tissues (KAUL and BATEMAN 2009). Larval locomotion of 
internal and external controls were similar, while TFAM knockdown larvae had 
reduced larval locomotion compared to both controls (Figure 3.11B). 
Flies with motoneuron specific knockdown of Polγ, Twinkle and TFAM were viable. 
Climbing assays were carried out in order to test adult behaviour. All three RNAi 
lines had reduced climbing performance compared to controls when male flies were 
tested (Figure 3.12A). In female flies there was a significantly lower climbing 
performance upon expression of dsRNAs against Polγ and TFAM, but not Twinkle 
(Figure 3.12B).  Since RNAi of TFAM gave the most severe locomotion phenotype, I 
investigated the effects of TFAM knockdown in detail. 
Motoneuron specific TFAM knockdown flies were aged for 30 days to test whether 
the climbing phenotype worsened with age. In order to reduce the variability, more 
flies were tested compared to the previous assay presented in Figure 3.12. 12-15 flies 
were tested on day 2 and 10 flies were tested on day 30. As shown in Figure 3.13A, a 
similar level of reduction was observed in male flies at both of the time points. 
Interestingly, when female flies were tested using 12 flies as opposed to 5 (in the 
previous assay shown in Figure 3.12), there was no difference in climbing 
performance on day 2 (Figure 3.13B). However, 10 female flies tested on day 30 had 
a significant reduction in the distance travelled compared to control flies (Figure 
3.13B). Female control flies at 30 days had significantly reduced climbing activity 
compared female controls at 2 days, while male control flies performance did not 
change with age. TFAMIR male flies exhibited a climbing defect early on inlife and 
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this did not change after 30 days. In contrast, female flies had a normal climbing 
performance early in life, but reduced climbing activity after 30 days. 
In summary, expressing dsRNA lines against mtDNA related genes in motoneurons 
did not cause lethality, but affected larval and adult behaviour. Furthermore, TFAM 
knockdown resulted in the strongest larval locomotion phenotype, compared to Polγ 
and Twinkle knockdown. Therefore, knockdown of TFAM using OK371-Gal4 
provides a potential platform for testing the consequences of mtDNA loss in 
motoneurons. The advantages of Drosophila larval motoneurons as an experimental 






Figure 3.11 Motoneuron specific RNAi of Twinkle and TFAM causes larval 
locomotion defects. 
 (A) Four larvae were tested per genotype for larval locomotion under light 
controlled conditions. Motoneuron specific knockdown of Twinkle and TFAM using 
the OK371,CD8GFP,Dcr2 driver line resulted in reduced larval movement compared 
to wild type (OreR) flies crossed to the driver. (B) Knockdown of TFAM using 
TFAMIR-3 significantly reduced larval movement compared to an internal control 
(Control-3, green bar) and an external control (Control-1, blue bar). Mean values +/- 





Figure 3.12 Motoneuron specific RNAi of Polγ, Twinkle and TFAM causes 
reduction in climbing ability. 
 (A) Polγ, Twinkle and TFAM RNAi male flies all show significantly reduced 
climbing performance compared to wild-type (OreR) flies crossed to the motoneuron 
driver OK371-Gal4. (B) Only PolγIR-1 and TFAMIR-3 were affected in female flies. 





Figure 3.13 Motoneuron specific knockdown of TFAM causes age dependent 
defects in the climbing performance of female flies. 
 (A) Male TFAM motoneuron knockdown flies have similarly reduced climbing 
activity at both 2 and 30 days. (B) In female TFAM motoneuron knockdown flies 
climbing ability is reduced at 30 days but not at 2 days. Controls were also reduced 
after 30 days compared to 2 days. Distance climbed in 10 seconds was tested in male 
and female flies separately. Mean values +/- SEM plotted on graph *=p<0.05, 







In this chapter, I have presented work which has resulted in the preliminary 
characterisation of a neuronal specific system to study mtDNA loss. Firstly, I 
demonstrated that EtBr can be used as a tool to deplete mtDNA levels in Drosophila. 
In order to study the consequences of mtDNA depletion at the cellular level, I 
adopted a gene-specific approach and studied the effects of various RNAi lines 
targeting mtDNA replication genes. I tested the requirement for several nuclear 
encoded proteins that are components of the mtDNA replication machinery for 
viability in Drosophila, by ubiquitous RNAi and scoring of lethality. Most of the 
RNAi lines tested caused lethality when ubiquitously expressed and so were further 
investigated to ascertain the necessity of these genes in neurons. This was undertaken 
by knockdown of these using driver lines in specific neuronal populations. Using 
MZ1407-Gal4, a neuroblast and neuronal specific driver resulted in marginally 
decreased mtDNA levels in fly heads. Further to this, using the MZ1407-Gal4 driver 
to knockdown TFAM affected larval development and caused behavioural 
phenotypes at both the larval and adult stage, even though neuroblast number was 
not affected at the larval stage.  
Gal4 drivers for two specific neuronal populations were also used to knockdown 
mtDNA replication genes. The mushroom body specific driver OK107-Gal4 driver 
was used to determine whether any of the RNAi lines affected axonal development. 
Finally, I used motoneurons as a model system to investigate mtDNA depletion. I 
observed behavioural phenotypes both at larval and adult stages for all three RNAi 
lines tested and motoneuron specific TFAM RNAi resulted in age-dependent climbing 
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defects in female flies. Overall the data presented provide the foundation for the 
subsequent detailed analysis of the consequences of mtDNA loss in a specific 









Mitochondrial disorders have been linked to abnormalities in mtDNA, such as 
mutations and deletions. Furthermore, loss of mtDNA results in a group of diseases 
known as mtDNA depletion syndromes (MDS). Replication of mtDNA is necessary 
to maintain an adequate mtDNA copy number. Manipulating TFAM expression 
levels has been reported to affect the mtDNA replication machinery, however the 
exact mechanisms are not known (reviewed in (CAMPBELL et al. 2012a)). In the 
previous chapter, I showed that expressing a dsRNA against TFAM in motoneurons 
caused behavioural defects.  Additionally, pan-neuronal TFAM knockdown using 
MZ1407-Gal4 resulted in slight but not significant depletion of mtDNA in neurons, 
which is in accordance with previous studies. Overexpression of TFAM has also been 
shown to result in mtDNA depletion in tissue culture cells (POHJOISMAKI et al. 
2006). Taken together, the results in the previous chapter and other published studies 
indicate that TFAM knockdown and TFAM overexpression can be used as methods to 
deplete mtDNA.  
In order to investigate the consequences of mtDNA depletion in detail, a tissue 
specific approach was taken. Ubiquitous depletion of mtDNA levels results in 
lethality in different organisms (OLIVEIRA et al. 2010). It has been previously shown 
that generation of tissue specific TFAM knockout mice results in cell death in cardiac 
128 
 
tissues (WANG et al. 2001). Several groups have studied Polγ mutants, the mtDNA 
specific polymerase, as a model of mtDNA depletion. Recently, RNAi of Polγ was 
shown to cause dopaminergic cell loss in flies (HUMPHREY et al. 2012). Motoneurons 
have distinct morphological features, in that synapses are formed on muscles to 
generate the neuromuscular system. SOD1 mutant rat motoneurons were recently 
used as an ALS (amyothropic lateral sclerosis) model to investigate synaptic 
alterations (MAGRANE et al. 2012). Synaptic dysfunction and loss of synapses has 
also been implicated in AD (SHENG and CAI 2012). In the previous chapter I showed 
that RNAi of TFAM in motoneurons results in defects in locomotion. I thus aimed to 
understand the mechanism which underlies these observed behavioural 
abnormalities. 
 
4.2 Ubiquitous knockdown and overexpression of TFAM causes 
different levels of mtDNA depletion 
 
Ubiquitous expression of two RNAi lines against TFAM, TFAMIR-2 and TFAMIR-3, 
caused lethality during the pupal stage (Table 3.1). However, it was possible to 
analyse larvae to determine whether TFAM mRNA levels were affected. In order to 
quantify TFAM transcript levels at the larval stage, qPCR against TFAM and RpL1 (a 
large ribosomal subunit gene) was carried out. Both of the TFAM RNAi lines were 
shown to have reduced TFAM transcript levels, although due to the variability only 
TFAMIR-3 reached significance (Figure 4.1A).  After demonstrating a reduction in 
TFAM expression at the level of mRNA, mtDNA levels were analysed at the third 
instar larval stage. qPCR analysis showed a reduction in mtDNA levels in both 
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TFAM RNAi lines when ubiquitously expressed, although only TFAMIR-3 reached 
significance (Figure 4.1B). 
It has been previously reported that TFAM overexpression can result in mtDNA 
depletion in cultured human cells (POHJOISMAKI et al. 2006). To test whether TFAM 
overexpression causes mtDNA loss in Drosophila, the Drosophila TFAM cDNA was 
cloned into pUAST and pTWG (generating a C-terminal GFP fusion) and used to 
generate transgenic flies (Materials and Methods). When ubiquitously overexpressed 
using Actin-Gal4, TFAMGFP and TFAM overexpression caused developmental 
arrest in the first and second instar respectively. The effects of ubiquitous TFAM 
overexpression on mtDNA levels was analysed by qPCR of genomic DNA isolated 
from first instar larvae (Materials and Methods). Ubiquitous expression of TFAM 
using Actin-Gal4 resulted in a significant decrease in mtDNA copy number (Figure 
4.1 C), while TFAMGFP overexpression also caused a moderate decrease, but this 
did not reach significance (Figure 4.1 C). Similar to third instar larvae (Figure 4.1 B), 
first instar TFAM RNAi larvae had significantly reduced mtDNA levels (Figure 4.1 
C). Taken together these data reveal TFAM RNAi can cause a slight reduction in 







Figure 4.1 Ubiquitous TFAM knockdown and overexpression causes variable 
levels of mtDNA depletion. 
 (A) TFAM transcript levels were reduced at the third instar larval stage in two of the 
TFAM-RNAi lines tested by qPCR. Control-2 and Control-3 were the RFP expressing 
larvae on the second and third chromosome respectively. TFAMIR-2 line was nearly 
significant, with a p value of 0.0557. (B) TFAMIR-3 larvae had a significantly lower 
level of mtDNA compared to RFP expressing control larvae at the third instar larval 
stage. (C) MtDNA levels were reduced both in TFAM knockdown and 
overexpression lines at the first instar larval stage. Control samples were obtained by 
crossing w
1118 
flies to Actin-Gal4 driver flies. P values for each of the experiments 





4.3 TFAM RNAi and overexpression disrupts wing development 
 
In order to assess the effect of TFAM RNAi and overexpression at the protein level I 
used a commercially available antibody that recognises Drosophila TFAM. Initial 
characterisation of this antibody showed that it gave strong punctate cytoplasmic 
staining that co-localised with mitochondrially-targeted GFP expression by 
immunofluorescence (not shown), similar to the expression pattern of TFAM seen in 
vertebrate cells (LEGROS et al. 2004). I decided to use the wing imaginal disc as a 
system to initially analyse the effect of TFAM RNAi and overexpression at the 
protein level by using MS1096-Gal4. MS1096-Gal4 is an X-linked Gal4 enhancer 
trap inserted in Beadex and is expressed in the dorsal compartment of the wing 
(CAPDEVILA and GUERRERO 1994). Given that the ventral compartment of the wing 
is unaffected, it can therefore be used as an internal control. Wingless (Wg) staining 
can be used to differentiate between the dorsal and ventral compartments (Figure 4.2 
A-A‟). Staining of wing discs with the TFAM antibody from larvae in which TFAM 
RNAi was driven with MS1096-Gal4 showed that in the dorsal compartment there 
was a reduction in the level of diffuse TFAM staining and small TFAM puncta, 
while larger puncta were more apparent (Figure 4.2B-B‟). The effect of TFAM and 
TFAMGFP overexpression was also analysed in the wing using MS1096-Gal4. 
Expression of both TFAM and TFAMGFP caused a dramatic increase in TFAM 
protein levels (Figure 4.2 C-C‟,D). These data confirm that RNAi and 
overexpression of TFAM causes either decreased or increased TFAM expression 
respectively, at the protein level. 
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Adult flies generated by RNAi or overexpression of TFAM with MS1096-Gal4 had 
distinct wing phenotypes. Wings from TFAM RNAi flies were curved upwards and 
were reduced in size compared to controls (Figure 4.3A,B). Both TFAM and 
TFAMGFP overexpression resulted in more severe phenotypes compared to the 
TFAM knockdown. TFAM overexpression wings were extremely small and abnormal 
compared both to controls and TFAM RNAi wings (Figure 4.3C,D). The basis for 
these phenotypes was not investigated further, but could result from decreased 







Figure 4.2 TFAM staining in the larval wing disc. 
 (A-A’) Whole wing disc from a third instar larvae. Reduced TFAM staining can be 
observed in the dorsal compartment (upper half of the box) wing imaginal disc where 
the dsRNA against TFAM is driven by the MS1096-Gal4 driver. Wingless (green) 
staining shows the boundary between dorsal and ventral compartments. Antibody 
staining against TFAM is shown in red and DAPI (blue) stained cell nuclei. (B-B’) 
Close up scan of the boxed area in the A-A‟. Expressing a dsRNA against TFAM in 
the dorsal compartment of the wing disc results in a decrease in TFAM staining. 
Increased TFAM staining was observed in the upper half of the panels when 
TFAMGFP and TFAM was expressed using MS1096-Gal4 (C-C’) and (D-D’). 
Overexpression of TFAM was seen in a wider area than TFAM RNAi and 











Figure 4.3 RNAi or overexpression of TFAM disrupts wing development. 
Control (w
1118
), TFAMIR-3, UAS-TFAMGFP and UAS-TFAM flies were crossed to 
the MS1096-Gal4 driver and developed at 25
0
C. Expressing a dsRNA against TFAM 
using  MS1096-Gal4 resulted in slightly curved and smaller wings (B) compared to 
control (A). (C-D) Expressing TFAMGFP and TFAM in the dorsal part of the wing 





4.4 Effect of TFAM RNAi and overexpression on TFAM protein in 
motoneuron cell bodies 
 
In the previous section I demonstrated that I was able to visualize both knockdown 
and overexpression of TFAM in the wing disc using an antibody against TFAM. 
These experiments not only confirmed that TFAM RNAi and overexpression had the 
expected effects at the protein level, but also validated the specificity of the TFAM 
antibody. However, the main aim of this study was to generate a neuronal model of 
mtDNA depletion. In order to investigate the consequences of mtDNA depletion in a 
neuronal specific system, TFAM levels were manipulated in the motoneuron 
population by using the OK371-Gal4 driver. The OK371-Gal4 stock included a 
UAS-CD8-GFP reporter transgene, so that cells expressing Gal4 could be visualized 
by fluorescence microscopy.  
When control (w
1118
) flies were crossed to the OK371-Gal4,UAS-CD8-GFP driver 
uniform TFAM staining was observed in the GFP expressing motoneuron cell bodies 
in the VNC (Figure 4.4A-A‟‟). However, when TFAM-RNAi flies were crossed to the 
driver line, there was a reduction in the TFAM protein levels (Figure 4.4B-B‟‟). 
Furthermore, most of the small TFAM puncta disappeared, with only large punctate 
structures being observed (Figure 4.4B-B‟‟). Expression of TFAM or TFAMGFP 
resulted in an increase in TFAM staining throughout the motoneuron cell body 
(Figure 4.4.C-D‟‟). In conclusion, similar to the results in the wing imaginal disc, 
manipulation of TFAM levels in motoneurons can be visualized using an antibody 
against TFAM. These data also confirm that RNAi and overexpression of TFAM 






Figure 4.4 Manipulating TFAM levels in motoneuron cell bodies. 
 (A-A’’) TFAM staining is distributed homogenously throughout the VNC in control 
brains. OK371-Gal4,UASCD8-GFP was used to knockdown or overexpress TFAM in 
larval motoneurons. TFAM antibody staining is shown in red and motoneuron cell 
bodies in green. Decreased TFAM staining was observed in the cell bodies 
expressing a dsRNA against TFAM (B-B’’), compared to control cell bodies (A-A’’). 
Control samples were dissected from the progeny of w
1118
 flies crossed to the 
OK371-Gal4,UASCD8-GFP line. Increased TFAM expression was observed in both 





4.5 TFAM RNAi and overexpression in motoneurons causes behavioural 
defects 
 
In the previous chapter, it was shown that knockdown of TFAM in motoneurons 
resulted in larval locomotion and adult climbing defects. Developmental and 
behavioural effects upon motoneuron manipulation of TFAM levels were 
investigated in more detail. Both RNAi and overexpression of TFAM in motoneurons 
appeared to result in viable progeny. To determine quantitatively whether there was 
any effect on viability egg laying cages were used and 300 first instar larvae were 
transferred to vials (50 larvae per vial) and the percentage of the adults that eclosed 
from each vial was documented. RNAi or overexpression of TFAMGFP resulted in 
similar numbers of viable adults to the control. However, overexpression of TFAM 
caused a significant decrease in the number of eclosed adults, although the number of 
pupae was unaffected (Figure 4.5A,B). Therefore motoneuron-specific knockdown 
of TFAM does not affect viability, while TFAM overexpression can reduce the ability 
of pupae to eclose from the pupal case (Figure 4.5.A).  
I also repeated the larval locomotion assay, which previously showed that 
motoneuron-specific RNAi of TFAM caused reduced locomotion (Figure 3.11), this 
time including TFAM and TFAMGFP overexpression. Both knockdown and 
overexpression of TFAM and TFAMGFP resulted in a significant decrease in larval 
motility (Figure 4.5C). 
Climbing assays were also carried out at the adult stage. In accordance with the 
climbing data in the previous chapter, RNAi of TFAM resulted in a decrease in 
climbing compared to controls in male flies (Figure 4.6A). Superficial examination 
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of motoneuron-specific TFAM or TFAMGFP overexpression revealed that, although 
viable, these flies had severe locomotion defects and had difficulty climbing. 
Quantification of climbing ability showed that motoneuron-specific expression of 
both TFAM and TFAMGFP caused a strong reduction, with TFAM expression 
causing a 90% decrease in climbing ablility compared to control flies (Figure 4.6A).  
I also asked whether overexpression of TFAMGFP could rescue the climbing 
phenotype caused by TFAM RNAi in motoneurons. This experiment is complicated 
by the fact that TFAMGFP overexpression also causes a climbing phenotype and that 
TFAM dsRNA expression will target both the endogenous TFAM expression and 
TFAMGFP transgenic expression. OK371-Gal4 driven expression of TFAM RNAi 
and TFAMGFP in the same flies resulted in a climbing phenotype similar to TFAM 
RNAi alone (Figure 4.6B). This result can be interpreted as a failure to „rescue‟ 
TFAM RNAi by TFAM-GFP expression, but this seems unlikely given that 
TFAMGFP has a stronger climbing phenotype than TFAM RNAi. It seems more 
likely that expression of the TFAM RNAi weakens the TFAMGFP phenotype by 
reducing the level of TFAMGFP expression. Further analysis will be required to 
determine which of these interpretations is correct, but this result highlights the 
difficulting in performing rescue experiments when overexpression of a particular 
gene causes a similar, or enhanced, phenotype to loss-of-function.  
In collaboration with Dr. Chris Elliot from the University of York, adult flies were 
tested in a jump response assay (see Section 2.2.12). A small, but significant 
reduction in the jump response was observed in motoneuron-specific TFAM RNAi 
flies, while overexpression of TFAMGFP resulted in a stronger defect (Figure 4.6C). 
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The effect of motoneuron-specific TFAM manipulation on lifespan was also tested. 
Male and female flies were tested separately, given that the sex of the flies can affect 
lifespan (BALLARD et al. 2007). TFAM knockdown and control flies had similar 
lifespan curves. However, expression of TFAMGFP resulted in a very strong 
reduction in lifespan (Figure 4.6 D-E). The median lifespan of control female and 
TFAM knockdown females was 40 days, while the median lifespan with TFAMGFP 
overexpression was 18 days. Male flies with the TFAM knockdown had slightly 
longer median lifespan compared to control, at 53 days versus 42 respectively and 
approached significance (p=0.0597). In contrast, the median lifespan of TFAMGFP 
overexpression males was significantly reduced (6 days). In order to be confident 
about the results, the longevity assays were repeated and similar results were 
observed with TFAMGFP overexpression (medium lifespan was 5 days for males 
and 17 days for females, compared to 49 days in males controls and 40 days in 
female controls). However, the lifespan increase in males upon TFAM knockdown 
did not repeat (they had a similar median lifespan (49 days) to controls (49 days). 
Motoneuron-specific TFAM overexpression flies were not tested since they died 
within a few days of eclosion.  
In conclusion, these data show that manipulating TFAM levels results in behavioural 
defects both at the larval and adult stages. Furthermore, overexpressing TFAM 







Figure 4.5 Motoneuron specific TFAM knockdown or overexpression causes 
behavioural defects at larval stage. 
Manipulation of TFAM levels does not affect larval development. (A) The number of 
larvae developed into adult flies was similar to controls in TFAM RNAi and 
TFAMGFP over-expression. (A- B) Expression of TFAM results in fewer eclosed 
adult flies, however the number of late pupae was similar to controls. (C) Larval 
locomotion assay shows a reduction in larval movement when TFAM was knocked-







Figure 4.6 Manipulating TFAM levels results in behavioural defects in adult 
flies. 
 (A) Climbing assays were carried out on flies developed at 29
0
C. Both TFAM 
knockdown and overexpression causes climbing defects. (B) TFAMGFP 
overexpression does not rescue the climbing defect caused by TFAM knockdown. 
(C) Jump ability is reduced both in TFAMIR-3 and TFAMGFP flies. (D-E) Lifespan 
of TFAMIR-3 flies was not significantly different from control flies (w
1118
 flies 
crossed to the driver line). 100 control and TFAM RNAi flies and 20 TFAMGFP flies 
were tested for lifespan. However, motoneuron specific expression of TFAMGFP 
significantly reduced lifespan both in male and females. Mean values +/- SEM 





4.6 TFAM overexpression disrupts synapse development 
 
Potential mechanisms causing behavioural phenotypes were investigated in the 
motoneuron system at a cellular level. The morphological properties of larval 
motoneurons are well characterized, which make them a valuable neuronal model 
(reviewed in (LANDGRAF and THOR 2006b; TISSOT and STOCKER 2000)).  
Motoneuron cell bodies are located in the larval VNC and axons extend to muscles to 
form synapses. It has been previously shown that murine TFAM-/- mutant embryos 
have a dramatic increase in apoptosis and tissue-specific TFAM knockouts cause 
apoptosis in the mouse heart (WANG et al. 2001). I knocked-down TFAM and 
overexpressed TFAM and TFAMGFP in motoneurons by crossing to OK371-
Gal4,UAS-CD8-GFP flies. In order to investigate if mtDNA depletion resulted in 
cell death, the number of motoneuron cell bodies in the VNC were quantified. 
Motoneurons were visualized by confocal microscopy using the CD8-GFP reporter. 
MtDNA depletion using either TFAM RNAi or overexpresson did not have any 
effect on the number of motoneuron cell bodies (Figure 4.7B). These data show that 
depletion of mtDNA levels in motoneurons does not effect cell survival at the larval 
stage. 
A more detailed analysis of motoneurons was carried out after eliminating the 
possibility of cell death. The morphological properties of different regions of 
motoneurons can be investigated since they have a well characterised morphology. It 
has been hypothesized that neurodegeneration is more severe in the distal 
compartments such as the synapses and mitochondrial transport to synapses is vital 
for neuronal function (MACASKILL and KITTLER 2010; STOWERS et al. 2002). 
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Drosophila motoneuron synapses are formed at different muscle groups known as 
neuromuscular junctions (NMJs). Altogether there are 30 muscle groups in each 
larval hemi-segment (numbered from 1 to 30), which are innervated by motoneurons 
through six nerve branches (HOANG and CHIBA 2001). Two of the most widely used 
synaptic models are NMJ 4 and NMJ 6/7, named since they form synapses on muscle 
groups 4 and 6/7 respectively. The morphology of these NMJs was visualized using a 
Cy3 conjugated HRP antibody (Figure 4.8). HRP antibodies are widely used to 
visualise neuronal membranes (JAN and JAN 1982). The circular structures observed 
at NMJs are termed boutons, and are the contact points between the neuron and 
muscle where neurotransmitter release occurs. There are two main types of boutons 
at NMJ 4 and 6/7, type Ib and type Is, both of which are glutamatergic. Type Ib 
boutons are large (about 3-6μm), while type Is are slightly smaller (2-4μm) and 
originate from different cell bodies (HOANG and CHIBA 2001). Additionally, NMJ 4 
has type II boutons, which are smaller still at about 1-2 μm and their 
neurostransmitter type is not known (HOANG and CHIBA 2001).  
To characterise the pattern of OK371-Gal4 expression at NMJ 4 and 6/7, driver 
expression was visualized by imaging GFP expression. Comparing GFP expression 
and HRP staining showed that the OK371-Gal4 drove strong GFP expression in type 
Ib boutons, but expression was weak or completely absent in type Is boutons of NMJ 
6/7 (Figure 4.8).  When the same analysis was carried out on NMJ 4, it revealed that 
the driver was also strongly expressed strongly in type Ib boutons, but expression 
was very weak in the type Is boutons (Figure 4.8). Type Ib and Is boutons localize 
very close to each other at NMJ 6/7 and most of the time they overlap, making them 
difficult to distinguish. However, at NMJ 4, type Ib and Is localize to different parts 
of the muscle, which makes them much easier to distinguish compared to NMJ 6/7. 
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For this reason I used NMJ 4 to analyse the effects of TFAM RNAi and 
overexpression on motoneuron morphology. 
Firstly I quantified the number of type Ib boutons at NMJ4 in abdominal segment 3 
(A3) for TFAM RNAi and TFAMGFP overexpression. Analysis of untagged TFAM 
overexpression was performed separately and is shown in Figure 4.10, but the results 
were similar to the overexpression of TFAMGFP described below. Both RNAi and 
overexpression of TFAM did not result in changes in bouton number compared to the 
control (Figure 4.9D). However, there did appear to be a difference in the 
morphology of TFAM overexpressing NMJs. Therefore, bouton size was determined 
by measuring bouton diameter (see Materials and Methods). The average diameter of 
the TFAMGFP expressing boutons was approximately 30% smaller than the control 
(Figure 4.9E). By contrast TFAM RNAi did not cause any reduction in bouton size 
(Figure 4.9E). Therefore, neither RNAi or overexpression of TFAM affect bouton 
number, but TFAM overexpression causes a reduction in bouton size.  
Boutons have both pre-synaptic and post synaptic contact sites. An antibody against 
the synaptic protein bruchpilot (brp), known as Nc82, was used to locate active zones 
(WAGH et al. 2006). Active zones are presynaptic neurotransmitter release sites, 
which are visualized as small punctuate structures in boutons. The number of active 
zone puncta was quantified in each of the boutons that were previously analysed for 
diameter. In accordance with the bouton diameter phenotype, TFAM knockdown did 
not affect the number of active zones per bouton. However, expression of TFAMGFP 
in motoneurons resulted in a significant decrease in the number of active zones 
(Figure 4.9F). In order to analyse whether the reduction in the number of active 
zones was proportional to the size of the bouton, active zone density was calculated.  
There was no difference in the active zone density between the control and TFAM 
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knockdown (Figure 4.9G). However, active zone density in TFAMGFP expressing 
boutons was significantly less than the control (Figure 4.9G). These data suggest that 
the reduction in active zone number caused by TFAM overexpression is not simply a 
result of the reduction in bouton size, but that additional mechanisms may directly 
affect active zone development. A similar active zone reduction phenotype was 
observed upon overexpression of TFAM (Figure 4.10E,F).  
In summary these results show that mtDNA depletion does not affect motoneuron 
cell number. However, TFAM overexpression caused defects in synapse size at NMJ 
4. Furthermore, overexpressing TFAM resulted in fewer active zones. These 
phenotypes may contribute to the severe locomotion defects caused by motoneuron-











Figure 4.7 TFAM RNAi or overexpression does not affect the number of 
motoneurons in the VNC. 
 (A) The OK371-Gal4 driver was used with CD8-GFP to visualize motoneurons. 
Representative figure showing motoneuron cell bodies in the VNC of control (w
1118
 
crossed to the motoneuron driver) larval CNS. GFP expressing cells were counted in 
the VNC. (B) Number of motoneurons was not significantly changed upon TFAM 
knockdown and TFAM overexpression. Mean values +/- SEM plotted on graph. 







Figure 4.8 OK371-Gal4 drives strongly in type Ib, but weakly in type Is 
motoneurons. 
 (A-A’’) An HRP antibody was used to visualize neuronal membranes at NMJ 6/7 
and NMJ 4. GFP expression was under control of the OK371-Gal4 driver to visualize 
the expression pattern of the driver. Left panel shows that HRP and OK371 specific 
GFP expression overlaps in type Ib boutons (arrows), but not in type Is (arrowheads) 
in NMJ 6/7. (B-B’’) Right panel shows that all of the type Ib boutons in NMJ 4 
express OK371 (arrow). Type Is boutons are not overlapping with type Ib boutons 








Figure 4.9 Motoneuron specific TFAM over expression results in smaller 
boutons and fewer active zones at NMJ 4. 
Representative scans of NMJ 4 of control (A-A’), TFAM-RNAi (B-B’) and 
TFAMGFP (C-C’). (A-C’) HRP (red) was used to stain NMJ boutons and brp 
(green) is a marker for active zones. (D) The number of boutons at NMJ 4 is similar 
for all three genotypes. Bouton diameter (E), number of active zones (F) and density 
of active zones (G) was similar between control and TFAM knockdown, however all 
were significantly decreased in TFAMGFP expressing boutons. Mean values +/- 







Figure 4.10 Overexpression of TFAM results in similar synaptic phenotypes to 
overexpression of TFAMGFP in motoneurons 
Representative scans of control (A-A‟) and TFAM overexpressing (B-B‟) NMJ 4. 
HRP (red) stains neuronal membranes and brp (blue) stains active zones. 
Overexpressing TFAM did not change the number of boutons (C), however it 
resulted in smaller boutons (D). (E-F) Both active zone number and active zone 
density was reduced compared to control. Mean values +/- SEM plotted on graphs C, 







4.7 TFAM RNAi and overexpression causes depletion of synaptic 
mitochondria 
 
Transport of mitochondria to the synapse is of particular importance and is necessary 
for synaptic function (SHENG and CAI 2012). It has been previously shown that 
NMJs are the first regions to degenerate in mitochondrial-related motoneuron disease 
(FREY et al. 2000; MAGRANE et al. 2012). Under normal conditions, all of the 
boutons in the Drosophila NMJ contain mitochondria (VERSTREKEN et al. 2005). To 
determine whether RNAi or overexpression of TFAM affected synaptic mitochondria 
type Ib boutons at NMJ 4 were analysed for their mitochondrial content. To achieve 
this a P-element containing a mitochondrially-targeted GFP (mito-GFP) (HORIUCHI 
et al. 2005), under UAS control, was recombined onto the same chromosome as 
OK371-Gal4. This stock was then used to knockdown or overexpress TFAM in 
motoneurons that simultaneously expressed mito-GFP, enabling visualisation of 
mitochondria. TFAMGFP expression was not used for analysis of mitochondria since 
there was no way to distinguish between the GFP signal from mito-GFP and 
TFAMGFP.  
In control boutons at NMJ 4 (segment A3) a range of numbers and sizes of 
mitochondria were observed in nearly all of the boutons in control NMJs (Figure 
4.11). This finding is in agreement with a previously published study which showed 
100% of the boutons have mitoGFP in NMJs (VERSTREKEN et al. 2005). Occasional 
small terminal boutons lacking mitochondria were observed in the control NMJs (not 
shown). Furthermore, I also observed that satellite boutons lacked mitochondria 
(arrows figure 4.11 A-A‟), but these are not included in the quantifications. Satellite 
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boutons are usually attacted to big boutons, and are continuously formed and 
degraded depending on synaptic activity. The number of boutons containing 
mitochondria were counted following TFAM knockdown and TFAM overexpression. 
This analysis showed that the percentage of boutons with mitochondria was the same 
both in the control and TFAM RNAi, at around 98% (Figure 4.11D). However, 
significantly more boutons lacked mitochondria when TFAM was overexpressed 
compared to the control, with this leading to mitochondrial absence in approximately 
14% of boutons at NMJ 4 (Figure 4.11D). 
It can be seen from the representative scans that there was a generalised reduction in 
mitoGFP signal at the NMJ of motoneurons expressing the dsRNA against TFAM 
and also in those overexpressing TFAM (Figure 4.11A-C). Therefore I quantified 
these mitochondria in more detail. The number of mitochondria was slightly (but not 
significantly) reduced in TFAM knockdown NMJs (Figure 4.11E). Although the 
percentage of boutons with mitochondria was same in control and TFAM knockdown 
NMJs (Figure 4.11E), the mitochondrial volume was significantly reduced in these 
boutons (Figure 4.11F). Overexpressing TFAM resulted in more severe phenotypes, 
with only 86% of the boutons displaying mitoGFP expression, (Figure 4.11D). 
Boutons with mitochondria were then analysed in more in detail. There was usually 
only a single, small mitoGFP signal in these boutons (Figure 4.11C). Mitochondrial 
abundance was consequently analysed and compared to control boutons. 
Significantly fewer mitochondria were found in boutons overexpressing TFAM and 
the mitochondrial volume was also significantly reduced (Figure 4.11E,F).  
In summary, the synaptic localization of mitochondria was investigated in detail. 
TFAM overexpression, but not knockdown, resulted in a significant increase in 
boutons completely devoid of mitochondria. In addition, mtDNA depletion via 
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TFAM knockdown resulted in smaller mitochondria in NMJ 4, while TFAM 
overexpression resulted in a dramatic reduction in the number and size of 
mitochondria at this NMJ. These mitochondrial phenotypes may potentially 








Figure 4.11 TFAM overexpression results in boutons that lack mitochondria. 
 (A-C’’) Representative scans showing mitochondrial localization at NMJ 4. HRP 
stains neuronal membranes and was used to visualize boutons. Mitochondrial 
targetted GFP (mitoGFP) used to visualize mitochondria.  Arrows indicate satellite 
boutons devoid of mitochondria that were not included in the analysis. (D) There 
were fewer boutons with mitochondria in TFAM overexpressing NMJs. Control 
boutons have a range of number and sized mitochondria, however both TFAM 
knockdown and and overexpression resulted in a weaker mitoGFP signal. (E) There 
were slightly fewer mitochondria in boutons expressing the dsRNA against TFAM 
and even fewer in TFAM overexpressing motoneurons. (F) The mitochondrial 
volume was reduced in boutons upon TFAM knockdown and overexpression.  Mean 






4.8 Effects of TFAM RNAi and overexpression on motoneuron cell body 
and axonal mitochondria 
 
In order to analyse whether mtDNA depletion caused mitochondrial defects only at 
synapses, or whether it had a more global effect, other regions of motoneurons were 
investigated. Firstly, the mitochondrial network in cell bodies was visualized by 
confocal microscopy. Groups of dorsal motoneuron cell bodies at the terminal 
segment of the VNC were imaged (Figure 4.12A). In control cells, a reticular 
mitochondrial network was observed. TFAM overexpression caused disruption of 
this reticular mitochondrial network (Figure 4.12D). Mitochondria were more 
fragmented and punctate in the cell bodies of motoneurons overexpressing TFAM 
(Figure 4.12D). TFAM RNAi did not result in a dramatic change in mitochondrial 
morphology in motoneuron cell bodies, compared to controls (Figure 4.12C). This 
suggests that TFAM overexpression results in a stronger phenotype when compared 
to TFAM knockdown, which correlates with the previous findings at the NMJ. 
Mitochondrial morphology, mitochondrial distribution along the axon, mitochondrial 
activity and axonal transport of mitochondria are all factors that can affect neuronal 
function (reviewed in (CHO et al. 2010; SCHON and PRZEDBORSKI 2011)). Proximal 
and distal segments of axons of motoneurons in which TFAM was knocked-down or 
overexpressed were imaged and the mitochondrial properties analysed. In order to 
analyse proximal segments, the initial segments of the axons exiting the VNC were 
scanned. In the proximal segments, RNAi of TFAM did not affect mitochondrial 
number (Figure 4.13 B,D,E). However, overexpression of TFAM resulted in a 
significantly reduced number of mitochondria (Figure 4.13 C,D). The average 
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volume of mitochondria in the proximal part of the axons was similar in control and 
both TFAM knockdown and overexpression motoneurons (Figure 4.13 B,C,E).The 
distal part of the axons close to NMJ 4 showed more dramatic phenotypes. RNAi and 
overexpression of TFAM resulted in smaller and fewer mitochondria in the distal part 
of the axon (Figure 4.13 F-J).  
In conclusion, TFAM RNAi resulted in a progressive mitochondrial phenotypes 
moving distally from the cell body. Overexpression of TFAM resulted in 
mitochondrial abnormalities in all regions analysed, that is, cell bodies, distal and 





Figure 4.12 TFAM overexpression disrupts the mitochondrial network in 
motoneuron cell bodies. 
Mitochondrial specific GFP expression was used to visualize the mitochondrial 
network in motoneuron cell bodies. (A) Specific groups of dorsal motoneuron cell 
bodies were scanned. (B-C) A tubular mitochondrial network can be seen in control 
cell bodies (driver line crossed to w
1118
 flies) and TFAM knockdown (TFAMIR-3). 
(D) Overexpression of TFAM results in smaller and more punctate mitochondria in 






Figure 4.13 TFAM knockdown and overexpression results in a decrease in 
axonal mitochondria. 
Representative scans of two axonal compartments: proximal axons (A-C) and distal 
axons (F-H). (D-E) There were slightly fewer mitochondria in the proximal parts of 
the axons upon TFAM overexpression, but no effect was observed at proximal axons 
when TFAM was knocked-down. (I-J) There were significantly fewer mitochondria 
in the motoneuron axons both in TFAM knockdown (TFAMIR-3) and TFAM 
overexpression, compared to control (w
1118
 crossed to driver) at the distal part of 
axons. However, mitochondrial volume was significantly reduced only upon TFAM 
overexpression, while TFAM knockdown slightly, but not significantly, (p=0.0789), 
reduced the mitochondrial volume. Quantification was performed in 150 X 50 μm 







In order to understand the consequences of mtDNA depletion in neurons, Drosophila 
motoneurons were used as a model system. Motoneuron cell bodies in the VNC were 
visualized upon TFAM manipulation. MtDNA depletion in motoneurons was shown 
to cause behavioural defects in both the larval and adult stages. However, only 
overexpression of TFAM resulted in a decrease in lifespan. The synaptic properties of 
motoneurons were investigated in detail and smaller boutons were observed in TFAM 
overexpressing motoneurons, suggesting synaptic developmental defects (Table 4.1). 
I was able to visualize the mitochondrial network throughout the motoneurons by 
using mitochondrial targeted GFP, which revealed that loss of mtDNA caused 
depletion of synaptic mitochondria. Other parts of the motoneurons were also 
visualized in an attempt to analyse mitochondrial phenotypes. Overexpression of 
TFAM resulted in smaller mitochondria, compared to the filamentous mitochondrial 
network observed in control cell bodies. Furthermore, the proximal and distal parts 
of the motoneuron axons were analysed. Only overexpression of TFAM resulted in a 
reduced number of mitochondria in the proximal axon. The more distal regions of the 
axons were affected more severely by mtDNA depletion, as both TFAM knockdown 
and overexpression resulted in smaller and fewer mitochondria. To conclude, 
mtDNA depletion results in abnormalities in the mitochondrial network, which 






TFAM RNAi  TFAM 
Overexpression  
Bouton Number  No effect  No effect  
Bouton Size  No effect  Smaller  
No of Active Zones  No effect  Reduced 
Active Zone Density  No effect  Reduced  
 
Table 4.1 Summary of the developmental phenotypes observed at NMJ 4 upon 




TFAM RNAi  TFAM O/E  
Cell Body  No effect  Smaller 
mitochondria  
Proximal Axon  No effect  Smaller and fewer 
mitochondria  
Distal Axon  Slightly smaller (but 
not significant)  and 
fewer mitochondria  
Smaller and fewer 
mitochondria  
NMJ 4  Smaller and fewer 
(not significant) 
mitochondria 
Smaller and fewer 
mitochondria 
Complete lossin 
some boutons.  
 
Table 4.2 Summary of the mitochondrial localization phenotypes observed in 




Chapter 5.  Use of a mitochondrially targeted restriction enzyme to 




TFAM knockdown and overexpression are two very useful models for depleting 
mtDNA, but the mechanism underlying the observed phenotypes is yet to be 
established. Additionally, TFAM is a transcription factor, meaning that mtDNA 
related transcriptional inhibition may contribute to the phenotypes observed in the 
previous chapters. Therefore, modelling mtDNA depletion in motoneurons using 
multiple methods could prove useful in attempts to understand the mechanisms 
causing the phenotypes observed. Specifically, using TFAM-independent methods of 
mtDNA depletion may be of value. In this chapter I aimed to use an alternative 
method of depleting mtDNA. TFAM manipulation caused aberrant synaptic 
development and a dramatic depletion of synaptic mitochondria. I hypothesised that 
these phenotypes were a general feature of neuronal mtDNA loss, rather than a 
specific feature of TFAM knockdown or overexpression. To test this hypothesis I 
investigated whether an alternative means of inducing mtDNA loss, expression of a 




5.2 Expression of a mitochondrially-targeted restriction enzyme affects 
mtDNA nucleoid morphology 
 
Restriction enzymes cut DNA in a sequence specific manner. Moraes and colleagues 
targeted various restriction enzymes to mitochondria as a way of introducing double-
strand breaks and depleting mtDNA (SRIVASTAVA and MORAES 2001; SRIVASTAVA 
and MORAES 2005). Cutting mtDNA once with a single cutter restriction enzyme 
linearizes mtDNA and results in the stalling of mtDNA replication (Figure 5.1A).  
One of these single cutting restriction enzymes is XhoI, which cuts within the 
Drosophila mtCoI gene, specifically at the –actcgagct- sequence (Figure 5.1 B-C). 
Xu et al. (2008) generated a construct using XhoI with an N-terminal mitochondrial 
targeting sequence and a C-terminal myc tag (XU et al. 2008). They showed that this 
construct can successfully target XhoI to mitochondria (Figure 5.1D). 
Firstly, the effect of mitochondrially targeted XhoI (mitoXhoI) expression on 
development was analysed (Table 5.1). Crossing UASp-mitoXhoI flies to the 
ubiquitous Actin-Gal4 driver resulted in embryonic lethality. Next, the pan-neuronal 
driver Elav-Gal4 was used to express mitoXhoI and also resulted in embryonic 
lethality. Motoneuron specific expression of mitoXhoI was carried out by crossing 
these flies to OK371-Gal4,UAS-CD8GFP flies. The progeny of this cross were able 
and developed to the larval stage, however pupal development was affected (Table 
5.1). Larval motoneuron activity was analysed using a locomotion assay under light 




Motoneuron cell bodies were investigated in detail following mitoXhoI expression. 
UASp-mitoXhoI flies were crossed to OK371-Gal4,CD8GFP flies. CD8-GFP 
expression is specific to motoneuron cells and motoneuron cell bodies and can be 
visualized by confocal imaging.  TFAM staining was carried out to visualize mtDNA 
nucleoids. Control cell bodies had evenly distributed punctuate TFAM staining 
(Figure 5.2A-A‟). However expression of mitoXhoI resulted in changes in TFAM 
localisation. In some cases a slight reduction in the TFAM levels was observed 
(Figure 5.2B-B‟), whereas in other cell bodies diffuse TFAM staining was observed 
(Figure 5.2C-D‟), compared to the TFAM localisation seen in the control cell bodies 
(Figure 5.2A). 
These results shows that mitochondrially targeted XhoI expression can lead to 
motoneuron dysfunction and dysmorphic mtDNA nucleoids. Thus, mitoXhoI is a 





Figure 5.1 Introduction to restriction enzyme mediated mtDNA loss in flies. 
 (A) Cutting mtDNA via a restriction enzyme linearizes mtDNA and results in 
replication inhibition which depletes mtDNA. (B) XhoI cuts mtDNA once in the 
mtCoI gene (position 2369). (C) Amino acid and DNA sequence of XhoI cutting site 
in mtCOI gene. (D) XhoI is targetted to mitochondria with a mitochondrial targeting 
sequence and myc staining was used to determine XhoI localization. Adapted from 
Xu and O‟Farell (2008). (E) Motoneuron specific expression of mitoXhoI causes 
behavioural defects at the larval stage compared to control (w
1118
 crossed to OK371-




 UASp-mitoXhoI  
Actin-Gal4  Embryonic Lethal  
Elav-Gal4  Embryonic Lethal  






Table 5.1 Motoneuron specific expression of mitoXhoI results in developmental 
behavioural defects.  
Crossing UASp-mitoXhoI to Actin-Gal4 and Elav-Gal4 at 25
0
C resulted in embryonic 







Figure 5.2 Motoneuron specific expression of UASp-mitoXhoI disrupts nucleoid 
structure. 
The OK371,CD8-GFP driver line crossed to control (w
1118
) and UASp-mitoXhoI 
flies. GFP expression shows motoneuron cell bodies and TFAM antibody is shown in 
red. (A-A’) Control cell bodies have evenly distributed TFAM nucleoids. (B-D’) 
Expressing mitoXhoI results in variable phenotypes which ranged from a slight 
decrease in TFAM staining (B-B‟‟), to more severe disruptions in TFAM localization 






5.3 Motoneuron specific expression of mitoXhoI results in synaptic 
defects 
 
Motoneuron synapses were investigated in detail in the previous chapter. It was 
shown that motoneuron specific knockdown and overexpression of TFAM resulted in 
smaller synaptic boutons and fewer active zones (Chapter 4.5).  
The developmental properties of NMJ 4 were investigated upon motoneuron specific 
mitoXhoI expression and compared to control crosses. The number of boutons was 
similar to controls, at around 20 (Figure 5.3C). However, motoneuron specific 
expression of mitoXhoI resulted in significantly smaller boutons (Figure 5.3 D). 
Bruchpilot (Nc82) staining was also carried out to visualize active zones. mitoXhoI 
expressing motoneurons had significantly fewer active zones and also resulted in 
significantly less dense active zones compared to control boutons (Figure 5.3F). 
Altogether these results show that mitoXhoI expression results in similar defects to 








Figure 5.3 Motoneuron specific expression of mitoXhoI results in smaller 
boutons and fewer active zones. 
Representative scans of control (A-A‟) and mitoXhoI (B-B‟) expressing boutons. 
HRP (red) stains for neuronal membranes and brp (green) was used to visualize 
active zones. (C-D) The number of boutons was similar, however boutons were 
significantly smaller upon expression of mitoXhoI. (E-F) Average number of active 
zones and density of active zones in boutons were significantly reduced in mitoXhoI 
expressing motoneurons. Mean values +/- SEM plotted on graph C,D,E and F. 




5.4 Motoneuron specific mitoXhoI expression depletes synaptic 
mitochondria 
 
In order to analyse mitochondrial localization in motoneuron synapses, 
mitochondrial targeted GFP was used with the OK371-Gal4 driver. Control and 
UASp-mitoXhoI flies were crossed to this driver and NMJ 4 synapses were imaged. 
Control synapses had evenly distributed mitochondria in boutons, while mitoXhoI 
expressing synapses had less mitochondrial GFP (Figure 5.4 A-B‟).  Nearly all of the 
boutons had at least one mitochondrion in control synapses, while 12% of boutons 
completely lacked mitochondria upon mitoXhoI expression (Figure 5.4C). This was 
very similar to what was observed with motoneuron specific TFAM overexpression 
(Chapter 4). 
The mitochondrial content of those boutons containing mitochondria was 
investigated in detail. There were fewer mitochondria in the mitoXhoI expressing 
boutons (Figure 5.4D). Furthermore, the mitochondrial volume to bouton volume 
ratio was significantly reduced upon mitoXhoI expression (Figure 5.4E). In 
conclusion, mitoXhoI expression resulted in the complete loss of mitochondria in 








Figure 5.4 Motoneuron specific expression of mitoXhoI depletes synaptic 
mitochondria. 
 (A-B’) Representative scans showing mitochondrial localization at the NMJ 4. GFP 
shows the mitochondrial targeted GFP and HRP (red) stains boutons. Boxes 
highlight the areas in A‟ and B‟. Control NMJ 4 has more mitoGFP compared to 
mitoXhoI expressing motoneurons. (C) In control NMJs, all of the boutons have 
mitoGFP, however upon expression of mitoXhoI 12% of the boutons completely lack 
mitoGFP. (D) Expression of mitoXhoI in the motoneurons resulted in a reduction in 
mitochondrial number. (E) Approximately 15 % of the bouton volume consists of 
mitochondria in control NMJs, however this percentage is greatly reduced upon 






5.5 Motoneuron specific mitoXhoI expression affects axonal and cell 
body mitochondria 
 
In order to analyse the effect of mitoXhoI expression on mitochondrial properties in 
other parts of the motoneurons, axonal branches were analysed. I showed that 
mitochondrial number and volume was reduced very strongly in distal axons (close 
to the NMJ) upon TFAM manipulation (Figure 5.5). Therefore I analysed both 
proximal and distal compartments of motoneuron axons expressing mitoXhoI. 
OK371-Gal4, UAS-mitoGFP flies were crossed to UASp-mitoXhoI flies and third 
instar larval motoneuron axons were imaged.  Significantly fewer mitochondria were 
observed in proximal axons in motoneurons expressing mitoXhoI (Figure 5.5B). 
Average mitochondrial volume was slightly higher compared to mitochondria in 
control axons, but this was not significant (Figure 5.5B,C). In distal axons 
significantly fewer and smaller mitochondria were observed in mitoXhoI expressing 
motoneurons compared to controls (Figure 5.5 E,F). 
Mitochondrial morphology in motoneuron cells bodies expressing mitoXhoI was also 
investigated. Similar to overexpression of TFAM, mitochondria in cell bodies of 
motoneurons expressing mitoXhoI were fragmented and more punctate than 
mitochondria in control cell bodies (Figure 5.5G,H). 
Next, the physiological state of axonal mitochondria was investigated. MtDNA loss 
beyond a critical threshold results in reduced ETC function and decreased 
mitochondrial membrane potential. It has been shown that mitochondria with 
depleted mtDNA were less functional than the mitochondria having normal levels of 
mtDNA. In order to analyse mitochondrial activity, Rhodamine-1,2,3 (Rh-123) 
180 
 
fluorescence was used as an indirect measurement of mitochondrial membrane 
potential. Mitochondrial membrane potential is generated by pumping of protons out 
of the mitochondrial matrix across the inner mitochondrial membrane by complex I, 
III and IV. This proton gradient results in an electrochemical potential and pH 
difference and across the inner mitochondrial membrane and is referred to as the 
mitochondrial membrane potential () (SUGRUE and TATTON 2001). In control 
axons nearly all mitochondria stained strongly with Rh-123 (Figure 5.6A-A‟). In 
order to check the sensitivity of the Rh-123 staining, control axons were treated with 
sodium azide (which inhibits cytochrome c oxidase) to deplete the mitochondrial 
membrane potential (BENNETT et al. 1996). In these axons Rh-123 fluorescence was 
much weaker than in controls (Figure 5.6 B-B‟), confirming that Rh-123 
fluorescence decreases when the mitochondrial membrane potential is depleted. 
Expression of mitoXhoI resulted decreased Rh-123 fluorescence, similar to that 
observed in sodium azide treated axons (Figure 5.6 C-C‟). In order to quantify the 
level of staining, Rh-123 levels were normalized to mitoGFP levels. Both sodium 
azide treated and mitoXhoI expressing motoneurons had significantly lower Rh-1,2,3 
levels than controls (Figure 5.6 D).  
Overall, these data show that mitoXhoI expression in motoneurons results in aberrant 
cell body mitochondrial morphology, fewer mitochondria in axons and the remaining 







Figure 5.5  Axonal mitochondrial distribution is affected upon mitoXhoI 
expression. 
 (A ,D) Representative scans showing proximal and distal axons. (B,E) mitoXhoI  
expression resulted in fewer mitochondria both at proximal and distal axons with a 
greater effect at distal sites. (C,F) Average mitochondrial volume was slightly (but 
not significantly) increased, however mitochondrial at distal parts of axons were 
smaller upon expression of mitoXhoI. The area quantified was 50 X 150 μm. Mean 
values +/- SEM plotted on graphs. (G,H) Mitochondria in the cell bodies were 
fragmented upon mitoXhoI expression compared to the control. Scale bars represent 





Figure 5.6 Expression of mitoXhoI in motoneurons reduces the membrane 
potential of axonal mitochondria. 
Mitochondria visualized by mitochondrially targetted GFP and Rh-1,2,3 (red) 
staining used to estimate changes in mitochondrial membrane potential. Control 
axons (A-A’) had a higher level of Rh-1,2,3 fluorescence compared to mitoXhoI 
expressing motoneurons (C-C’) . (B-B’) Sodium azide was used to deplete the 
membrane potential of mitochondria. (D) Rh-1,2,3 levels normalized to mitoGFP 
levels and a significant reduction was observed in sodium azide treated controls and 







In this chapter I firstly analysed different regions of motoneurons upon mtDNA 
depletion via expression of the mitochondrially targeted restriction enzyme XhoI. 
Expression of this enzyme in motoneurons resulted in reduced larval motility. 
Motoneuron cell bodies showed abnormal mtDNA nucleoid morphology upon 
staining with an antibody against TFAM. Synaptic properties were investigated in 
detail as a potential cause of the observed behavioural phenotypes.  I observed 
smaller boutons with fewer active zones and a reduction in synaptic mitochondria in 
the boutons. The synaptic phenotypes observed with mitoXhoI expression 
phenocopied those observed upon TFAM overexpression. The mitochondrial network 
was also investigated in the motoneuron axons. Fewer mitochondria were observed 
in the axons and the membrane potential of the axonal mitochondria was reduced. In 






Chapter 6. Investigating the affects of manipulation of the TOR 




The TFAM overexpression and mitoXhoI motoneuron phenotypes have several 
common features. In both of the cases, smaller boutons, fewer active zones and a 
dramatic depletion of synaptic mitochondria were observed, ultimately resulting in 
motoneuron dysfunction. The reduced bouton size could be explained by defects in 
translation, while depletion of synaptic mitochondria could be the result of increased 
mitophagy (mitochondrial specific autophagy) (Figure 6.1) (TWIG et al. 2008a). 
Autophagy is a survival mechanism that is a response to stress and starvation. 
Autophagy is vital for the recycling of unwanted and damaged organelles, such as 
dysfunctional mitochondria. It has been reported that dysfunctional mitochondria can 
be degraded by the autophagy machinery (NARENDRA et al. 2008). The TOR (target 
of rapamycin) signalling pathway has been shown to regulate autophagy and 
translation in both lower and higher eukaryotes (Figure 6.1). Upstream regulators of 
this pathway include growth factors, nutrients, ATP levels and hypoxia (reviewed in 
(WULLSCHLEGER et al. 2006)). One of the proximal upstream components of this 
pathway is PI3K (phosphatidylinositol 3-kinase), which is recruited upon binding of 
insulin/insulin like growth factors (IGFs) to their receptors. The TOR pathway has 
been shown to regulate synaptic size in vertebrates and activation of PI3K, or the 
TOR target S6 kinase results in increased bouton size in Drosophila motoneurons 
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(CHENG et al. 2011; KNOX et al. 2007). The TOR pathway also senses energy levels, 
since the cellular energy sensor AMP kinase inhibits TOR activity through regulation 
of TSC2 (HARDIE et al. 2012). Given the roles of the TOR pathway in mitophagy 
and translational control I investigated the effects of TOR pathway activation and 









Figure 6.1 Schematic representation of TOR signalling pathway and its possible 
interaction with mitochondrial homeostasis. 
TOR is at the central point linking the TSC1/2 complex with processes such as 
translation and autophagy. The possible relationships with mitochondrial dysfunction 





6.2 Effects of motoneuron specific TOR pathway manipulation on 
behaviour 
 
The TOR pathway has been implicated in regulation of mitochondrial oxygen 
consumption and oxidative capacity (SCHIEKE et al. 2006). The effect of inhibition of 
the TOR pathway on Drosophila NMJ development was studied recently (PENNEY et 
al. 2012). However, there are no detailed studies on the relationship of the TOR 
pathway with mitochondrial localization at Drosophila motoneuron synapses.  
Investigating the mitochondrial phenotypes in motoneuron synapses upon regulation 
of TOR pathway components may provide an explanation for the previous 
phenotypes observed. Therefore, both activation and inhibition of the TOR pathway 
was investigated in motoneurons. A dominant negative form of TOR (TOR
DN
) and 
an activated form of Dp110 (Dp110
active
), which is a membrane targeted (activated) 
form of catalytic subunit of PI3K, were used to investigate the effects of TOR 
pathway manipulation in motoneurons. 





motoneurons using OK371-Gal4. Both resulted in a slight reduction in the climbing 
performance and Dp110
active
 expression resulted in significant reduction, however 
TOR
DN 
expression was not significant with the number of flies (n=10) tested (Figure 









Figure 6.2 Manipulation of the TOR pathway causes climbing defects. 
Expressing TOR
DN
 in motoneurons results in slightly decreased (not statistically 
significant with p=0.0618) climbing performance. However, Dp110
active 
expression 
results in significantly reduced climbing performance compared to control flies 
(w
1118
 flies crossed to the OK371-Gal4 driver). Mean values +/- SEM plotted on 





6.3 Motoneuron specific manipulation of the TOR pathway affects 
synapse development 
 
TFAM and mitoXhoI overexpression experiments were carried out by expressing 
these genes in motoneurons using OK371-Gal4 driver and investigating behavioral 





 in motoneurons. Firstly, the number of boutons at NMJ 4 was 
quantified and compared to controls. There was a significant increase in bouton 
number upon expression of Dp110
active
. Furthermore, these synapses had more 
satellite boutons (Figure 6.3C). Satellite boutons were not included in the 
quantification of the bouton number and subsequent analyses. TOR
DN
 expression did 





 expressing motoneurons. Motoneurons expressing Dp110
active
 
had similar sized boutons to controls, however TOR
DN
 expressing boutons were 
significantly smaller (Figure 6.3E). Next, Bruchpilot (Nc82) staining was carried out 
to quantify the number of active zones in boutons (Figure 6.3 A‟, B‟, C‟). The 
number of active zones per bouton in motoneurons expressing Dp110
active
 was 
reduced, but this was not significant (Figure 6.3F). Expression of TOR
DN
 resulted in 
significantly fewer active zones in per bouton (Figure 6.3F). The density of active 
zones in these boutons was calculated as a ratio of the number of active zones to 





 resulted in a significant reduction in active zone density. Moreover, the 





 expression (Figure 6.3G). Therefore, both inhibition and activation 






Figure 6.3 The effect of TOR activity on motoneuron synapse development.   
Representative NMJ 4 images of control (A-A’), motoneuron specific expression of 
TOR
DN
  (B-B’) and Dp110active (C-C’). HRP (red) stains neuronal membranes and brp 
(blue) is a marker of active zones. (C) Yellow arrows show satellite boutons. (D-E) 
Expression of Dp110
active
 resulted in an increase in bouton number, however 
expressing TOR
DN 
resulted in smaller boutons. (F-G) Active zone number and 
density was reduced upon TOR
DN
 expression. Expressing activated Dp110
active
 had a 
slight affect on active zone number and density. Mean values +/- SEM plotted on 





)  and means are shown as black lines  on graph F and G.. 





6.4 Motoneuron specific manipulation of the TOR pathway alters 
synaptic mitochondrial localization 
 
The TOR pathway regulates macroautophagy via inhibition of the protein kinase 
Atg1, which is a core component of the the autophagic machinary (KAMADA et al. 
2000). Mitophagy is a form of autophagy specific to mitochondria and loss of the 
mitochondrial membrane potential induces mitophagy in mammalian and Drosophila 
cultured cells (NARENDRA et al. 2008; YOULE and NARENDRA 2011; ZIVIANI and 
WHITWORTH 2010). Therefore, the effect of TOR pathway manipulation upon 
mitochondrial localization was investigated at motoneuron synapses. Expressing 
TOR
DN 
resulted in a strong reduction in the appearance of mitochondria at NMJ 4, 
compared to controls (Figure 6.4B-B‟). However, none of the boutons were entirely 
devoid of mitoGFP expression. This shows that the reduction of mitochondria with 
TOR
DN 
expression was not as strong as with overexpression of TFAM or mitoXhoI. 
The same analysis was carried out for motoneurons expressing Dp110
active
 (Figure 
6.4C-C‟). Strong levels of mitoGFP expression were observed in NMJ 4 boutons and 
the number of boutons containing mitochondria was similar to controls (Figure 
6.4D). 





. Both the number of mitochondria and mitochondrial volume 
were significantly reduced upon expression of TOR
DN
 (Figure 6.4 E-F). Expression 
of Dp110
active
 resulted in a more variable phenotype. The ratio of mitochondrial 
volume to bouton volume was similar to control boutons, however there were 
significantly fewer mitochondria in these boutons (Figure 6.4 E-F). These data 
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suggested that mitochondrial volume may be increased. Therefore absolute 
mitochondrial volume was determined for the same boutons and was found to be 
nearly 85% increased, compared to control mitochondria, although this did not reach 
significance (Figure 6.4G). However, upon Dp110
active
 expression I observed more 
mitochondria with a larger volume.These data suggest that activation of the TOR 
pathway causes synaptic mitochondrial volume to increase, but numbers of 
individual mitochondria to decrease. Conversely, inhibition of TOR signalling causes 
a strong reduction in both synaptic mitochondrial volume and mitochondrial number. 
Therefore TOR signalling has profound effects on synaptic mitochondria in 











  affects synaptic mitochondria in 
motoneurons.  
 (A-C’) Representative scans of NMJ 4. MitoGFP was used to visualize 
mitochondria and HRP (red) stains neuronal membranes. Scale bar is 20μm. (D) 
There was a slight reduction in the overall mitoGFP expression in the motoneurons 
expressing TOR
DN
, however the number of  boutons with mitoGFP was similar for 
all of the genotypes tested. (E-F) Both number and volume of mitochondria in 
boutons was reduced upon expression of TOR
DN
. In contrast, Dp110
active
 expression 
resulted in boutons with slightly fewer mitochondria compared to control boutons 
(w
1118
 crossed to the driver line). (G) Average volume of each mitochondria was 
slightly larger upon expression of Dp110
active 
(p=0.08). Mean values +/- SEM plotted 
on graphs D and G. Individual data plotted on graphs E and F with mean values 






6.5 Directly increasing autophagy depletes synaptic mitochondria 
 
Inhibition of TOR signalling increases autophagy, but TOR regulates many other 
processes in addition to autophagy.  In order to test whether direct activation of 
autophagy affects synaptic mitochondria, I overexpressed the Atg1 in motoneurons 
using using the OK371-Gal4 driver. Overexpression of Atg1 in motoneurons caused 
pupal lethality, suggesting motoneuron function was severly perturbed. Autophagy 
genes have been shown to be required for motoneuron development in Drosophila. 
Mutants in Atg1, Atg2, Atg6 and Atg18 were shown to have reduced bouton numbers 
at NMJ 4 (SHEN and GANETZKY 2009). Overexpression of Atg1 in motoneurons was 
also shown to increase bouton numbers (SHEN and GANETZKY 2009). In agreement 
with this I found that motoneuron specific Atg1 overexpression resulted in a 25% 
increase in bouton number (Figure 6.5C). In addition, Atg1 overexpression resulted 
in smaller boutons (Figure 6.5D). Active zone number and density were also 
analysed. Both the number of active zones in each bouton and the density of active 
zones were significantly reduced compared to control boutons (Figure 6.5 E-F).  
These results show that, in addition to the previously documented increase in bouton 
number, direct activation of autophagy causes decreased bouton size, active zone 
number and active zone density and inhibits motoneuron function.  
Mitochondrial localization was analysed in motoneurons overexpressing Atg1. Atg1 
overexpression resulted in a dramatic depletion of synaptic mitochondria. Nearly 
45% of the boutons at NMJ4 were devoid of mitochondria upon Atg1 overexpression 
(Figure 6.6C).  Those boutons containing mitochondria were then further analysed. 
They were found to mostly contain one single small mitochondrion (Figure 6.6B). 
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Quantification showed that the total volume and number of mitochondria in these 
boutons was much less than in control boutons (Figure 6.6 D,E). In conclusion, direct 
activation of autophagy in motoneurons by Atg1 overexpression resulted in a severe 







Figure 6.5 Activation of autophagy affects synaptic development. 
 (A-B’) Representative scans of NMJ 4 showing boutons (red) and active zones (brp, 
blue) upon Atg1 overexpression. Scale bar is 20μm. (C-D) Atg1 overexpression 
results in increased bouton number and smaller boutons. (E-F) Atg1 overexpression 
results in fewer active zones and decreased active zone density. Mean values +/- 
SEM plotted on graph C and D. Individual data plotted as circles (control), squares 







Figure 6.6 Activation of autophagy depletes synaptic mitochondria. 
 (A-B’) Representative scans of NMJ 4 showing mitoGFP (green) and boutons (HRP, 
red) in control and boutons overexpressing Atg1. Scale bar is 20 μm. (C) 
Mitochondria are absent in approximately 45 % of the boutons upon motoneuron 
specific Atg1 expression. (D-E) Mitochondrial number and mitochondrial volume 
per bouton were significantly reduced upon Atg1 overexpression. Mean values +/- 
SEM plotted on graph C. Individual values plotted with mean values shown as black 







In order to investigate the possible mechanisms contributing to the motoneuron 
dysfunction caused by mtDNA loss, the TOR signalling pathway was investigated. 
Activating the TOR pathway by expressing an activated form of PI3K resulted in an 
increase in bouton number, while the mitochondrial network was similar to the 
control cells. However, inhibiting the pathway by expressing a dominant negative 
form of TOR resulted in adverse phenotypes in motoneurons. Synaptic boutons were 
smaller and they had fewer active zones. Although I did not observe complete 
depletion of mitochondria in these boutons, there were fewer mitochondria in the 
synapses. Reduction in the amount of mitochondria in the synapses suggested 
mitochondrial specific autophagy (mitophagy) may be the mechanism responsible for 
this phenotype. I expressed Atg1 in order to activate autophagy in motoneurons and 
observed an increased number of smaller boutons that had fewer active zones. 
Strikingly, the number and volume of mitochondria was dramatically reduced in 
these boutons, suggesting that activation of autophagy directly depletes synaptic 
mitochondria. 
In summary, the motoneuron synaptic phenotypes observed with mtDNA loss can 





Chapter 7. Discussion, Conclusion and Future Directions 
 
7.1 Characterization of a Drosophila model of neuronal mtDNA loss 
 
The primary function of mitochondria is to produce energy in the form of ATP, via 
oxidative phosphorylation. Mitochondria are unique organelles in most animal cells 
in that they have their own genome, mtDNA, which is approximately 19.5 kb in flies. 
The genome encodes 13 polypeptides, all of which are components of the OXPHOS 
machinery. Mutations and deletions in mtDNA have been reported in various disease 
states (PARK and LARSSON 2011). Furthermore, depletion of mtDNA copy number 
constitutes a risk factor for neurodegenerative diseases (SUOMALAINEN and ISOHANNI 
2010). The cellular mtDNA copy number varies between 1000 to 10000, dependent 
on cell type (COPELAND 2008). My main aim in this study was to develop a model of 
mtDNA depletion in flies and to investigate its link to neuronal function and 
potentially neurodegeneration. 
The first method trialled in my attempts to deplete mtDNA levels was to feed flies 
with EtBr. This was in light of the fact that it has been previously shown that EtBr, 
which is a DNA intercalating dye, can disrupt mtDNA replication, inhibit mtDNA 
transcription and break-down existing mtDNA (FUKUHARA and KUJAWA 1970; 
SLONIMSKI et al. 1968). It has also been shown that EtBr treatment can result in 
abnormal mitochondrial structures and cause aberrant larval development. In the 
same study also observed a slight increase in the lifespan of flies (FLEMING et al. 
1981). I demonstrated that EtBr treatment in larvae resulted in defective larval 
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development, similar to that observed in previous studies (Figure 3.1A). I 
hypothesized that low levels of EtBr consumption could cause mtDNA depletion. I 
found that 1 mM EtBr treatment slightly decreased mtDNA copy number at the third 
instar larval stage, while very high concentrations of EtBr (5mM) caused arrested 
development. This may be due to a greater reduction in mtDNA copy number, or 
alternatively owing to EtBr exerting toxic effects when consumed at this high 
concentration.  Furthermore, I tested the consequences of EtBr treatment on adult 
flies developed on normal food and then transferred to EtBr containing media.  No 
difference was observed in the lifespan of the flies aged on either 0.2mM or 2mM 
EtBr containing media, compared to media without EtBr. Interestingly however, 
EtBr consumption at the adult stage did result in mtDNA depletion. The observed 
phenotypes are difficult to explain as it is hard to determine the actual target of EtBr 
once it enters the body. It is plausible that ingested EtBr does not reach some tissues, 
such as neuronal structures, while other tissues such as the gut could be strongly 
affected, meaning that the lifespan of the organism is not significantly impacted. This 
could therefore explain my observations that reduced mtDNA levels had no effect on 
adult lifespan. Future studies could investigate the degree to which EtBr is taken up 
by different tissues and how tissue-specific mtDNA levels are affected during 
development and in adult flies.  
Owing to the limitations presented by using a DNA intercalating agent, namely the 
potential toxic effects and that it is not tissue specific, I decided to take a genetic 
approach to study mtDNA depletion. The extensive genetic toolkit afforded by 
Drosophila meant I was able to exploit the advantages of the yeast-derived 
UAS/Gal4 system. This system has been adapted for use in flies in order to facilitate 
the tissue-specific expression of genes via the Gal4 transcription factor (BRAND and 
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PERRIMON 1993). Firstly, I used various RNAi lines targeting genes involved in 
mtDNA replication (Table 3.1). RNAi lines against Polγ, Twinkle, TFAM and DNK 
were crossed to the Act-Gal4 driver in order to cause ubiquitous knockdown of these 
genes. Most of the dsRNA lines were found to be lethal when expressed 
ubiquitously, as I had anticipated given that mtDNA replication is necessary for 
viability. Polγ has been studied in flies previously and mutations in the tamas gene 
were found to cause lethality just before pupariation (IYENGAR et al. 1999). Similar 
to this and my observations, null mutations in the accessory subunit of Polγ cause 
lethality at the early pupal stage (IYENGAR et al. 2002). This could be because 
maternal mtDNA is sufficient for the organism to develop until the late larval stage, 
however efficient mtDNA replication is needed for further developmental processes. 
Alternatively, the maternal contribution of the mtDNA polymerase could be 
sufficient to maintain mtDNA levels until the late larval stage. 
In order to determine whether these RNAi lines deplete mtDNA in the nervous 
system, I crossed them to the pan-neuronal driver Elav-Gal4. I subsequently 
performed qPCR on genomic DNA extracted from the dissected adult CNS from the 
progeny of these crosses. However, I did not observe any difference in mtDNA 
levels using dsRNAs against Polγ, Twinkle or TFAM. It is important to bear in mind 
that there are other cells in the CNS, such as glia and fat body cells, which were not 
targeted in these crosses, given that Elav-Gal4 expression is neuron specific.  These 
cells constitute a significant proportion of the CNS and so could therefore be the 
reason why I did not observe a reduction in mtDNA copy number. This could 
potentially be circumvented by using fluorescent activated cells sorting (FACS) to 
purify neurons from the CNS, followed by qPCR to determine mtDNA levels in this 
enriched population. This experiment was also carried out with three samples per 
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genotype and five brains were dissected per sample. It is possible that these numbers 
may not be sufficient to generate a significant difference (Figure 3.2).   
The next assay I carried out in the neuronal specific knockdown was to measure ATP 
levels. In the brain samples from male flies, I observed a reduction in the ATP levels 
(Figure 3.3B). Furthermore, there was a reduction in the ATP levels in the CNS of 
female flies, apart from in the Polγ RNAi (Figure 3.3A). However, this experiment 
was only performed once and so would need to be repeated to determine if the 
decrease was genuine. Given that I observed mild phenotypes in the previous 
neuronal experiments, I subsequently decided to use a stronger neuronal driver line. 
It has been previously published that overexpression of catalytic subunit of  Polγ 
using MZ1407-Gal4 caused mtDNA depletion, increased apoptosis and reduced 
lifespan in flies (MARTINEZ-AZORIN et al. 2008). MZ1407-Gal4 is an enhancer trap 
line, which has been used as an early neuroblast specific driver, and is also expressed 
in most of the neurons in CNS and in all neurons of the PNS (LUO et al. 1994). 
Firstly, I analysed mtDNA levels by isolating DNA from whole fly heads. From this 
I observed a mild consistent reduction in the mtDNA levels in all of the RNAi lines 
tested although this reduction did not reach significance compared to the control 
(Figure 3.5). This was an interesting result compared to the previous mtDNA 
measurements using Elav-Gal4, in which I found no effect on mtDNA levels. These 
data suggest either that MZ1407-Gal4 is a stronger driver than Elav-Gal4, or that 
strong expression in neuroblasts caused by MZ1407-Gal4 is sufficient to cause a 
detectable reduction in mtDNA levels in the CNS. 
I also checked the MZ1407-Gal4 driver expression pattern by crossing to UAS-nGFP 
and then staining neuroblasts with an antibody against Miranda. From this, I 
observed that GFP positive cells colocalised with the Miranda staining. Also, GFP 
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positive neurons were observed throughout the optic lobes, central brain and thoracic 
VNC. These data confirmed that MZ1407-Gal4 is expressed in neuroblasts and also 
in neurons throughout the majority of the CNS. 
Since I had shown that RNAi of mtDNA replication genes using MZ1407-GAL4 
causes a slight reduction in mtDNA levels, which although it was not statistically 
significant, was a consistent down regulation and more experiments were carried out 
with this driver to analyse if this results in other defects. I decided to investigate 
larval and adult behaviour using two TFAM RNAi lines (TFAMIR-2 and TFAMIR-3).  
I crossed both of these lines to the MZ1407-Gal4 driver at 25
0
C and found that 
TFAMIR-2 was lethal and TFAMIR-3 has reduced viability compared to the control 
(Figure 3.7A). The same crosses performed at 21
0
C rather than 25 
0
C rescued the 
viability of TFAMIR-2 completely and TFAMIR-3 partially (Figure 3.7B).  
Furthermore, both dsRNAs against TFAM resulted in a reduction in larval movement 
(Figure 3.7C). In order to verify the specificity of TFAM-RNAi, I used other TFAM 
RNAi lines in addition to TFAMIR-2 and TFAMIR-3. Apart from the TFAMIR-2 line, 
all the other TFAM RNAi lines were viable at 25
0
C. However, all of the viable 
TFAM RNAi lines expressed with MZ1407-Gal4 had defects in the wing expansion 
(Figure 3.8A-E). Testing both overlapping and non-overlapping TFAM RNAi lines 
and observing similar phenotypes reduces the likelihood that the phenotypes are the 
result of off-target effects.  Furthermore, both TFAMIR-2 and TFAMIR-3 resulted in 
climbing defects both in male and female flies (Figure 3.8B and C). It is possible that 
these observed defects may be the result of neuroblast cell death or reduced 
proliferation. In order to test this hypothesis, I counted the number of neuroblasts in 
the VNC, but observed no differences in either of the TFAM RNAi lines tested 
compared to the control (Figure 3.9B).  
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Taken together these experiments demonstrate that MZ1407-Gal4 is a useful driver, 
when combined with RNAi of mtDNA replication genes, to reduce mtDNA levels 
throughout the CNS. In contrast Elav-Gal4 may not be strong enough, or have the 
correct spatio-temporal expression pattern to significantly deplete mtDNA using 
these RNAi lines. However, my aim was to deplete mtDNA levels specifically in 
differentiated neurons, rather than proliferating neuronal progenitors. In light of this, 
I decided to test neuronal-specific Gal4 drivers to deplete mtDNA levels in specific 
neuronal populations using RNAi of Polγ, Twinkle, TFAM.  
MB neurons have been widely used to model neurodegeneration in flies, specifically 
for axonal degeneration using the MB γ axons (LUO and O'LEARY 2005). OK107-
Gal4 is the MB-specific driver and I used this driver together with a CD8-GFP 
reporter to enable visualisation of neuronal morphology. dsRNAs against Polγ, 
Twinkle and TFAM were expressed in the MBs and I found that flies aged for one 
month had the strongest phenotype. MB morphology was normal in young adult flies 
(data not shown), but I observed thinner α/α‟ lobe branches in Polγ and TFAM RNAi 
flies (Figure 3.10). This shows that depleting mtDNA levels in MB neurons can 
induce axonal degeneration and that knockdown of Polγ and TFAM are useful tools 
for this. 
In addition to the MB neurons I also used a second specific neuronal population, the 
motoneurons, to study the effects of mtDNA loss. Motoneurons have been previously 
used as a model to study neurodegenerative diseases (reviewed in (KESHISHIAN et al. 
1996)).  The OK371-Gal4 driver has been shown to be expressed in motoneurons 
and inter neurons (MAHR and ABERLE 2006).  I used OK371-Gal4 to knockdown 
Polγ, Twinkle and TFAM in motoneurons. This resulted in reduced larval motility 
with Twinkle and TFAM RNAi lines, although no difference was observed with Polγ 
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RNAi (Figure 3.11A). Behavioural assays can be affected by environmental 
conditions and nutrition and so variation in larval density between vials can 
potentially affect locomotion phenotypes. To circumvent this, I used larvae carrying 
an RFP reporter grown in the same vials as an internal control. External control 
(OreR) and internal control RFP expressing larvae travelled approximately the same 
distances, while TFAMIR-3 larvae displayed a reduction in locomotion (Figure 
3.11B). This test thus verified the larval locomotion defect observed previously and 
highlighted the requirement for TFAM expression in motoneurons for normal larval 
locomotor activity. 
Motoneuron specific knockdown of Polγ, Twinkle and TFAM resulted in viable adult 
flies that were used to test climbing ability. Polγ and TFAM RNAi resulted in 
reduced climbing ability both in mean male and female flies, while only female 
Twinkle RNAi flies displayed a reduction (Figure 3.12). The climbing phenotype 
observed with motoneuron specific TFAM knockdown concurs with the results of 
previous behavioural assays. Thus, expression of mtDNA replication genes are likely 
required in motoneurons throughout development.  To confirm the climbing 
phenotypes with TFAM RNAi, I repeated the climbing assay using more flies.  
Repeating the experiment with 15 male flies still resulted in a climbing defect and 
ageing them for 1 month had no effect on the level of reduction (Figure 3.12A). 
Interestingly, when the climbing assay of TFAM RNAi flies was repeated using 12 
female flies, no difference was observed compared to controls. However, when I 
aged these flies for 1 month, they displayed significantly reduced climbing activity 
(Figure 3.12B). This sexual dimorphism could be due to a difference in OK371-Gal4 
driver strength between males and females, although this is unlikely as the Gal4 
insertion is autosomal. Alternatively, I observed that male flies climb significantly 
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faster than female flies and so male flies may be more sensitive to deficits in 
motoneuron function. A study in Drosophila simulans, showed that female flies have 
a higher mtDNA levels and higher levels of hydrogen peroxide production 
(BALLARD et al. 2007).  Therefore, the reason that I observed a stronger affect on 
locomotion in males than females upon motoneuron-specific TFAM knockdown 
could be because female flies have a higher mtDNA copy number and so are more 
resistant to reductions in TFAM expression than to male flies. It would be interesting 
in future to compare mtDNA copy number in wild-type and TFAM knockdown male 
and female flies. 
Most of the dsRNA lines used against genes involved in mtDNA replication showed 
these genes to be necessary for viability, although tissue specific knockdown of these 
genes mostly resulted in viable adult flies. Expression of dsRNAs against TFAM 
generally resulted in the strongest phenotypes. In addition, motoneuron function can 
be analysed using behavioural tests, by imaging and electrophysiologically and so 
motoneuron-specific knockdown of TFAM was further characterised as a means of 
studying the effects of neuronal mtDNA loss. 
 
7.2 Manipulation of TFAM expression to deplete mtDNA in 
motoneurons 
 
Adequate mtDNA levels are vital for the survival of the cells and organisms. The 
main mechanism regulating the mtDNA content of the cell is the rate of mtDNA 
replication, with various nuclear encoded proteins having roles in this process (see 
212 
 
Chapter 3.1). TFAM has multiple functions in mtDNA metabolism and is essential 
for mtDNA maintenance and replication. It has been shown previously that TFAM 
knockdown results in mtDNA depletion (reviewed in (OLIVEIRA et al. 2010)). 
Ubiquitous expression of dsRNAs against TFAM caused lethality at the early pupal 
stage. This is similar to mutants in the catalytic and regulatory subunits of Pol-γ, 
which are also pupal lethal (IYENGAR et al. 2002; IYENGAR et al. 1999). I used two 
non-overlapping RNAi lines against TFAM (TFAMIR-2 and TFAMIR-3). The 
TFAMIR-3 line resulted in a much stronger reduction in TFAM transcript level. I also 
observed a significant depletion in mtDNA level when TFAMIR-3 was crossed to the 
ubiquitous driver Actin-Gal4. Furthermore, qPCR analysis using first instar larvae 
showed a significant reduction in mtDNA copy number. These data show that TFAM 
knockdown causes a reduction in the level of mtDNA from an early developmental 
stage. ActGal4>TFAMIR larvae develop up to the third instar larval stage and pupate 
with an approximately 50% reduction in the mtDNA level. Reduced TFAM levels 
results in reduced mtDNA replication, which in turn affects the development of the 
organism. MtDNA related disorders vary in phenotype depending on the severity of 
the mtDNA depletion or amount of mutated mtDNA. Several studies have shown 
that mutant mtDNA, or the level of depleted mtDNA, must reach a „critical 
threshold‟ in order to severely affect the organism (LARSSON and CLAYTON 1995; 
WALLACE and FAN 2009). Maternal contribution of mtDNA may be sufficient for the 
organism to pass through the early developmental stages. However, in order to 
complete development the organism may require efficient mtDNA replication to 
maintain mtDNA levels above the critical threshold. Defects in the mtDNA 
replication machinery resulted in arrest of development at the early pupal stage. It is 
thus clear that passage from the early pupal stage to the adult requires mtDNA levels 
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above a threshold of around 50%. I did not establish the mechanism causing the 
failure of TFAM RNAi pupae to develop to adulthood. It could be that the lack of an 
external food supply makes pupae particularly sensitive to mitochondrial 
dysfunction. Alternatively, the morphogenesis of adult structures, that occurs during 
the pupal stage, may arrest if mtDNA levels are below a specific threshold.   
Increased TFAM levels have been linked to various phenotypes in previous studies, 
depending on the genetic background, with overexpression of human TFAM shown 
to improve some mitochondrial disease phenotypes in mouse models (IKEUCHI et al. 
2005; MORIMOTO et al. 2012; NISHIYAMA et al. 2010).  Overexpression of human 
TFAM in HeLa cells resulted in an increase in mtDNA copy number after 14 days, 
since it takes 10 days to express TFAM stably (KANKI et al. 2004). Furthermore 
expression of human TFAM at physiological levels in mice can result in an increase 
in mtDNA copy number (YLIKALLIO et al. 2010). However, the Jacobs group 
investigated the effects of human TFAM overexpression in HEK cells and observed a 
decrease in mtDNA level upon TFAM overexpression after 10 days, although a slight 
increase was observed after 16 hours (POHJOISMAKI et al. 2006). Ubiquitous 
overexpression of TFAM in Drosophila resulted in lethality at
 
the first or second 
larval instar. Both TFAM and TFAMGFP expression resulted in reduction in mtDNA 
levels. The level of reduction was not as strong as that caused by TFAM knockdown, 
although developmental arrest occurred earlier in TFAM overexpressing flies. I 
hypothesized that although mtDNA depletion was not as strong as TFAM knock 
down flies, TFAM overexpression can cause more detrimental effects through 
additional mechanisms. TFAM is a transcription factor and so increased TFAM 
levels could affect mitochondrial gene transcription. Mouse and human TFAM differ 
in their C-terminal region, which is required for transcriptional activity. Expression 
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of human TFAM in a mouse TFAM-/- mutant does not rescue the embryonic lethality 
and this has been suggested to be due to differences in transcriptional activity 
between the two proteins (EKSTRAND et al. 2004).  
The role of TFAM in binding and packaging mtDNA has been widely studied. 
Overexpressing TFAM could result in excessive binding to mtDNA, making it 
inaccessible to the replication and transcription machineries. The contradictory 
results of TFAM overexpression observed in different systems could be due to the 
different binding efficiency of different forms of TFAM (human versus mouse or 
Drosophila) over-expressed in different cell types. Furthermore, the level of 
expression could be different in different systems. I suggest that overcrowding the 
mtDNA with very high amounts of TFAM may be detrimental and cause mtDNA 
loss, while a slight increase in TFAM levels could stabilize mtDNA and increase 
mtDNA replication and transcription.  
Ubiquitous knockdown of TFAM resulted in pupal lethality, which limits 
investigations into the consequences of mtDNA loss at later stages in development 
and in adults. Furthermore, using a ubiquitous driver is not suitable to investigate the 
cell type specific requirements for mtDNA. In light of these reasons I decided to use 
a tissue specific driver. One of the tissues that is widely used for developmental 
studies in Drosophila is the wing. RNAi of TFAM using MS1096-Gal4 resulted in 
smaller adult wings, while overexpression of TFAM affected wing development more 
severely (Figure 4.2). I observed a reduction in the level of diffuse TFAM staining 
and small TFAM puncta, while larger puncta were more apparent upon RNAi of 
TFAM (Figure 4.2). This observation is similar to what has been reported in human 
tissue culture cells (KASASHIMA et al. 2011). In this study, PicoGreen staining (a 
DNA specific dye) was used to visualize mtDNA and it was shown that knockdown 
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of TFAM resulted in nucleoid enlargement (KASASHIMA et al. 2011). Despite 
attempts to stain mtDNA nucleoids in the wing disc using several DNA-specific dyes 
I was not able to consistently visualise these structures. Therefore I was not able to 
confirm that the alteration in TFAM localisation in TFAM RNAi cells caused 
nucleoid enlargement in my experiments. Expression of both GFP tagged and 
untagged forms of TFAM in the wing disc caused an increase in TFAM levels and 
both knockdown and overexpression of TFAM caused abnormal adult wing 
morphology (Figure 4.3). In accordance with the earlier lethality caused by 
ubiquitous overexpression of TFAM compared to TFAM knockdown, I observed 
stronger morphological defects in the TFAM overexpressing wings, compared to 
TFAM knockdown. Altogether this data shows that maintenance of mtDNA is 
required for proper development of the Drosophila wing. The underlying mechanism 
causing these phenotypes is not known, however this is potentially a useful 
phenotype to screen for novel genes that interact with TFAM and that are involved in 
mtDNA maintenance. 
In the previous chapter I identified the motoneuron system as a model to investigate 
the consequences of mtDNA depletion in neurons. TFAM knockdown in 
motoneurons caused behavioural phenotypes both at larval and adult stages. In 
TFAM RNAi motoneuron cell bodies I observed a reduced level of TFAM 
expression with several enlarged TFAM puncta (Figure 4.4). This finding correlated 
with TFAM staining in the wing (Figure 4.3) and with previous studies in tissue 
culture cells (KASASHIMA et al. 2011). I observed increased TFAM antibody staining 
in TFAM and TFAMGFP overexpressing motoneuron cell bodies (Figure 4.4). In 
some motoneuron cell bodies expressing TFAMGFP very large green fluorescent 
puncta were observed that did not colocalise with TFAM antibody staining. These 
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very large puncta were never observed in motoneurons overexpressing un-tagged 
TFAM and so are presumably aggregates that result from the GFP fusion. Whether 
these puncta contain mtDNA could not be determined as I was not able to stain 
motoneuron cell bodies with a DNA-specific dye. Until it is known whether these 
aggregates are benign, or cause defects that are specific to the tagged protein, results 
obtained with TFAMGFP overexpression should be treated with caution and 
reproduced with un-tagged TFAM.   
Next, I tested if mtDNA depletion in motoneurons impaired development. Viablity 
tests were performed, showing that approximately the same percentage of adult flies 
eclosed with motoneuron-specific TFAM RNAi or TFAMGFP expression as with 
controls. However, motoneuron specific expression of TFAMGFP, but not TFAM 
RNAi, resulted in reduced adult lifespan. Overexpression of un-tagged TFAM in 
motoneurons resulted reduced viability, caused by a defect in late pupal 
development, as the numbers of pupae were similar to the controls. Although the 
majority of TFAM overexpressing flies did eclose they died within a few days. 
Therefore, as with the viability upon ubiquitous expression and wing expression 
phenotypes, TFAM overexpression in motoneurons caused a stronger phenotype than 
TFAM RNAi.  
I observed reduced larval movement with motoneuron-specific RNAi and 
overexpression of TFAM, suggesting that maintenance of mtDNA is required for 
normal larval motoneuron activity. I also wanted to test whether the behavioural 
defects occurred in adult flies. I found that RNAi and overexpression of TFAM 
resulted in defects in adult climbing. Both GFP tagged and untagged overexpression 
of TFAM resulted in stronger climbing defects compared to TFAM knockdown 
(Figure 4.6). Jump assays also demonstrated that TFAM overexpression caused a 
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more severe phenotype than TFAM RNAi. These data strongly suggested that 
mtDNA loss affects motoneuron function throughout development and led me to 
investigate the effects of manipulation of TFAM levels on motoneuron development. 
In a recent study the catalytic subunit of Polγ was silenced in specific neurons 
(cholinergic, dopaminergic and serotonergic) in adult flies and only dopaminergic 
neuron specific RNAi of Polγ-α was found to cause climbing defects. In the same 
study, open field motion was analysed and similar results were obtained (HUMPHREY 
et al. 2012). It would be interesting to manipulate TFAM levels in these neuronal 
types and to assess behavioural performance to determine whether TFAM-induced 
mtDNA loss gives similar phenotypes to knockdown of Polγ-α. It has been 
previously reported that mtDNA depletion via over-expression of Polγ-α can reduce 
the median lifespan of Drosophila (MARTINEZ-AZORIN et al. 2008). I analysed the 
lifespan of male and female flies separately and found no difference in the flies 
expressing dsRNA against TFAM. In correlation with the strong behavioural defects 
observed, overexpressing TFAMGFP resulted in a significantly shorter lifespan. This 
further suggests that overexpressing TFAM results in more detrimental defects than 
TFAM knockdown, which might not only be caused by mtDNA depletion but also 
through other mechanisms as discussed above.  
I then investigated motoneuron dysfunction at a cellular level using confocal 
microscopy. Firstly I hypothesized that cell death may be responsible for the 
motoneuron dysfunction caused by TFAM RNAi and overexpression since it has 
been shown that TFAM knockout mice have increased apoptosis (WANG et al. 2001). 
In order to test this hypothesis, motoneurons in the ventral nerve cord were counted, 
but no difference was found between the control and TFAM RNAi or overexpression. 
Therefore, the observed behavioural phenotypes were not caused by motoneuron cell 
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death. I next hypothesized that either development of the motoneurons or disruption 
of the mitochondrial network might contribute to the behavioural abnormalities.  
Larval motoneuron axons exit from the VNC and span up to several hundred microns 
to reach target muscles and form synapses. Two of the most widely analysed 
synapses are at muscle groups 4 and 6/7. In checking the expression of the OK371-
Gal4 driver in boutons at these NMJs, I observed that it was strongly expressed in 
type Ib, but only weakly in type Is. This difference in expression of OK371-Gal4 has 
not been described previously and could have important experimental consequences 
for quantification of bouton phenotypes using this driver. I therefore decided to 
analyse only type Ib boutons. NMJ 6/7 is not ideal for this purpose, as type Ib and Is 
boutons are found very close to each other and are not easy to differentiate one from 
the other. However, at NMJ 4 I was able to easily differentiate type Ib and Is 
boutons.  
One of the most common ways to study synapse development is to count the number 
of boutons in the NMJ. I observed around 20 boutons in controls at NMJ 4, which is 
similar to other studies (CHEN and GANETZKY 2012; SHEN and GANETZKY 2009). I 
found that bouton number was not changed by TFAM knockdown or overexpression. 
Therefore I decided to analyse the size of the boutons by quantifying bouton 
diameter. The average diameter of the boutons was significantly reduced when 
TFAM was overexpressed. However, there was no difference to controls in the 
TFAM knockdown boutons at NMJ 4. Most of the previous studies on Drosophila 
NMJs have analysed bouton number rather than bouton size. For example, studies of 
Neuroligin 1 (dnlg1) mutants and spinster mutants (a lysosomal storage disease 
model) found that bouton number was increased, but did not analyse bouton size 
(BANOVIC et al. 2010) and recently a Drosophila model of ALS (overexpression of 
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Fus/Caz) found a decrease in bouton number (XIA et al. 2012). Atg mutants have 
been shown to have reduced bouton number and appear to also have smaller boutons, 
but bouton size was not analysed (SHEN and GANETZKY 2009).  The fact that bouton 
size is reduced without affecting bouton number suggests that these properties are 
separable. However, reduction of either bouton size or number both result in reduced 
NMJ area and so may have similar phenotypic consequences. 
To better understand why TFAM overexpression caused bouton size defects I 
investigated other properties of motoneurons. There are several synaptic markers for 
Drosophila NMJs, one of which is an antibody against bruchpilot (Nc82), an 
antibody used to visualize active zones, which highlight the regions of presynaptic 
release sites. TFAM overexpression caused a decrease in the number of active zones 
per bouton and the density of active zones. These data suggest that mtDNA loss 
directly affects active zone development, over and above the expected reduction in 
active zone number as a consequence of reduced bouton size. Loss of mtDNA could 
affect synaptic mitochondria causing local synaptic energy defects, which affect 
active zone development. The mechanism by which active zones are affected 
requires further investigation and could result from a requirement for ATP directly 
during active zone development, or indirectly through aberrant motor neuron 
development affecting active zone number. 
I then investigated the relationship between synapse development and synaptic 
mitochondria. The mitochondrial network is highly dynamic in neurons and 
mitochondria are transported both in anteriograde and retrograde directions along 
axons. The mitochondrial supply to synapses is maintained via this axonal transport 
of mitochondria. I hypothesized that the mitochondrial network may be more 
disrupted in distal regions of the motoneuron. 
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In control and TFAM knockdown boutons, almost all boutons had mitochondria. 
However, overexpression of TFAM resulted in loss of mitochondria in around 14% 
of the boutons. Although I observed a same percentage of boutons to contain 
mitochondria and the similar number of mitochondria per bouton as controls when 
TFAM was knocked-down, there was a reduction in mitochondrial volume in these 
boutons.  By contrast, in boutons overexpressing TFAM I found there was typically 
only one mitochondrion present and mitochondrial volume was dramatically 
reduced. It is not known whether the absence of mitochondria caused the reduced 
bouton size, or whether smaller boutons caused by developmental defects resulted in 
the depletion of mitochondria. However, it is interesting that TFAM RNAi did not 
result in smaller boutons, nor complete depletion of mitochondria in boutons, but did 
result in reduced mitochondrial volume, suggesting that mtDNA loss primarily 
affects mitochondrial abundance. The fact the TFAM RNAi causes a mild 
mitochondrial phenotype and did not affect bouton size, while TFAM overexpression 
caused a strong mitochondrial phenotype and reduced bouton size suggests that there 
is a threshold of mitochondrial depletion below which bouton size is affected. 
Mitochondrial depletion has been recently reported in DA (dopamine) neurons of 
MitoPark mice, which is a DA neuron-specific TFAM knockout (STERKY et al. 
2011).These neurons were found to contain more fragmented mitochondria in the 
cell bodies, similar to my observation upon TFAM overexpression. MitoPark mice 
exhibit a progressive parkinsonian phenotype, with the initial defects in 
motorfunction (reduced locomotion and rearing) observed around 14-15 weeks of 
age (EKSTRAND et al. 2007). Neurochemical and electrophysiological defects were 
also observed at earlier timepoints in the asymptomatic mice. DA release was 
impaired and HCN (hyperpolarization-activated cyclic nucleotide-gated) ion channel 
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function was reduced in the MitoPark mice (GOOD et al. 2011). This may suggest 
that motoneuron dysfunction observed in my experiments was due to defects in 
neurotransmitter release and ion channel properties. Furthermore, loss of DA neurons 
was first observed at 12 weeks of age, several weeks after the neurochemical and 
electrophysiological phenotypes were first observed (EKSTRAND et al. 2007). I did 
not observe any motoneuron cell loss in adult TFAM RNAi or overexpression flies 
(preliminary data, not shown here), but it would be interesting to repeat this 
experiment in aged flies. Alternatively, motoneurons might be less sensitive to 
mtDNA loss than DA neurons, similar to the difference between cholinergic and DA 
neurons (HUMPHREY et al. 2012).  
I also analysed mitochondrial morphology in other regions of the motoneuron. In 
control motoneurons cell body mitochondria formed in a filamentous network. 
mtDNA depletion using TFAM knockdown did not cause morphological defects in 
the cell body. However, overexpression of TFAM resulted in smaller mitochondria 
and overall disruption of the mitochondrial network. In order to understand the 
overall effect of mtDNA depletion, I analysed proximal and distal axons. RNAi or 
overexpression of TFAM did not affect the mitochondrial number at proximal axons, 
however mitochondrial volume was reduced when TFAM was overexpressed (Figure 
4.13). Thus, similar to the cell body, only TFAM overexpression caused a 
mitochondrial phenotype in the proximal axon. In distal axons both TFAM 
knockdown and overexpression caused mitochondrial phenotypes. These data 
suggest that fewer mitochondria are transported along axons to the synapses when 
TFAM is knocked-down or overexpressed. Another possible mechanism is 
dysregulation of fusion/fission events, as it has been previously shown that increased 
fission can cause smaller mitochondria in neurons (SESAKI and JENSEN 1999). 
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Mitochondrial distribution in neurons is of particular importance and transport of 
mitochondria to regions with a high energy demand is vital for neuronal function. It 
was previously reported that synapses may consume up to 10% of the energy 
required for neuronal signalling (LAUGHLIN 2001). Drosophila photoreceptor 
terminals have been used as a model to investigate the importance of synaptic 
mitochondria and depletion of mitochondria found to cause blindness and failure in 
synaptic transmission (STOWERS et al. 2002). Furthermore Miro (mitochondrial Rho-
GTPase) mutants have depleted synaptic mitochondria at NMJ 6/7 (GUO et al. 2005). 
Miro mutants have impaired larval locomotion such that larval crawling behaviour is 
affected. These studies highlight the importance of axonal transport of mitochondria 
to synapses and the behavioural phenotypes I observed with motoneuron specific 
TFAM manipulation could thus be a consequence of reduced mitochondrial transport 
to synapses. Future experiments will analyse mitochondrial transport in axons upon 
manipulation of TFAM levels.  
Another possible explanation for the mitochondrial phenotypes observed could be 
linked to mitochondrial quality control mechanisms. Observing smaller sized 
mitochondria at synapses upon TFAM RNAi and overexpression could be related to 
inbalanced mitochondrial fusion/fission or increased mitophagy. Mitophagy is the 
selective autophagy of mitochondria and requires mitochondrial fragmentation (TWIG 
et al. 2008a). Opa1 (dynamin-related GTPase optic atrophy 1) and MFN (mitofusins) 
1 and 2 are fusion related proteins, while mitochondrial fission is controlled by 
DRP1 (CIPOLAT et al. 2004; SANTEL and FULLER 2001; SMIRNOVA et al. 2001). It 
has been recently shown that upon induction on autophagy, mitochondria elongate 
and are spared from autophagic degradation in a DRP1 dependent manner (GOMES et 
al. 2011). This further demonstrates the dynamic nature of the mitochondrial network 
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and how fusion/fission and the autophagy machinery work together to shape a 
healthy mitochondrial network. In the same study silencing target of rapamycin 
(TOR) expression caused mitochondrial elongation (GOMES et al. 2011). 
In conclusion, axonal transport of mitochondria, mitochondrial quality control and 
autophagy could all potentially contribute to the phenotypes observed. Investigating 
the bioenergetic properties of mitochondria in motoneurons with reduced or 
increased TFAM expression could provide insight into the role of mitochondrial 
quality control. In order to test which these potential mechanisms contribute to the 
observed phenotypes, genetic interaction experiments could be carried out. 
Manipulating levels of DRP1 or autophagy related proteins (such as Atg1, or TOR 
pathway proteins) in combination with TFAM RNAi or overexpression could be 
insightful.  
 
7.3 mitoXhoI as a tool to induce mtDNA loss in motoneurons 
 
In Chapter 3 and 4 I showed that mtDNA loss can be studied in motoneuron synapses 
using TFAM mediated methods.  However, regulating mtDNA homeostasis and 
causing mtDNA loss in motoneurons via alternative mechanisms may prove useful 
for number of reasons. Firstly, depleting mtDNA in motoneurons and observing 
similar phenotypes would make us more confident about the previous results. 
Secondly, these other methods could be used as new models to study mtDNA 
depletion. Finally, any similarities and differences observed using the new models 
could provide mechanistic insight into the underlying cause of synaptic dysfunction. 
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Moraes and colleagues introduced a new method for studying mtDNA, by expressing 
mitochondrially targeted restriction enzymes (SRIVASTAVA and MORAES 2001; 
SRIVASTAVA and MORAES 2005). Xu and O‟Farell adapted this method for flies and 
by isolating suppressors from crosses in which mitoXhoI was expressed in the 
germline, used it to generate mutations in the mitochondrial genome (XU et al. 
2008). XhoI cuts the Drosophila mtDNA once and thus linearizes the mtDNA, 
resulting in reduced mtDNA replication. Expressing mitoXhoI using drivers such as 
the ubiquitous driver Actin-Gal4 and the panneuronal driver Elav-Gal4 caused 
lethality (at third instar larval stage). Motoneuron specific expression resulted in 
pupal lethality, meaning third instar larvae could be used to investigate mtDNA 
related defects.  
In order to investigate the effect of mitoXhoI expression on mtDNA nucleoids, 
motoneuron cell bodies were stained with an antibody against TFAM. In control cell 
bodies homogeneous, punctate nucleoids were observed, which contrasted with 
various phenotypes upon mitoXhoI expression. The most striking phenotype was 
diffuse TFAM staining, as opposed to the punctate structures seen in control cell 
bodies (Figure 5.2), suggesting that nucleoid morphology was severely disrupted. 
Studies from the Moraes lab have shown that mitochondrially targeted restriction 
enzyme expression in cardiac tissues in mice causes both mtDNA deletions and 
depletion (XU et al. 2008). The precise affect of mitoXhoI on mtDNA in Drosophila 
motoneurons can only be inferred from my observations and future studies will be 
required to determine the precise affect of mitoXhoI on mtDNA in these cells.  
NMJ 4 in mitoXhoI expressing motoneurons was subsequently investigated. I found 
that the number of boutons remained the same as controls, but mitoXhoI expression 
resulted in smaller boutons. This was similar to what was observed upon TFAM 
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overexpression. Furthermore active zone number and active zone density were 
reduced, again similar to what was observed upon TFAM overexpression. The next 
analysis was of mitochondrial localization at NMJ 4. Approximately 12% of the 
boutons completely lacked mitochondria and boutons with mitochondria had smaller 
and fewer mitochondria compared to control boutons (Figure 5.4). Overall these 
results show that mtDNA depletion via different methods results in similar 
phenotypes, including smaller boutons, fewer active zones, depletion of synaptic 
mitochondria and motoneuron dysfunction. 
The bioenergetic properties of axonal mitochondria were analysed in mitoXhoI 
expressing motoneurons using Rh-1,2,3. Expression of mitoXhoI resulted in 
mitochondria with decreased membrane potential, suggesting that mtDNA loss, 
caused by mitoXhoI expression, leads to inhibition of the proton motive force used to 
generate the mitochondrial membrane potential. It will be interesting in future to 
determine the mitochondrial membrane potential in motoneurons with knocked-
down or overexpressed TFAM. I would predict that TFAM overexpression would 
cause a strong reduction in membrane potential, similar to mitoXhoI expression, 
while TFAM RNAi would have a much weaker effect.  
Mitochondrial targeted restriction enzyme expression in dopaminergic neurons has 
been reported as a PD model in mice (PICKRELL et al. 2011). These mice had defects 
in motor-related behaviour, tested using the pole test and rotarod. Progressive DA 
neuron loss was observed after 9 months in these mice. Dopamine levels were 
significantly reduced both in 4 months and >12 month oldmice. ι-DOPA treatment 
was shown to improve these symptoms. Overall these results correlate with the 
phenotypes seen in the “MitoPark” mice and confirm that loss of mtDNA in DA 
neurons results in defects in neurotransmission and neurodegeneration. 
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7.4 Potential mechanisms contributing to the defects in motoneuron 
development caused by mtDNA loss 
 
7.4.1 Motoneuron specific TOR inhibition or Atg1 overexpression phenocopy 
TFAM overexpression 
 
The most striking phenotypes caused by TFAM overexpression and mitoXhoI 
expression were smaller boutons completely lacking, or with fewer mitochondria. 
Furthermore both resulted in fewer active zones in these boutons. The mechanisms 
causing these phenotypes are not known. However, these phenotypes suggest the 
possible involvement of a signalling pathway since both developmental and activity 
related phenotypes were observed. The central regulator of cell growth and 
metabolism is the serine/threonine kinase TOR. Given its pivotal role in cell growth 
and metabolism, the TOR pathway has been implicated in metabolic diseases, 
neurodegeneration, cancer and ageing (LAPLANTE and SABATINI 2012; ZONCU et al. 
2011). In mammalian cells there are two TOR complexes, mTORC1 and mTORC2, 
which regulate other kinases such as S6 kinase (S6K) and Akt (ZONCU et al. 2011). 
An increasing number of cellular processes have been show to be controlled by the 
TOR pathway including protein synthesis, lipid synthesis, autophagy, lysosome 
biogenesis, energy metabolism, cell survival and cytoskeleton organization 
(reviewed in (LAPLANTE and SABATINI 2012)). Several of these processes can be 
linked with mitochondrial biology and could potentially contribute to the phenotypes 
I observed upon mtDNA depletion (Figure 6.1). Furthermore there is growing 
evidence linking the TOR pathway to synaptic plasticity and the modulation of 
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behaviour (COSTA-MATTIOLI et al. 2009; HOEFFER and KLANN 2010; SWIECH et al. 
2008; TANG et al. 2002). I hypothesized that inhibition of the TOR pathway may 
affect mitochondrial localization in motoneuron synapses, similar to what was 
observed with TFAM overexpression and mito-XhoI expression. 
 In order to analyse the functional role of TOR at synapses I used genetic tools 
causing both inhibition and activation of the pathway. PI3K an upstream component 
of the TOR pathay that is recruited to insulin or IGF receptor upon binding of insulin 
or growth factors. It has been previously reported that neuronal specific activation of 
the TOR pathway via Rheb and PI3K expression results in larger boutons and 
enhanced synaptic function in Drosophila NMJ 6/7 (KNOX et al. 2007; MARTIN-
PENA et al. 2006). Furthermore, several studies have found that mutations in S6K do 
not to affect bouton number, but result in smaller boutons (CHENG et al. 2011; KNOX 
et al. 2007; SHEN and GANETZKY 2009). I found that inhibition of the TOR pathway, 
by expressing a dominant negative form of TOR resulted in same number, but 
smaller boutons. A recent study of transheterozygous TOR mutant larvae showed 
that these larvae had similar bouton size and number presynaptic active zones to 
controls (PENNEY et al. 2012). However in the same study, it has been shown that 
expression of TOR postsynaptically triggered a retrograde increase in 
neurotransmitter release. Although the smaller boutons I observed are contradictory 
to this study, there are experimental differences in that I expressed TOR
DN
 
presynaptically rather than using mutant larvae and also the mutant combination used 
in the previous study resulted in hypomorphic phenotypes.  
Activation of the TOR pathway by expressing an activated form of Dp110 
significantly increased the number of boutons and resulted in an increased 
appearance of satellite boutons (Figure 6.3). As a measure of synaptic function, I 
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quantified the number of active zones in each bouton. Expressing a dominant 
negative form of TOR resulted in a strong reduction in the number and density of 
active zones in each bouton. In contrast, expression of the activated form of Dp110 
caused a significant decrease in the density of active zones in each bouton, while the 
number of active zones was approximately same. Therefore activation of the TOR 
pathway may not perturb synaptic function, as the increased bouton number could 
compensate for the marginal decrease in active zone density. Having more boutons 
may result in there being similar numbers of active zones throughout the synapse.  In 
contrast, inhibition of the TOR pathway by expressing a dominant negative form of 
TOR resulted smaller boutons with fewer and less dense active zones. Taken 
together, the PI3K and TOR data confirm the importance of the TOR pathway in 
motoneuron synapse development and activity. Interestingly both inhibition and 
activation of the TOR pathway resulted in decreased climbing performance. 
Expression of TOR
DN
 caused only a slight defect, while expression of Dp110
active
 
resulted in stronger climbing defect (Figure 6.3). This is in contrast to a previous 
study that found that overexpression of wild-type Dp110 in Drosophila motoneurons 
caused an increase in locomotion activity in larvae (MARTIN-PENA et al. 2006). 
Future experiments will investigate further the effects of TOR pathway activation on 
motoneuron function. 
As a first step to testing the hypothesis that the mitochondrial phenotypes caused by 
mtDNA loss in motoneurons were due to misregulation of the TOR pathway I 




 did not 
result in the total loss of mitochondria from boutons. However, there was an overall 
reduction of mitochondria upon expression of TOR
DN
 (Figure 6.4). There was not a 





Therefore I investigated the boutons in detail. Expressing TOR
DN 
resulted in smaller 
and fewer mitochondria in each bouton (Figure 6.4). Conversely, activation of PI3K 
resulted in significantly fewer but larger mitochondria (Figure 6.4E-G).  Surprisingly 
therefore, both inhibition and activation of the TOR pathway affected synaptic 
mitochondria. It has been reported that siRNA of TOR in tissue culture cells results 
in elongated mitochondria, which is different to what I observed (GOMES et al. 
2011). It will be useful to visualize other compartments of the motoneurons to 
understand the global effect of TOR pathway inhibition on mitochondrial 
morphology.  
The effect of PI3K
active
 expression on synaptic mitochondria is interesting in that, 
similar to TFAM RNAi, there was a mitochondrial phenotype, but no effect on 
bouton size or active zone number. This again suggests that synaptic mitochondrial 
phenotypes may occur before effects on overall synapse development. The reason 
that I did not observe an increase in the mitochondrial volume to bouton volume ratio 
with expression of PI3K
active
 could be that mitochondrial volume may be at the 
physiological limit. The reduction in the motor behaviour in PI3K
active
 expressing 
flies could be the result of larger synaptic mitochondria, or of increased bouton 
number.  
Motoneuron specific expression of Atg1 resulted in late third instar developmental 
arrest.I observed increased bouton number upon Atg1 overexpression, however these 
boutons were significantly smaller compared to control boutons. Furthermore fewer 
active zones were observed in these boutons, confirming previous observations that 
autophagy affects motoneuron synaptic development (SHEN and GANETZKY 2009). 
The specific type of autophagy that is implicated in the clearance of damaged 
mitochondria is termed “mitophagy”. Several studies have shown that mitophagy is 
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responsible for degrading dysfunctional mitochondria in a Drosophila PD model 
(LIU et al. 2012). Furthermore, the PINK1/Parkin pathway is currently being studied 
in detail as a mitochondrial quality control mechanism (WHITWORTH and PALLANCK 
2009). I observed a dramatic depletion of mitochondria from synapses upon Atg1 
overexpression in motoneurons. Approximately 45 % of boutons were completely 
devoid of mitochondria upon autophagy activation (Figure 6.6). These data are 
consistent with the hypothesis that mtDNA loss causes increased mitophagy leading 
to loss of synaptic mitochondria and potentially motoneuron dysfunction. 
In order to evaluate the consequences of mtDNA loss in motoneurons, it is important 
to try to understand the relationships of the phenotypes observed. I will discuss the 
potential mechanisms contributing to the following phenotypes: (i) the decrease in 
bouton size and active zones at NMJs, (ii) the mitochondrial alterations resulting 
from mtDNA loss in motoneurons.  
 
 
7.4.2 Potential mechanisms responsible for bouton size and active zone 
number reduction in motoneurons with depleted mtDNA 
 
Mitochondrial dysfunction causing reduced ATP levels is the most likely result of 
mtDNA loss. This could directly retard bouton growth due to inhibition of one or 
multiple ATP dependent processes. The identity of these processes are not known but 
restoring ATP levels would be a potential way of suppressing the developmental 
phenotypes observed. Before considering attempting such experiments it would be 
231 
 
important analyse the ATP levels in mtDNA depleted motoneurons. One possible 
method of doing would be using luciferase activity in motor neurons to detect ATP 
levels. Luciferase expression in the fly brain has been used as a readout of circadian 
rhythm (CHEN et al. 2011), but has not been adapted for in vivo ATP detection in 
Drosophila and requires highly sensitive imaging techniques and a method to add the 
substrate, luciferin, to the target tissue.  
Mitochondrial ATP generation has been suggested to be critical for motoneuron 
activity in a mouse model of motoneuron disease that expresses the G93A mutant 
SOD1 enzyme. In this model inhibition of glycolysis, which restricts ATP production 
to mitochondria, caused a reduction in evoked synaptic transmission; while synaptic 
activity was similar to controls in glucose containing media (which allows ATP 
generation via glycolysis) (CARRASCO et al. 2012). However, a Drosophila study 
modelling the mitochondrial encephalopathy Leigh Syndrome, using a mutant in 
mitochondrial complex II, showed that progressive synapse degeneration at 
photoreceptors was independent of ATP levels (MAST et al. 2008). The synaptic 
degeneration observed was related to increased ROS levels. ROS levels were also 
shown to be important for NMJ development in Drosophila, where induction of 
oxidative stress resulted in NMJ overgrowth (increased bouton number) of NMJ 6/7 
(MILTON et al. 2011). It seems unlikely therefore that the NMJ phenotypes I 
observed upon TFAM or mitoXhoI overexpression are due primarily to increased 
ROS as bouton number was not increased. In summary, ATP and ROS levels can 
result in various phenotypes depending on the neuronal cell type or disease model. 
A second possible mechanism that could contribute to reduced bouton size upon 
mtDNA loss could be reduced translation.  The decreased bouton size observed upon 
expression of TOR
DN
 supports this hypothesis as TOR is a major regulator of growth 
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through translational regulation. Furthermore S6k mutant larvae were found to have a 
similar phenotype in that bouton number was not affected but the bouton size was 
reduced by 40% (CHENG et al. 2011). I propose a model in which mitochondrial 
dysfunction, resulting from mtDNA loss, inhibits TOR signalling (via activation of 
AMPK due to decreased ATP levels), which leads to reduced translation and so 
decreased bouton size (Figure 6.1). In order to test if mtDNA depletion results in 
TOR inhibition, staining of motoneurons overexpressing TFAM or mitoXhoI with a 
phospho-S6k (P-S6k) specific antibody, or western blot analysis of P-S6k in larvae 
overexpressing TFAM or mitoXhoI, could be performed  to determine whether TOR 
activity is affected by mtDNA loss. Subsequently, rescue experiments could be 
performed to determine whether activation of the TOR pathway restores activity in 
motoneurons overexpressing TFAM or mitoXhoI. 
Motoneuron specific mtDNA loss resulted in a reduction in the number of active 
zones. The data presented in chapters 4, 5 and 6 show that the active zone reduction 
is probably not simply due to the bouton size reduction as active zone density is 
reduced upon overexpression of TFAM, mitoXhoI and TOR
DN
. This is an interesting 
and important point, highlighting the specific effect of mtDNA depletion on active 
zone development. One possible reason for this could be inhibition of ATP 
dependent processes regulating active zone development. Neurotransmitter release is 
an ATP-dependent process in part because synaptic vesicle priming (exocytosis of 
docked vesicles) is regulated by the NSF (N-ethyl-maleimide-sensitive factor) 
protein, which has two ATPase domains (ZHENG and BOBICH 1998). The molecular 
composition of the active zone in Drosophila is only beginning to be understood, 
with the identification of key components such as Rab3-interacting molecule (RIM)-
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binding protein (DRBP) (LIU et al. 2011). The potential regulation of active zone 
development by ATP levels will be an important future direction.  
 
7.4.3 Potential mechanisms that contribute to the mitochondrial phenotypes 
caused by motoneuron mtDNA loss 
 
I observed a progressive defect in mitochondrial localization from motoneuron cell 
bodies to the synapses with some synaptic boutons completely devoid of 
mitochondria upon overexpression of TFAM and mitoXhoI. This could result from 
defective axonal transport of mitochondria to the cell bodies. It has been shown in 
Drosophila that mutations in Miro, which is required for anteriograde transport, 
result in depletion of synaptic mitochondria (GORSKA-ANDRZEJAK et al. 2003; GUO 
et al. 2005; STOWERS et al. 2002). It will be important to analyse mitochondrial 
transport in motoneuron axons by live imaging to determine if transport defects 
contribute to the depletion of synaptic mitochondria in motoneurons with decreased 
mtDNA. If so, increasing mitochondrial transport could be a means of rescuing the 
phenotypes observed upon mtDNA depletion. 
Alterations in the fission/fusion machinery could also result in defects in the 
mitochondrial network and it has been shown that down-regulation of Drp1 
expression in mammalian cells results in mtDNA loss (PARONE et al. 2008). 
Overexpression of TFAM and mitoXhoI result in smaller mitochondria at synapses 
and in axons. Additionally, overexpression of TFAM and mitoXhoI caused 
morphological changes in motoneuron cell body mitochondria. These morphological 
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changes may be due to an increase in fission events and would suggest that mtDNA 
depletion may result in activation of mitochondrial fission. Enhancing mitochondrial 
fusion or inhibiting mitochondrial fission may therefore compensate for the 
mitochondrial phenotypes observed upon mtDNA depletion. In a recent study, loss of 
membrane potential and mitochondrial fragmentation were linked. ARL4D, a 
member of the ADP-ribosylation factor/ARF-like protein (ARF/ARL) family of 
GTPases, which are involved in membrane transport, organelle integrity, membrane 
lipid modification and cytoskeletal dynamics, was shown to be targeted to 
mitochondria with altered mitochondrial membrane potential where it affected 
mitochondrial morphology (LI et al. 2012). This represents a potential mechanism 
linking loss of mtDNA and the resulting decreased membrane potential with 
alterations in mitcochondrial morphology. 
The TOR pathway is a regulator of autophagy. Autophagy is a response mechanism 
which is activated in stress conditions, such as starvation, to recover cellular 
nutrients. TOR complex 1 (mTORC1) inhibits autophagy by interacting with Atg13 
(KAMADA et al. 2000).  Furthermore activation of PI3K can suppress autophagy in C. 
elegans, mammalian cells and human tissue culture cells (MELENDEZ et al. 2003; 
PETIOT et al. 2000; SEGLEN and BOHLEY 1992). It has also been shown that the PI3K 
pathway is linked with programmed autophagy (which is followed by cell death for 
tissue remodelling) in the Drosophila fat body, such that downregulation of PI3K by 
ecdysone signalling results in induction of programmed autophagy (RUSTEN et al. 
2004). Approximately 20 ATG genes (autophagy related genes) have been identified 
in yeast (KLIONSKY et al. 2003). It has been also been reported that overexpression of 
Atg1 is sufficient to induce autophagy in flies and this inhibits cell growth (SCOTT et 
al. 2007). In the same study, Atg1 expression was also shown to result in negative 
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regulation of TOR activity. Interestingly, it has been shown that increased autophagy 
promotes synapse development in flies (SHEN and GANETZKY 2009). In my 
experiments overexpression of Atg1 in motoneurons resulted in more, but smaller 
boutons. It would be interesting to see what effect inhibition of autophagy has on the 
mitochondrial and motoneuron developmental defects caused by overexpression of 
TFAM or mitoXhoI. 
Strong mitochondrial depletion at synapses could also result from a reduction in 
mitochondrial biogenesis. PGC-1α is the main regulator of mitochondrial biogenesis 
in vertebrates and PGC-1α -overexpression in mouse skeletal muscle and heart 
increases mitochondrial biogenesis and mitochondrial function (LEHMAN et al. 2000; 
WENZ et al. 2008). It has been shown that overexpression of PGC-1α  in mtDNA 
mutator mice (which express a proofreading deficient version of Polγ), results in 
increased mitochondrial biogenesis, which can ameliorate the skeletal and heart 
phenotypes without decreasing (even slightly increases) the accumulation of mtDNA 
mutations (DILLON et al. 2012). The PGC-1α homologue in Drosophila is Spargel 
and it has been shown that Spargel regulates mitochondrial activity, cell growth and 
transcription in response to insulin signalling in the Drosophila fat body 
(TIEFENBOCK et al. 2010). Loss of mtDNA in motoneurons may activate a retrograde 
signal to the nucleus to down regulate Spargel expression and reduce mitochondrial 
biogenesis. Mitochondrial-to-nuclear retrograde signalling has not been widely 
studied in Drosophila. However in C. elegans the unfolded protein response (UPR) 
is a well characterised mechanism in which abnormalities in protein folding in 
mitochondrial matrix cause signalling to the nucleus that regulates the expression of 
nuclear encoded mitochondrial genes (HAYNES and RON 2010). It would thus be 
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interesting to analyse the expression of Spargel and other genes involved in 
mitochondrial biogenesis in motoneurons overexpressing TFAM or mitoXhoI.  
Although I have discussed them separately the bouton size, active zone and 
mitochondrial phenotypes caused by loss of mtDNA in motoneurons are likely to be 
linked by common mechanisms. In the model I have proposed mitochondrial 
dysfunction is linked to bouton size regulation through the TOR pathway (Figure 
6.1). However, as discussed above, TOR signalling regulates autophagy and so 
inhibition of TOR signalling by mtDNA loss could then activate autophagy, resulting 
in the degradation of synaptic mitochondria. Increased mitophagy may then further 
decrease ATP levels in a feed-forward loop that further inhibits TOR signalling. It 
may therefore be difficult to separate the phenotypes observed by inhibition or 
overexpression of regulators of these processes. However, as discussed above, 
analysis of the phenotype of motoneuron specific RNAi of TFAM suggests that 
synaptic mitochondrial depletion may be the primary driver of the motoneuron 
dysfunction resulting from mtDNA loss.  
 
7.5 Conclusion and Future Directions  
 
I have developed a Drosophila model for studying mtDNA depletion in motoneurons 
via manipulation of TFAM levels. In summary, the phenotypes observed upon 
mtDNA depletion were reduced motor function, mitochondrial depletion at synapses 
and axons and synaptic developmental defects. Similar phenotypes were observed by 
depletion of mtDNA levels using a mitochondrially targeted restriction enzyme. 
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These phenotypes may represent the initial pathological consequences of mtDNA 
loss in neurodegenerative disease. Application of other techniques such as electron 
microscopy and electrophysiology, (both of which are ongoing in the lab or through 
collaborations), will further our understanding of the consequences of mtDNA loss in 
neurons. Investigation of the TOR pathway and autophagy machinery are suggested 
as a potential mechanistic route by which mtDNA loss causes the motoneuron 
development phenotypes I observed. My results have suggested a number of 
experiments which will help to further our understanding of the consequences of 
neuronal mtDNA loss. In future this understanding may lead to therapeutic 
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